Picolinamide compound, and preparation method therefor and use thereof
By developing pyridine amide compounds with specific structures, the problem of lacking effective treatments for RSV and hMPV infections has been solved, achieving effective prevention and treatment of these viruses, especially protective effects in high-risk groups.
Patent Information
- Application Number
- PCT/CN2026/097571
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-14
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Currently, there are no effective treatments to combat respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections, especially in high-risk populations. These viral infections can lead to severe lower respiratory tract infections and a high risk of death, and the use of existing vaccines and antibody-based preventative drugs has limitations.
A pyridine amide compound with specific structural features, such as 8-12 membered bicyclic fused heteroaryl groups or 5-7 membered heteroaryl substituents, is provided for the preparation of pharmaceutical compositions for the prevention or treatment of infections caused by respiratory syncytial virus and human metapneumovirus.
This compound exhibits antiviral activity against RSV and hMPV, and can effectively prevent or treat infections caused by these viruses, especially in high-risk populations, reducing disease severity and the risk of death.
Smart Images

Figure CN2026097571_19112026_PF_FP_ABST
Abstract
Description
A pyridine amide compound, its preparation method and uses Technical Field
[0001] This invention belongs to the pharmaceutical field and relates to a pyridine amide compound with anti-respiratory syncytial virus and metapneumovirus activity, pharmaceutical compositions containing the same, and their uses. Background Technology
[0002] Respiratory syncytial virus (RSV) is a major pathogen causing respiratory infections, especially in infants and the elderly, where it has a high incidence and pathogenicity. RSV infection can spread from the upper respiratory tract to the lower respiratory tract, leading to clinical symptoms such as airway infection, bronchiolitis, and pneumonia, and in severe cases, even respiratory failure. RSV is the leading cause of hospitalization for lower respiratory tract infections in infants and young children. Furthermore, immunosuppressed patients after transplantation and immunocompromised individuals are also at high risk of RSV infection, and severe lower respiratory tract infections in them carry an extremely high risk of death.
[0003] Currently, there are no approved effective treatments specifically for respiratory syncytial virus (RSV) infection worldwide. Most infected individuals still rely on supportive and symptomatic treatment, lacking specific antiviral therapies. Although vaccines and antibody-based preventative drugs have been approved, their application has limitations.
[0004] Human metapneumovirus (hMPV) belongs to the family Pneumoviridae and genus Metapneumovirus. It often co-circulates with RSV and is a common cause of acute lower respiratory tract infection (ALRTI). In high-risk groups, such as children under 5 years of age, adults over 65 years of age, and adults with underlying medical conditions (e.g., chronic obstructive pulmonary disease (COPD), asthma, congestive heart failure, or diabetes), this virus can be life-threatening. Currently, there are no treatments or medications available for hMPV infection. Summary of the Invention
[0005] The first aspect of the present invention provides a compound of formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof.
[0006] in:
[0007] Ring A is an 8-12 membered bicyclic fused heteroaryl group or a 5-7 membered heteroaryl group, wherein the 8-12 membered bicyclic fused heteroaryl group is optionally surrounded by one or more -C groups. 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 Cycloalkyl substitution, wherein -C 3-5 cycloalkyl, -C 1-3 Alkyl, -C 1-3 Alkyl or -OC3-5 The cycloalkyl group is optionally substituted with one or more halogens or D, and / or the substituents on the two adjacent atoms of the 8-12 membered bicyclic fused heteroaryl group form a 3-6 membered heterocycloalkyl group with the atom to which they are attached; the 5-7 membered heteroaryl group is optionally substituted with -C 1-3 Alkyl or 5-8-membered heteroaryl groups are substituted, wherein the 5-8-membered heteroaryl group is further optionally replaced by one or more halogens or -C. 1-3 Alkyl substitution;
[0008] p is 0, 1, 2, 3, 4 or 5;
[0009] R 1 Each is independently a halogen, -C 1-3 Alkyl or -C 1-3 Halogenated alkyl groups;
[0010] R 2 -H, halogen, -C 1-5 Alkyl, -C 1-3 Alkoxy, -C 3-6 cycloalkyl, the -C 1-5 Alkyl, -C 1-3 Alkoxy, -C 3-6 The cycloalkyl group may optionally be substituted with one or more halogens;
[0011] R 3 -C 1-5 Alkyl or -C 3-6 cycloalkyl, the -C 1-5 Alkyl and -C 3-6 The cycloalkyl group may optionally be substituted with one or more -OH, -NH2 or halogens;
[0012] or R 2 R 3 The C atoms connected to it form a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is surrounded by one or more -C atoms. 1-3 Alkyl and / or -C(=O)NH2 substitution;
[0013] L 1 For bond or -(CH2) n O(CH2) m -, n and m are each independently 0, 1, 2 or 3;
[0014] And at least one of the following conditions must be met:
[0015] (a)R 2 -C 1-5 Alkyl, -C 1-3 Alkoxy, -C 3-6 cycloalkyl, the -C 1-5 Alkyl, -C 1-3Alkoxy, -C 3-6 The cycloalkyl group may optionally be substituted with one or more halogens;
[0016] (b)R 2 R 3 The C atoms connected to it form a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is surrounded by one or more -C atoms. 1-3 Alkyl and / or -C(=O)NH2 substitution;
[0017] (c) Ring A is an optionally substituted 8-12 membered bicyclic fused and heteroaryl group, R 3 -C replaced by one or more -OH groups 1-5 Alkyl groups or -C groups optionally substituted with one or more -OH, -NH2, or halogens 3-6 cycloalkyl;
[0018] (d) Ring A is an optionally substituted 8-12 membered bicyclic fused and heteroaryl group, R 2 -Cl;
[0019] (e) Ring A is a 10-12 membered bicyclic fused and heteroaryl group that is optionally substituted.
[0020] In some implementations, R 2 -H, -Cl, -C 1-3 Alkyl, -C 1-3 Alkoxy, -C 3-6 cycloalkyl, the -C 1-3 Alkyl, -C 1-3 Alkoxy, -C 3-6 The cycloalkyl group may optionally be replaced by one or more halogens.
[0021] In some embodiments, ring A is an 8-10 membered bicyclic fused and heteroaryl group, optionally surrounded by one or more -C groups. 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 Cycloalkyl substitution, wherein -C 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group is optionally substituted with one or more -F or D groups, or the substituents on two adjacent atoms of the 8-10 membered bicyclic fused and heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atom to which they are attached; preferably a 9-10 membered bicyclic fused and heteroaryl group.
[0022] In some embodiments, the heteroatom of the bicyclic fused heteroaryl group is N or O; and / or the number of the heteroatom is 2 or 3, preferably 2.
[0023] In some embodiments, the bicyclic fused and heteroaryl group is
[0024] In some embodiments, the bicyclic fused and heteroaryl group is
[0025] In some embodiments, the bicyclic fused and heteroaryl group is optionally replaced by one or more methyl, ethyl, difluoromethyl, trifluoromethyl, -CD3, cyclopropyl, or other compounds. Methoxy, -OCD3 or cyclopropyloxy substitution; and / or
[0026] The substituents on the two atoms of the bicyclic fused group and the heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atoms they are attached to, wherein the heteroatom of the heterocyclic alkyl group is O; and / or the number of heteroatoms is 1 or 2, preferably 2; more preferably 5 membered heterocyclic alkyl group; even more preferably, the substituents on the two atoms of the bicyclic fused group and the heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atoms they are attached to.
[0027] In some embodiments, ring A is a 5-membered heteroaryl group, optionally surrounded by one or more 6-membered heteroaryl groups, -C 1-3 Alkyl substitution, wherein the 6-membered heteroaryl group is further optionally replaced by one or more halogens or -C 1-3 Alkyl substitution.
[0028] In some embodiments, the number of heteroatoms in the 5-membered heteroaryl group is 1 or 2, preferably 2; and / or the heteroatoms are N, S, or O, preferably N and / or S; more preferably, the 5-membered heteroaryl group is
[0029] In some embodiments, the number of heteroatoms in the 6-membered heteroaryl group is 1 or 2, preferably 2; and / or the heteroatoms are N, S, or O, preferably N; more preferably, the 6-membered aromatic heterocycle is
[0030] In some implementations, ring A is a ring that is... Replacement And optionally substituted with one or more methyl groups, the Further optionally substituted with one or more -F or methyl groups; preferably, the It can be further optionally replaced by one or more -F.
[0031] In some implementations, p is 0, 1, or 2, preferably 1 or 2, and more preferably 1.
[0032] In some implementations, R 1 The structure formed with the ring it is in is
[0033] In some implementations, R 1 The structure formed with the ring it is in is
[0034] In some implementations, R 1 Each is independently a halogen, preferably -F or -Cl, more preferably -F.
[0035] In some implementations, R 1 The structure formed with the ring it is in is
[0036] In some implementations, R 2 -H, -F, -Cl, -C 1-3 Alkyl, -C 1-3 alkoxy or -C 3-4 cycloalkyl, the -C 1-3 Alkyl or -C 1-3 The alkoxy group is optionally substituted with one or more -F groups; preferably, R... 2 The derivative is -H, -F, -Cl, methyl, ethyl, cyclopropyl, or methoxy, wherein the methyl, ethyl, or methoxy group is optionally substituted with one or more -F groups; more preferably, R... 2 It can be -H, -Cl, methyl, ethyl, cyclopropyl, methoxy, or difluoromethyl.
[0037] In some implementations, R 2 -C 1-3 Alkyl or -C 3-4 cycloalkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; preferably, R 2 -C 1-3 Alkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R... 2 It is methyl, ethyl, or difluoromethyl; more preferably, R 2 It is a methyl group.
[0038] In some implementations, R 3 -C 1-3 Alkyl groups, optionally substituted with one or more -OH or -NH2 groups; preferably, R 3 It is n-propyl or isopropyl, optionally substituted with a -OH or -NH2 group; more preferably, R 3 for
[0039] In some implementations, R 3 -C 3-6Cycloalkyl groups, optionally substituted with one or more -OH or -NH2 groups; preferably, R 3 The group is cyclopropyl, optionally substituted with one or more -OH or -NH2 groups; more preferably, R3 is...
[0040] In some implementations, R 2 R 3 The C group connected thereto forms a 5-membered heterocyclic group, wherein the 5-membered heterocyclic group is surrounded by one or more -C groups. 1- 3-alkyl and / or -C(=O)NH2 substitution; preferably, the number of heteroatoms in the 5-membered heterocyclic group is 1, and the heteroatom is O; more preferably, the 5-membered heterocyclic group is It is substituted with one or more methyl groups and / or -C(=O)NH2; more preferably, for Even more preferably, for
[0041] In some implementations, L 1 -(CH2) n O(CH2) m -, n and m are each independently 0 or 1; preferably, L 1 It is -O-.
[0042] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ia):
[0043] Among them, R 1 R 2 R 3 p, L 1 Each is independent as described above;
[0044] R 4 H or -C 1-3 alkyl;
[0045] R 5 -C 1-3 Alkyl, -C 1-3 Alkyl or -OC 3-5 cycloalkyl, the -C 1-3 Alkyl, -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group may optionally be substituted with one or more halogens or D;
[0046] or R 4 With R 5 The linkage forms 3-6 membered heterocyclic alkyl groups;
[0047] X 1 X 2 Each can be independently represented as C or N;
[0048] X 3 It can be CH, O, S or N;
[0049] X 4 For CR 6 or NR 6 ;
[0050] R 6 H, halogen, -C 1-3 Alkyl or -C 3-5 cycloalkyl, the -C 1-3 Alkyl or -C 3-5 The cycloalkyl group may optionally be substituted with one or more D or halogens;
[0051] Preferably, R 1 Each is independently a halogen, -C 1-3 Alkyl or -C 1-3 Haloalkyl, p is 0, 1, 2, 3, 4 or 5;
[0052] R 2 -Cl, -C 1-3 Alkyl, -C 1-3 Alkoxy, -C 3-6 cycloalkyl, the -C 1-3 Alkyl, -C 1-3 Alkoxy, -C 3-6 The cycloalkyl group may optionally be substituted with one or more halogens, hydroxyl groups, and alkyl groups;
[0053] R 3 -C 1-5 Alkyl, the -C 1-5 The alkyl group may optionally be substituted with one or more -OH, -NH2 or halogens;
[0054] R 4 H or -C 1-3 alkyl;
[0055] R 5 -C 1-3 Alkyl, -C 1-3 Alkyl or -OC 3-5 cycloalkyl, the -C 1-3 Alkyl, -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group may optionally be substituted with one or more halogens or D;
[0056] or R 4 With R 5The linkage forms 3-6 membered heterocyclic alkyl groups;
[0057] X 1 X 2 Each can be independently represented as C or N;
[0058] X 3 It can be CH, O, S or N;
[0059] X 4 For CR 6 or NR 6 ;
[0060] R 6 H, halogen, -C 1-3 Alkyl or -C 3-5 cycloalkyl, the -C 1-3 Alkyl or -C 3-5 The cycloalkyl group may optionally be substituted with one or more D or halogens;
[0061] L 1 For bond or -(CH2) n O(CH2) m -, n and m are each independently 0, 1, 2 or 3;
[0062] More preferably, R 2 -C 1-3 Alkyl or -C 3-4 cycloalkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R 2 -C 1-3 Alkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R... 2 It is methyl, ethyl, or difluoromethyl; more preferably, R 2 It is a methyl group.
[0063] In some implementations, R 4 It is H, methyl or ethyl, preferably H.
[0064] In some implementations, R 5 H, methyl, methoxy, ethoxy, or cyclopropoxy, wherein the methyl, methoxy, ethoxy, or cyclopropoxy group is optionally substituted with one or more F or D groups; preferably methyl, methoxy, or cyclopropoxy, wherein the methyl group is optionally substituted with one or more F groups, and the methoxy group is optionally substituted with one or more D groups; more preferably, R 5 It can be methoxy, cyclopropoxy, trifluoromethyl, or -OCD3.
[0065] In some implementations, R 4 With R5 The linkage forms a 3-6 membered heterocyclic alkyl group; preferably, R 4 With R 5 The heterocyclic alkyl group is linked to form a 4-6 membered heterocyclic alkyl group, wherein the heterocyclic alkyl group has 1 or 2 heteroatoms; and / or the heteroatoms of the heterocyclic alkyl group are O or N; more preferably, the heteroatoms of the heterocyclic alkyl group are O; even more preferably, the structure formed by the heterocyclic alkyl group and the adjacent ring is as follows: Further preferred is More preferably, ring A is
[0066] In some implementations, X 3 It can be CH, O or N, preferably CH or O.
[0067] In some implementations, X 4 For CR 6 or NR 6 R 6 H, -C 1-3 Alkyl or -C 3-5 cycloalkyl, the -C 1-3 Alkyl or -C 3-5 The cycloalkyl group is optionally substituted with one or more D or F; preferably, R 6 The methyl or cyclopropyl group is optionally substituted by one or more D or F groups; more preferably, R 6 It is methyl, difluoromethyl, cyclopropyl, -CD3 or
[0068] In some implementations, X 1 X 2 X 3 and X 4 It contains at least one heteroatom; preferably, X 1 X 2 X 3 and X 4 It contains one heteroatom.
[0069] In some implementations, X 4 For NR 6 X 1 X 2 X 3 For CH.
[0070] In some implementations, X 1 X 2 One is N, the other is C, and X 3 For CH, X 4 For CR 6 .
[0071] In some implementations, X 3 For O, X 1 X 2 For CH, X 4 For CR 6 .
[0072] In some implementations, ring A is
[0073] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ib):
[0074] Among them, R 1 R 2 R 3 p, L 1 Each is independent as described above;
[0075] R 7 -C 1-3 Alkyl groups, preferably methyl groups;
[0076] R 8 -H, -C 1-3 Alkyl or halogen, preferably -H, methyl or -F, more preferably -H or -F;
[0077] Preferably, R 2 -C 1-3 Alkyl or -C 3-4 cycloalkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R 2 -C 1-3 Alkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R... 2 It is methyl, ethyl, or difluoromethyl; more preferably, R 2 It is a methyl group.
[0078] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ic):
[0079] Among them, R 1 R 2 R 3 p, L 1 Each is independent as described above;
[0080] R 4 H or -C1-3 alkyl;
[0081] R 5 H, -C 1-3 Alkyl or -OC 3-5 cycloalkyl, the -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group is optionally substituted with one or more D atoms;
[0082] or R 4 With R 5 The linkage forms 3-6 membered heterocyclic alkyl groups;
[0083] R 6 H, -C 1-3 Alkyl or 3-6 membered cycloalkyl, wherein the -C 1-3 Alkyl groups may optionally be substituted with one or more D or halogens.
[0084] In some implementations, R 4 It is H, methyl or ethyl, preferably H.
[0085] In some implementations, R 5 H, methoxy, ethoxy, or cyclopropoxy, wherein the methoxy, ethoxy, or cyclopropoxy is optionally substituted with one or more D; preferably methoxy, wherein the methoxy is optionally substituted with one or more D; more preferably, R 5 It is methoxy or -OCD3; more preferably methoxy.
[0086] In some implementations, R 4 With R 5 The linkage forms a 3-6 membered heterocyclic alkyl group; preferably, R 4 With R 5 The heterocyclic alkyl group is linked to form a 4-6 membered heterocyclic alkyl group, wherein the heterocyclic alkyl group has 1 or 2 heteroatoms; and / or the heteroatoms of the heterocyclic alkyl group are O or N; more preferably, the heteroatoms of the heterocyclic alkyl group are O; even more preferably, the structure formed by the heterocyclic alkyl group and the adjacent ring is as follows: Further preferred is
[0087] In some implementations, R 6 The alkyl group is H, methyl, ethyl, or a 3-5 membered cycloalkyl group, wherein the methyl or ethyl group is optionally substituted with one or more D groups or halogens; preferably, R 6 The methyl group is methyl or cyclopropyl, wherein the methyl group is optionally substituted by one or more D or F groups; more preferably, R 6 It is methyl, -CD3, -CHF2 or cyclopropyl; more preferably methyl.
[0088] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (I'):
[0089] Among them, rings A and R 1 R 2 R 3 p and p are independent as described above.
[0090] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ia'):
[0091] Among them, R 1 R 2 R 3 R 4 R 5 p, X 1 X 2 X 3 X 4 Each is independent as described above.
[0092] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ib'):
[0093] Among them, R 1 R 2 R 3 R 7 R 8 p and p are independent as described above.
[0094] In some embodiments, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof have the structure represented by formula (Ic'):
[0095] Among them, R 1 R 2 R 3 R 4 R 5 p and p are independent as described above.
[0096] In some embodiments of the present invention, the compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof include the following structures:
[0097] A second aspect of the present invention provides a pharmaceutical composition comprising at least one compound described in the first aspect of the present invention, its stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers and / or additives.
[0098] The third aspect of the present invention provides the use of the compound, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof described in the first aspect of the present invention, or the pharmaceutical composition described in the second aspect of the present invention, in the preparation of a medicament for the prevention or treatment of viral infection; preferably, the viral infection is an infection caused by respiratory syncytial virus and human metapneumovirus. Detailed Implementation
[0099] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated herein by reference in their entirety. Where there are multiple definitions for terms used herein, the one in this section shall prevail unless otherwise stated. Where the number of any given substituent is not specified, one or more substituents may be present. In the description herein, where chemical structures and chemical names contradict each other, the chemical structure shall prevail. When used herein, abbreviations for any protecting groups, amino acids and other compounds are, unless otherwise stated, represented by their commonly used and accepted abbreviations, or according to the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochem. 1972, 77:942-944).
[0100] Unless otherwise stated, the terms used in the specification and claims shall have the following meanings.
[0101] The terms “optional” or “optionally” mean that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of such event or environment. For example, “optionally alkyl-substituted heterocyclic alkyl” means that alkyl may but does not have to be present, and the description includes cases where heterocyclic alkyl is substituted with alkyl and cases where heterocyclic alkyl is not substituted with alkyl.
[0102] "Substituted" refers to one or more hydrogen atoms in a group that are independently replaced by a corresponding number of substituents. Substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort.
[0103] The term "alkyl," either alone or as part of another substituent, refers to a saturated aliphatic hydrocarbon group having a specified number of carbon atoms, which is an uncyclic straight-chain or branched carbon chain (or carbon), or a combination thereof. For example, -C1-3 Alkyl refers to methyl, ethyl, n-propyl, and isopropyl. Whenever it appears in this document, the numerical range is indicated by "-C". 1-5 "Alkyl" means that an alkyl group can contain 1, 2, 3, 4, or 5 carbon atoms. Alkyl groups can be substituted or unsubstituted, and when substituted, the substituents can be replaced at any usable connection point.
[0104] The term "alkoxy" refers to -O-alkyl and -O-unsubstituted cycloalkyl, wherein alkyl and cycloalkyl are defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, etc.
[0105] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, etc. Cycloalkyl groups can be optionally substituted or unsubstituted, and when substituted, the substituents can be replaced at any usable connection point.
[0106] The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, as well as any quaternized form of basic nitrogen.
[0107] The term "heterocyclic alkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon group, wherein one or more ring atoms are selected from heteroatoms of N, O, S(=O), or S(=O)₂, excluding the ring moiety of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Non-limiting examples of monocyclic heterocyclic alkyl groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, tetrahydrofuranyl, etc. Heterocyclic alkyl groups can be optionally substituted or unsubstituted, and when substituted, the substituents can be substituted at any usable connection point.
[0108] As used herein, the terms "aromatic system," "aromatic group," or "aromatic group" alone or as part of another group refer to a ring system comprising an optionally substituted allotropic or heterocyclic conjoined planar ring or ring system including delocalized electrons. The present invention The ring in question represents an aromatic system, for example...
[0109] The term "heteroaryl" is used herein to refer to a heterocyclic ring system having aromatic properties. The term "heteroaryl" includes polycyclic (e.g., bicyclic) ring systems in which one or more rings are non-aromatic, provided that at least one ring is aromatic. In such polycyclic systems, the ring system can be attached to the remainder of the compound via an aromatic ring or via a non-aromatic ring. Examples of heteroaryls are monocyclic and bicyclic groups containing 5 to 12 ring members. Heteroaryls can be, for example, 5-8 membered heteroaryls or 8-12 membered bicyclic fused heteroaryls, where "5-8 membered heteroaryl" refers to a 5- to 8 membered monocyclic heteroaryl, and "8-12 membered bicyclic fused heteroaryl" refers to an 8-12 membered bicyclic fused heteroaryl formed by the fusion of two fused rings selected from five-, six-, and seven-membered rings. Preferably, the heteroaryl can be a 5- to 7 membered monocyclic heteroaryl, such as a five- or six-membered ring, including... Or 8-10 member bicyclic fused and heteroaryl groups formed by two fused six-membered rings or two fused five-membered rings, such as 9 member bicyclic fused and heteroaryl groups, including but not limited to... For example, 10-membered bicyclic fused and heteroaryl compounds, including but not limited to...
[0110] Heteroaryl ring systems can contain up to about five heteroatoms, typically selected from nitrogen, oxygen, and sulfur. Typically, a heteroaryl ring will contain up to four heteroatoms, more typically up to three heteroatoms, and even more typically up to two, such as a single heteroatom. The nitrogen atom in the heteroaryl ring can be basic, as in the case of imidazole or pyridine, or substantially non-basic, as in the case of indole or pyrrole nitrogen. It should be understood that the heteroaryl group can be linked by a heteroatom in the ring (where chemically possible) or by a carbon atom comprising the carbon of the heteroaryl ring. Generally, the number of basic nitrogen atoms present in the heteroaryl group (including any amino substituents in the ring) will be less than five.
[0111] The term "halogen" includes fluorine, chlorine, bromine, and iodine.
[0112] In this invention, unless specifically specified, the term "compound" encompasses its free base, pharmaceutically acceptable salt, stereoisomer, tautomer, isotopic derivative, etc. The compounds of this invention may also exist as hydrates or solvates. The compounds of this invention may exist in both non-solventized and solvated forms. The term "solvent" is used herein to describe a molecular complex comprising the compounds of this invention and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol).
[0113] The compounds of the present invention can exist in polymorphs, that is, in more than one form or crystal structure. Optically pure enantiomers and pure diastereomers of the present invention can be obtained by chiral resolution or by chiral synthesis. In some embodiments of the present invention, the compounds, their stereoisomers, tautomers, or pharmaceutically acceptable salts thereof can be isotopic derivatives (e.g., deuterated derivatives). In some embodiments of the present invention, the compounds, their stereoisomers, tautomers, or pharmaceutically acceptable salts thereof can be metabolites.
[0114] The compounds of the present invention can be administered in crystalline or amorphous forms. They can be administered alone or in combination with one or more other compounds of the present invention or in combination with one or more other pharmaceutical products. Typically, they are administered as a formulation associated with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than one or more compounds of the present invention. The selection of excipients depends largely on factors such as the specific route of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
[0115] The term "isotope derivative" refers to a derivative of a compound in which one or more atoms are replaced by their isotopes (atoms with the same atomic number but different atomic masses or mass numbers from the dominant atomic mass or mass number found in nature). Examples of isotopes include, but are not limited to, isotopes of hydrogen (e.g., 2 H, 3 H), carbon isotopes (e.g.) 11 C 13 C and 14 C) Isotopes of fluorine (e.g.) 18 F), nitrogen isotopes (e.g.) 13 N and 15 N), isotopes of oxygen (e.g. 15 O、 17 O and 18 O).
[0116] The pharmaceutical compositions provided by this invention can be prepared in any form. Depending on the clinical indication, route of administration, and method of administration, the pharmaceutical compositions include, but are not limited to, oral formulations such as tablets, gels, soft / hard capsules, emulsions, dispersible powders, granules, and water / oil suspensions; injectable formulations including intravenous injections, intramuscular injections, intraperitoneal injections, rectal suppositories, and intracranial injections, which may be aqueous or oil solutions; topical formulations including creams, ointments, gels, water / oil solutions, and inclusion complex formulations; and inhaled formulations including fine powders, liquid aerosols, and various formulations suitable for implantation.
[0117] The pharmaceutical compositions of the present invention may further comprise one or more pharmaceutically acceptable carriers. These carriers will be suitably formulated for administration. The pharmaceutical compositions of the present invention may also comprise pharmaceutically acceptable additives, such as diluents, lubricants, binders, glidants, disintegrants, sweeteners, flavoring agents, humectants, dispersants, surfactants, solvents, coating agents, foaming agents, or flavoring agents. These carriers, diluents, or excipients shall comply with pharmaceutical formulation manufacturing process rules and be compatible with the active ingredient. Carriers for solid oral dosage forms include, but are not limited to, mannitol, lactose, starch, magnesium stearate, cellulose, glucose, sucrose, cyclodextrin, and the intestinal absorption-promoting molecular carrier vitamin E-PEG1000. Appropriate colorants, sweeteners, flavoring agents, and preservatives may be added to the oral dosage forms. Carriers for injectable dosage forms include, but are not limited to, cyclodextrin, polyethylene glycol, glycerol, and medicinal vegetable oils.
[0118] The term "pharmaceutical salt" refers to a salt of an active compound prepared with a relatively non-toxic acid or base, depending on the specific substituents found on the compounds described herein. When the compounds of the present invention contain relatively acidic functional groups, a base addition salt can be obtained by contacting such a compound in its neutral form with a sufficient amount of the desired base (pure or in a suitable inert solvent). When the compounds of the present invention contain relatively basic functional groups, an acid addition salt can be obtained by contacting such a compound in its neutral form with a sufficient amount of the desired acid (pure or in a suitable inert solvent). Examples of pharmaceutically acceptable acid addition salts can be found, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19. Certain specific compounds of the present invention contain both basic and acidic functional groups, which allows the compounds to be converted into base or acid addition salts. The acid can be an inorganic acid, including but not limited to: hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid; or it can be an organic acid, including but not limited to: citric acid, maleic acid, oxalic acid, formic acid, acetic acid, propionic acid, valeric acid, glycolic acid, benzoic acid, fumaric acid, trifluoroacetic acid, succinic acid, tartaric acid, lactic acid, glutamic acid, aspartic acid, salicylic acid, pyruvic acid, methanesulfonic acid, benzenesulfonic acid, and p-benzenesulfonic acid. The base may be an inorganic base, including but not limited to: sodium hydroxide, potassium hydroxide, magnesium hydroxide, and calcium hydroxide; or an organic base, including but not limited to: ammonium hydroxide, triethylamine, N,N-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucosamine, procaine, N-benzylphenylethylamine, arginine, or lysine; or an alkali metal salt, including but not limited to: lithium, potassium, and sodium salts; or an alkaline earth metal salt, including but not limited to: barium, calcium, and magnesium salts; or a transition metal salt, including but not limited to: zinc salts; or other metal salts, including but not limited to: sodium hydrogen phosphate and disodium hydrogen phosphate.
[0119] "Pharmaceutically acceptable carriers and / or additives" refer to substances that facilitate the administration and absorption of compounds to an individual and can be included in the compositions of the present invention without causing significant adverse toxicity to the patient. Such formulations are sterilizable and, if desired, can be mixed with adjuvants that do not react harmfully with the compounds of the present invention, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring and / or aromatic substances, etc. Those skilled in the art will recognize the usefulness of pharmaceutical carriers and / or diluents in the present invention.
[0120] The term "treatment" refers to any indication of successful treatment or improvement of an injury, disease, pathology, or symptom, including any objective or subjective parameter such as symptom relief; remission; reduction or making the injury, pathology, or symptom more tolerable for the patient; slowing the rate of degeneration or decline; making the degenerative endpoint less severe; or improving the patient's physical or mental health. Treatment or improvement of symptoms may be based on objective or subjective parameters, including the results of physical examination, neuropsychiatric examination, and / or psychiatric evaluation. The term "treatment" and variations thereof may include prevention of injury, pathology, symptom, or disease. In an implementation, treatment is prevention. In an implementation, treatment does not include prevention. As used herein, "treatment" includes prophylactic treatment. Treatment methods include administering a therapeutically effective amount of the compound described herein to an individual. Administration steps may include a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the symptom, the patient's age, the concentration of the compound, the activity of the composition used for treatment, and their combination. It should also be understood that the effective amount of the agent used for treatment or prevention may increase or decrease as a particular treatment or prevention regimen progresses. Dosage changes can be obtained and become apparent through standard diagnostic analyses known in the art.
[0121] The term "prevention" refers to reducing the occurrence of disease symptoms in a patient. As described above, prevention can be complete (no detectable symptoms) or partial prevention, resulting in fewer observed symptoms than would be possible without treatment. In embodiments, prevention means slowing the progression of a disease, symptom, or condition, or inhibiting its progression to a harmful or other undesirable state. The term "patient" or "individual in need" refers to a living organism that suffers from or is susceptible to a disease or condition that can be treated by administration of the pharmaceutical compositions provided herein. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, monkeys, goats, sheep, dairy cows, deer, and other non-mammalian animals. In some embodiments, the patient is a human.
[0122] A person skilled in the art of treating infectious diseases will be able to determine the effective dose from the test results presented below. Typically, the expected daily effective dose will be from 0.01 mg / kg to 50 mg / kg body weight, more preferably from 0.1 mg / kg to 20 mg / kg body weight. The required dose may be appropriately administered throughout the day as two, three, four, or more sub-dose at suitable time intervals. These sub-dose may be formulated into unit dosage forms, for example, each unit containing 1 to 1000 mg, and specifically 5 mg to 200 mg of the active ingredient.
[0123] The compounds of the present invention may also be present in combination with other active ingredients, particularly with one or more active ingredients that have shown beneficial effects in the prevention or treatment of viral infections, especially those caused by respiratory syncytial virus (RSV) and human metapneumovirus (HMV). Preferably, the active ingredient composition includes an antiviral active compound; more preferably, the active ingredient is an RSV fusion inhibitor or an RSV polymerase inhibitor.
[0124] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, and the combination of drugs; in addition, the optimal treatment mode, such as the treatment pattern, the daily dosage of the compound of the present invention, or the type of pharmaceutically acceptable salt can be verified based on conventional treatment protocols.
[0125] To achieve the objectives of the compounds of this invention, the following synthetic route is mainly adopted:
[0126] Option 1:
[0127] Step 1: In a suitable solvent, in the presence of a base, a catalyst, and a ligand, formula (I) 1 The compound shown is similar to that of formula (I) 2 The compound shown in the figure can be obtained by nucleophilic substitution, coupling reaction or addition reaction to yield the compound of formula (I). 3 The compound shown in the figure;
[0128] The solvent includes tetrahydrofuran, acetonitrile, dichloromethane, N,N-dimethylformamide, toluene, N-methylpyrrolidone, cyclopentyl methyl ether, or trifluorotoluene; the base includes potassium carbonate, potassium phosphate, sodium carbonate, potassium tert-butoxide, or sodium tert-butoxide; the catalyst is preferably palladium acetate, Pd2(dba)3, Pd(dppf)Cl2, or Pd(PPh3)4; the ligand includes Ad-BippyPhos, triphenylphosphine, BINAP, Xantphos, or Xphos.
[0129] Step 2: In a suitable solvent, under suitable deprotection conditions, formula (I) 3 The compound shown in the figure has J removed. 2 Equation (I) is obtained 4 The compound shown in the figure;
[0130] The solvent includes tetrahydrofuran, dichloromethane, methanol, ethanol, ethyl acetate, and toluene; the base is preferably triethylamine, N,N-diisopropylethylamine, DMAP, or pyridine; the acid is preferably trifluoroacetic acid or hydrochloric acid; and the deprotection conditions are conventional conditions for removing amino protecting groups in the art.
[0131] Step 3: In a suitable solvent, in the presence of a base and a condensing agent, formula (I) 4 The compound shown is similar to that of formula (I) 5 The compound shown in formula (I) was prepared by reacting the compound shown in formula (I).
[0132] The solvents include DMF, THF, acetonitrile, dichloromethane, 1,4-dioxane, or toluene;
[0133] The base includes triethylamine, N,N-diisopropylethylamine, DMAP, pyridine, or N-methylmorpholine;
[0134] The condensing agent includes HATU, EDC, DCC, BOP, PYBOP, or HBTU;
[0135] Option 2:
[0136] Step 1: In a suitable solvent, in the presence of a base, a catalyst, and a ligand, formula (Ia) 1 The compound shown in the figure can be converted to the compound of formula (Ia) by carbonyl insertion reaction. 2 The compound shown in the figure;
[0137] The solvents include tetrahydrofuran, DME, dichloromethane, N,N-dimethylformamide, toluene, N-methylpyrrolidone, DMSO, or acetonitrile;
[0138] The base includes potassium carbonate, potassium phosphate, sodium carbonate, potassium tert-butoxide, sodium tert-butoxide, sodium acetate, potassium acetate, and DMAP; the catalyst is preferably palladium acetate, Pd2(dba)3, Pd(dppf)Cl2, or Pd(PPh3)4; the ligand includes dppf, dppb, triphenylphosphine, Xantphos, or Xphos.
[0139] Step 2: In a suitable solvent, under the conditions of a suitable base (or acid) and water (or anhydrous), formula (Ia) 2 The compound shown in the figure is hydrolyzed to obtain formula (Ia) 3 The compound shown in the figure;
[0140] The solvent includes tetrahydrofuran, methanol, ethanol, and dioxane; the base is preferably lithium hydroxide, sodium hydroxide, potassium hydroxide, or potassium carbonate; and the acid is preferably hydrochloric acid. The ester hydrolysis conditions are conventional hydrolysis conditions in the art.
[0141] Step 3: In a suitable solvent, in the presence of a base and a condensing agent, formula (Ia) 3 The compound shown is similar to the compound of formula (Ia) 4 The compound shown in the figure was reacted to prepare the compound shown in formula (Ia);
[0142] The solvent includes DMF, THF, acetonitrile, dichloromethane, 1,4-dioxane, or toluene; the base includes triethylamine, N,N-diisopropylethylamine, DMAP, pyridine, or N-methylmorpholine; and the condensing agent includes HATU, EDC, DCC, BOP, PYBOP, or HBTU.
[0143] Option 3:
[0144] Step 1: In a suitable solvent, in the presence of a base, a catalyst, and a ligand, formula (Ib) 1 The compound shown in the figure was coupled to obtain the compound of formula (Ib) through a coupling reaction. 2 The compound shown in the figure;
[0145] The solvent includes tetrahydrofuran, dioxane, dichloromethane, N,N-dimethylformamide, toluene, N-methylpyrrolidone, DMSO, acetonitrile; or a mixture of the above solvents and water; the base includes potassium carbonate, potassium phosphate, sodium carbonate, potassium tert-butoxide, sodium tert-butoxide, sodium acetate, potassium acetate, DMAP; the catalyst is preferably palladium acetate, Pd2(dba)3, Pd(dppf)Cl2 or Pd(PPh3)4; the ligand includes RuPhos, SPhos, dppf, triphenylphosphine, Xantphos or Xphos;
[0146] Step 2: In a suitable solvent, under the conditions of a suitable base (or acid) and water (or anhydrous), formula (Ib) 3 The compound shown in the figure is hydrolyzed to obtain the compound of formula (Ib). 4 The compound shown in the figure;
[0147] The solvent includes tetrahydrofuran, methanol, ethanol, and dioxane; the base is preferably lithium hydroxide, sodium hydroxide, potassium hydroxide, or potassium carbonate; the acid is preferably hydrochloric acid; and the ester hydrolysis conditions are conventional hydrolysis conditions in the art.
[0148] Step 3: In a suitable solvent, in the presence of a base and a condensing agent, formula (Ib) 4The compound shown is similar to the compound of formula (Ib) 5 The compound shown in (Ib) was prepared by reacting the compound shown in (Ib).
[0149] The solvent includes DMF, THF, acetonitrile, dichloromethane, 1,4-dioxane, or toluene; the base includes triethylamine, N,N-diisopropylethylamine, DMAP, pyridine, or N-methylmorpholine; the condensing agent includes HATU, EDC, DCC, BOP, PYBOP, or HBTU; Scheme Four:
[0150] Step 1: In a suitable solvent, in the presence of a base and a condensing agent, formula (I) 4 The compound shown is similar to the compound of formula (Ic) 1 The compound shown in the figure was reacted to prepare the compound shown in formula (Ic);
[0151] The solvent includes DMF, THF, acetonitrile, dichloromethane, 1,4-dioxane, or toluene; the base includes triethylamine, N,N-diisopropylethylamine, DMAP, pyridine, or N-methylmorpholine; and the condensing agent includes HATU, EDC, DCC, BOP, PYBOP, or HBTU.
[0152] Among them, J 1 It is -OH or halogen, preferably -OH or -Cl;
[0153] J 2 Amino protecting groups include BOC, Cbz, Fmoc, Pmb, or Bn;
[0154] J 3 It is -OH;
[0155] J 4 Halogens are preferred, especially -Cl, -Br, and -I.
[0156] J 5 -C 1-3 Alkyl groups, preferably methyl or ethyl;
[0157] J 6 It is a -boronic acid group, -borate group, -borate group, or -organotin group, including but not limited to -SnBu3, -SnMe3, -SnPh3, -SnCy3, -B(OH)2, -BF3K,
[0158] R 1 R 2 R 3 R 4 R 5 R 6 R7 R 8 L 1 p, X 1 X 2 X 3 X 4 Each is independent as described in the first aspect of the invention;
[0159] Other synthetic routes for preparing compounds of general formulas (I), (Ia), (Ib), and (Ic) have been described in experimental sections and specific examples as general preparation methods.
[0160] The names of the compounds in this invention were generated by ChemDraw Professional.
[0161] Unless otherwise specified, all raw materials or reagents used in the embodiments of this invention are commercially available. The abbreviations used in this invention have their conventional meanings in the art. For example, the following abbreviations have the following meanings: BOC: tert-butyloxycarbonyl; Cbz: benzyloxycarbonyl; Fmoc: 9-fluorenylmethoxycarbonyl; Pmb: p-methoxybenzyl; Bn: benzyl; Pd2(dba)3: tris(dibenzylideneacetone)palladium; Pd(dppf)Cl2: [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride; dppf: 1,1′-bis(diphenylphosphine)ferrocene; Pd(PPh3)4: tetrakistriphenylphosphine palladium; Ad-BippyPhos: 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1 'H-1,4'-Bipyrazole; BINAP: 1,1'-Binaphthyl-2,2'-bis(diphenylphosphine); Xantphos: 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene; Xphos: 2-Dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl; DMAP: 4-dimethylaminopyridine; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; DIEA: N,N-diisopropylethylamine; ditin: hexaalkylditin compounds, referring to hexabutylditin in this article; 2-(Diphenylphosphino)pyridine: diphenyl-2-pyridinephosphine; Jones Reagent: Jones Reagent (CAS: 65272-70-0); THF: Tetrahydrofuran; HATU: 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-Tetramethylurea hexafluorophosphate; EDC: 1-Ethyl-(3-dimethylaminopropyl)carbodiimide; DCC: N,N'-Dicyclohexylcarbodiimide; BOP: Benzotriazol-1-yloxotri(dimethylamino)phosphine hexafluorophosphate; PYBOP: Benzotriazol-1-yloxotripyrrolidinylphosphine hexafluorophosphate; HBTU: Benzotriazol-1-yloxytetramethylurea hexafluorophosphate; TBAF: Tetrabutylammonium fluoride; DCM: Dichloromethane; acetone: Acetone; TFA: Trifluoroacetic acid; DIPEA: N,N-diisopropylethylamine; CPME: Cyclopentyl methyl ether; DMEM: DMEM medium; FBS: Fetal bovine serum; Penn / Strep: Penicillin-streptomycin solution; PBS: Phosphate buffer; Triten-100: Polyethylene glycol octylphenyl ether; PBST: Phosphate buffer containing Tween 20; Tween20: Polysorbate-20; rpm: Rotations per minute; BSA: Bovine serum albumin; TPCK: Protease inhibitor; RT-qPCR: Reverse transcription quantitative PCR; Flash: Fast column chromatography; Ti(OiPr)4: Tetraisopropyl titanate; con.: Concentrated; t-BuOK: Potassium tert-butoxide; NMP: N-methylpyrrolidone; EC 50 : Half-maximal effective concentration; CC50 : Half-maximal cytotoxic concentration; PEG1000: polyethylene glycol 1000; TFAA: trifluoroacetic anhydride.
[0162] Preparation methods of compounds
[0163] The invention is further illustrated by the following examples, which are illustrative and do not limit the invention in any way. Any modifications or alterations to the invention that are readily achievable by those skilled in the art will fall within the scope of the invention.
[0164] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6 The unit (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard. MS measurements were performed using a liquid chromatography-mass spectrometry system (Agilent Technologies, 1260HPLC and 6120MSD, Excsep, 5μm, 4.6*30mm, ESI+). HPLC measurements were performed using a high-performance liquid chromatograph (SHIMADZU, LC-2030C 3D, Sunfire, 5μm, 4.6*150mm). Column chromatography was generally performed using Flash (Biotage Isolera Prime 3.2).
[0165] The known starting materials of this invention can be synthesized using methods known in the art, or purchased from Shanghai Darui Fine Chemicals Co., Ltd., Shanghai Titan Technology Co., Ltd., Shanghai Runjie Chemical Reagent Co., Ltd., TCI, or Aldrich Chemical Company. Experimental methods not specifically described in the examples are generally performed under conventional conditions or as recommended by the manufacturers of the raw materials or products. Reagents not specifically named are commercially available reagents. Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere. An argon or nitrogen atmosphere refers to a reaction flask connected to an approximately 1L volume argon or nitrogen balloon. Unless otherwise specified in the examples, solutions refer to aqueous solutions. Unless otherwise specified in the examples, the reaction temperature is room temperature, 20-30°C.
[0166] Example 1: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indazol-5-yl) methyl ketone (1)
[0167] Step 1: Preparation of methyl 3-bromo-5-fluoro-4-nitrobenzoate (1a)
[0168] 50% hydrogen peroxide (150 mL) was dissolved in dichloromethane (300 mL), and trifluoroacetic anhydride (155.76 g, 0.741 mol) was added at 0 °C. After slowly raising the temperature to room temperature, methyl 4-amino-3-bromo-5-fluorobenzoate (23.0 g, 92.7 mmol) was dissolved in dichloromethane (100 mL) and added. The mixture was stirred at 45 °C for 1 hour. The temperature was lowered to 0 °C, quenched with saturated sodium thiosulfate aqueous solution (300 mL), and extracted with dichloromethane (200 mL * 2). The organic phases were combined, washed with water and brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give compound 1a (25 g).
[0169] 1 H NMR (400MHz, DMSO-d6) δ: 8.20 (s, 1H), 8.13 (dd, J = 1.2Hz, 9.6Hz, 1H), 3.93 (s, 3H).
[0170] Step 2: Preparation of methyl 3-bromo-5-methoxy-4-nitrobenzoate (1b)
[0171] Compound 1a (26.5 g, 95.3 mmol) and sodium methoxide methanol solution (25.74 g, 142.9 mmol, w / w = 30%) were dissolved in methanol (200 mL) and reacted at 25 °C for 16 hours. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give compound 1b (17 g).
[0172] 1 H NMR(400MHz, DMSO-d6)δ:7.87(s,1H),7.77(s,1H),4.00(s,3H),3.91(s,3H).
[0173] Step 3: Preparation of methyl 3-methoxy-4-nitro-5-vinylbenzoate (1c)
[0174] Compound 1b (15.0 g, 51.7 mmol), potassium ethylenetrifluoroborate (10.39 g, 77.5 mmol), cesium carbonate (50.53 g, 155.1 mmol), and 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride (3.78 g, 5.17 mmol) were added to DMF (150 mL), and the mixture was reacted at 85 °C under nitrogen for 16 hours. Water (200 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with water (200 mL) and brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) yielded compound 1c (7.5 g).
[0175] LCMS(ESI+): m / z = 238.2[M+H] +
[0176] Step 4: Preparation of methyl 3-aldehyde-5-methoxy-4-nitrobenzoate (1d)
[0177] Compound 1c (7.0 g, 29.5 mmol) and potassium osmium tetroxide dihydrate (0.54 g, 1.47 mmol) were added to tetrahydrofuran (70 mL) and water (15 mL). Sodium periodate (18.93 g, 88.5 mmol) was slowly added at 0 °C, and the mixture was heated to 25 °C and reacted for 3 hours. The mixture was then poured into ice water (100 mL), and the aqueous phase was extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 1d (7.0 g).
[0178] 1 H NMR(400MHz, DMSO-d6)δ:10.00(s,1H),8.26(s,1H),8.07(s,1H),4.03(s,3H),3.96(s,3H).
[0179] Step 5: Preparation of methyl 3-((cyclopropylamino)methyl)-5-methoxy-4-nitrobenzoate (1e)
[0180] Compound 1d (7 g, 0.029 mol) and cyclopropane (5.02 g, 0.087 mol) were dissolved in dichloromethane (140 mL). After stirring at 25 °C for 3 hours, sodium cyanoborohydride (5.52 g, 0.087 mol), methanol (140 mL), and acetic acid (10.56 g, 0.175 mol) were added. The reaction was carried out at 25 °C for 3 hours. The mixture was concentrated under reduced pressure, dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate solution (150 mL), and the organic phase was washed with brine (100 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1e (8.0 g).
[0181] LCMS(ESI+): m / z = 302.9[M+Na] +
[0182] 1 H NMR(400MHz,DMSO-d6)δ:7.77(s,1H),7.64(s,1H),4.03-4.01(m,1H),3.94(s,3H), 3.90(s,3H),3.75(s,2H),0.71–0.64(m,1H),0.31–0.29(m,2H),0.17–0.16(m,2H).
[0183] Step 6: Preparation of 2-cyclopropyl-7-methoxy-2H-indazole-5-carboxylic acid (1f)
[0184] Compound 1e (9.5 g, 33.9 mmol) was dissolved in 1,4-dioxane (190 mL), and activated zinc powder (8.87 g, 135.6 mol) was added. The mixture was stirred at room temperature for 1 hour, and then sodium hydroxide aqueous solution (13.56 g, 0.339 mol, 190 mL) was added. The reaction was carried out at 25 °C for 6 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The pH was adjusted to 2 with 3.0 M HCl, and the mixture was extracted with ethyl acetate (100 mL * 2). The organic phases were combined. The organic phase was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to give compound 1f (1.8 g).
[0185] LCMS(ESI+): m / z = 233.2[M+H] +
[0186] 1 H NMR(400MHz, DMSO)δ:12.67(s,1H),8.63(s,1H),7.99(s,1H),7.04(s,1H),4.17–4.14(m,1H),3.93(s,3H),1.28–1.13(m,2H),1.12–1.10(m,2H).
[0187] Step 7: Preparation of 2-chloro-3-methylisonicotinonitrile (1 h)
[0188] 1 g (10 g, 39.51 mmol) of 2-chloro-4-iodo-3-methylpyridine and 7.03 g (79.20 mmol) of cuprous cyanide were dissolved in DMF (100 mL), and the mixture was purged with nitrogen three times and reacted at 100 °C for 16 hours. Water (300 mL) was added, and the mixture was extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1) to give compound 1 h (3.0 g).
[0189] LCMS(ESI+): m / z = 153.0 [M+H] +
[0190] 1 H NMR (400MHz, CDCl3) δ: 8.40 (d, J = 4.9 Hz, 1H), 7.44 (d, J = 4.9 Hz, 1H), 2.63 (s, 3H).
[0191] Step 8: Preparation of 2-(4-fluorophenyl)-3-methylisonicotinamide (1i)
[0192] Compound 1h (4 g, 26.21 mmol), 4-fluorophenylboronic acid (4.4 g, 31.41 mmol), potassium carbonate (10.86 g, 78.62 mmol), and tetrakis(triphenylphosphine)palladium (1.92 g, 2.62 mmol) were dissolved in dioxane:water (10:1, 30 mL + 3 mL), and the reaction was carried out at 100 °C under nitrogen for 16 hours. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was achieved by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1) to give compound 1i (5.0 g).
[0193] LCMS(ESI+): m / z = 213.1[M+H] +
[0194] 1 H NMR (400MHz, CDCl3) δ: 8.66 (d, J = 4.9 Hz, 1H), 7.62–7.39 (m, 3H), 7.18 (t, J = 8.6 Hz, 2H), 2.57 (s, 3H).
[0195] Step 9: Preparation of 1-oxide of 4-cyano-2-(4-fluorophenyl)-3-methylpyridine (1j)
[0196] Compound 1i (5.0 g, 23.6 mmol) and m-chloroperoxybenzoic acid (7.19 g, 35.4 mmol) were dissolved in dichloromethane (100 mL) and reacted at 40 °C for 16 hours. The reaction was quenched with saturated sodium bicarbonate aqueous solution (100 mL), extracted with dichloromethane (100 mL * 2), and the organic phases were combined. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and pulped and filtered with methyl tert-butyl ether (10 mL) to give compound 1j (4.0 g).
[0197] LCMS(ESI+): m / z = 229.1 [M+H] +
[0198] 1 H NMR (400MHz, CDCl3) δ: 8.23 (d, J = 6.8Hz, 1H), 7.47 (d, J = 6.8Hz, 1H), 7.31 (dd, J = 8.6, 5.4Hz, 2H), 7.23 (d, J = 8.7Hz, 2H), 2.32 (s, 3H).
[0199] Step 10: Preparation of 6-chloro-2-(4-fluorophenyl)-3-methylisonicotinonitrile (1k)
[0200] Compound 1j (4.0 g, 17.51 mmol) was added to toluene (100 mL), and phosphorus oxychloride (13.5 g, 87.51 mmol) was slowly added at 25 °C. The reaction was carried out at 100 °C for 2 hours under nitrogen. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give compound 1k (4.0 g).
[0201] LCMS(ESI+): m / z = 247.0 [M+H] +
[0202] 1 H NMR (400MHz, CDCl3) δ: 7.60–7.40 (m, 3H), 7.18 (t, J = 8.6Hz, 2H), 2.54 (s, 3H).
[0203] Step 11: Preparation of 2-(6-chloro-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propylamino-2-amine (1l)
[0204] Compound 1k (2.0 g, 8.1 mmol) was dissolved in tetrahydrofuran (20 mL). The temperature was lowered to -10 °C under nitrogen, and a tetrahydrofuran solution of methyl magnesium bromide (3.0 M, 8.1 mL, 24.31 mmol) was slowly added dropwise. After the addition was complete, the reaction was allowed to proceed for 1 hour. Then, tetraisopropyl titanate (2.3 g, 8.11 mmol) was slowly added dropwise to the temperature of 0 °C, and the reaction was allowed to proceed to 50 °C for 4 hours. The mixture was then poured into a saturated sodium carbonate aqueous solution (50 mL), filtered, and the filter cake was washed with ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was achieved by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 1l (600 mg).
[0205] LCMS(ESI+): m / z = 279.1 [M+H] +
[0206] 1 H NMR(400MHz, CDCl3)δ:7.62(s,1H),7.44–7.40(m,2H),7.21–7.17(m,2H),2.40(s,3H),1.59(s,6H).
[0207] Step 12: Preparation of benzyl (2-(6-chloro-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propane-2-yl)carbamate (1m)
[0208] Compound 1L (600 mg, 2.15 mmol) was dissolved in tetrahydrofuran (10 mL) and water (5.0 mL), sodium bicarbonate (542 mg, 6.46 mmol) was added, and the mixture was cooled to 0 °C. Benzyl chloroformate (551 mg, 3.23 mmol) was then added dropwise. After the addition was complete, the mixture was heated to 25 °C and reacted for 16 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (50 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give compound 1M (1.0 g).
[0209] LCMS(ESI+): m / z = 413.2[M+H] +
[0210] 1 H NMR (400MHz, CDCl3) δ: 7.36–7.26 (m, 7H), 7.08 (t, J = 8.6Hz, 2H), 5.12 (s, 1H), 5.02 (s, 2H), 2.22 (s, 3H), 1.72 (s, 6H).
[0211] Step 13: Preparation of tert-butyl(1R,5S,6S)-6-((4-(2-(((benzyloxy)carboxyl)amino)propane-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (1n)
[0212] Compound 1m (500 mg, 1.21 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (243 mg, 1.21 mmol), and anhydrous potassium phosphate (771 mg, 3.63 mmol) were dissolved in cyclopentyl methyl ether (5.0 mL) and trifluorotoluene (5.0 mL). 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (161 mg, 0.242 mmol) and tris(dibenzylideneacetone)dipalladium (111 mg, 0.121 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 3 / 1) to give compound 1n (250 mg).
[0213] LCMS(ESI+): m / z = 576.0 [M+H] +
[0214] 1 H NMR (400MHz, CDCl3) δ: 7.34 (br.s, 7H), 7.08 (t, J = 8.7Hz, 3H), 5.03 (s, 2H), 3.81 (s, 1H), 3.68 (d, J = 10.6Hz ,1H),3.58(d,J=10.7Hz,1H),3.46(d,J=11.2Hz,2H),2.23(s,3H),1.79(s,2H),1.72(s,6H),1.44(s,9H).
[0215] Step 14: Preparation of benzyl (2-(6-(((1R,5S,6S)-3-azatricyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (1o)
[0216] Compound 1n (250 mg, 0.43 mmol) was dissolved in dichloromethane (3.0 mL), and trifluoroacetic acid (1.0 mL) was added. The mixture was reacted at 25 °C for 2 hours. The solution was concentrated under reduced pressure, dissolved in dichloromethane (10 mL), washed with saturated sodium bicarbonate aqueous solution and saturated saline solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1o (150 mg).
[0217] LCMS(ESI+): m / z = 476.1 [M+H] +
[0218] 1 H NMR(400MHz, CDCl3)δ:7.34(br.s,7H),7.14–7.01(m,3H),6.79(s,1H),5.03(s,2H),4.04(s ,1H),3.36(d,J=11.5Hz,2H),3.25(d,J=10.6Hz,2H),2.22(s,3H),1.79(s,2H),1.72(s,6H).
[0219] Step 15: Preparation of benzyl(2-(6-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propionic acid-2-yl)carbamate (1p)
[0220] Compound 1o (150 mg, 0.31 mmol), compound 1g (73 mg, 0.31 mmol), and N,N-diisopropylethylamine (122 mg, 0.94 mmol) were dissolved in dichloromethane (5.0 mL), and HATU (180 mg, 0.47 mmol) was added. The reaction was carried out at 25 °C for 16 hours. Water (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to give compound 1p (230 mg).
[0221] LCMS(ESI+): m / z = 345.8 [M / 2 + H] +
[0222] 1 H NMR(400MHz, CDCl3)δ:8.47(s,1H),7.93(s,1H),7.43–7.28(m,8H),7.17(t,J=8.8Hz,2H),6.72(s,1H),6.61(s,1H),4.94(s,2H),4.17–4.10( m,1H),4.06–3.97(m,1H),3.93(s,1H),3.86(s,3H),3.79(s,1H),3.18– 3.05(m,2H),2.14(s,3H),1.93(s,2H),1.57(s,6H),1.16–1.07(m,4H).
[0223] Step 16: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indazol-5-yl) methyl ketone (1)
[0224] Compound 1p (100 mg, 0.15 mmol) was suspended in concentrated hydrochloric acid (5.0 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7-8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 15 / 1) to give compound 1 (12 mg).
[0225] LCMS(ESI+): m / z = 556.3 [M+H] +
[0226] 1 H NMR(400MHz, CDCl3)δ:8.31(s,1H),7.43–7.39(m,2H),7.36(s,1H),7.09(t ,J=8.8Hz,2H),7.02(s,1H),6.68(s,1H),4.20(d,J=12.1Hz,1H),4.05–4.00 (m,1H),3.96(s,3H),3.83(s,1H),3.81–3.56(m,3H),2.36(s,3H),2.01(br .s,1H),1.93(br.s,1H),1.59(s,6H),1.34–1.29(m,2H),1.21–1.16(m,2H).
[0227] Example 2: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(difluoromethyl)-7-methoxy-2H-indole-5-yl)methyl ketone (2)
[0228] Step 1: Preparation of 5-bromo-2-(difluoromethyl)-7-methoxy-2H-indazole (2a)
[0229] 5-Bromo-7-methoxy-2H-indazole (1.0 g, 4.43 mmol) and potassium carbonate (1.2 g, 8.85 mmol) were dissolved in ethyl acetate (20 mL), and 2,2-difluoro-2-(fluorosulfonyl)acetic acid (946 mg, 5.31 mmol) was added dropwise. The mixture was stirred at 25 °C for 15 hours. The solution was quenched with saturated sodium bicarbonate solution and extracted with ethyl acetate (30 mL * 2). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1-5 / 1) to give compound 2a (800 mg).
[0230] LCMS(ESI+):m / z=277.0 / 279.2[M+H] +
[0231] 1 H NMR (400MHz, CDCl3-d) δ: 8.26 (s, 1H), 7.64-7.30 (m, 2H), 6.68 (d, J = 1.2Hz, 1H), 4.03 (s, 3H).
[0232] Step 2: Preparation of ethyl 2-(difluoromethyl)-7-methoxy-2H-indazole-5-carboxylic acid ester (2b)
[0233] Compound 2a (800 mg, 2.90 mmol), sodium acetate (452 mg, 5.5 mmol), 1,1'-bis(diphenylphosphine)ferrocene (161 mg, 0.29 mmol), and palladium acetate (33 mg, 0.14 mmol) were dissolved in anhydrous ethanol (16 mL) and stirred at 80 °C for 15 hours under carbon monoxide. The solution was evaporated to dryness, diluted with water, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1-3 / 1) yielded compound 2b (590 mg).
[0234] LCMS(ESI+): m / z = 271.2[M+H] +
[0235] 1 H NMR (400MHz, CDCl3-d) δ: 8.46 (s, 1H), 8.14 (d, J = 0.8Hz, 1H), 7.49 (t, J = 60.4H z,1H),7.22(s,1H),4.41(q,J=8.0Hz,2H),4.09(s,3H),1.43(t,J=8.0Hz,3H).
[0236] Step 3: Preparation of 2-(difluoromethyl)-7-methoxy-2H-indazole-5-carboxylic acid (2c)
[0237] Compound 2b (500 mg, 1.85 mmol) and lithium hydroxide (443 mg, 18.5 mmol) were dissolved in tetrahydrofuran (10 mL) and water (2 mL), and reacted at 45 °C for 15 hours. The pH was adjusted to 3 with 1 N hydrochloric acid, filtered, and the filter cake was dried under reduced pressure to give compound 2c (400 mg).
[0238] LCMS(ESI+): m / z = 243.0 [M+H] +
[0239] Step 4: Preparation of benzyl (2-(6-(((1R,5S,6S)-3-(2-(difluoromethyl)-7-methoxy-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)isopropyl)carbamate (2d)
[0240] Compound 2c (18 mg, 0.076 mmol), compound 1o (30 mg, 0.063 mmol), HATU (36 mg, 0.095 mmol), and N,N-diisopropylethylamine (24 mg, 0.19 mmol) were dissolved in N,N-dimethylformamide (16 mL) and reacted at 25 °C for 3 h. The reaction was quenched with water and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (eluent: dichloromethane / methanol = 15 / 1) yielded compound 2d (27 mg).
[0241] LCMS(ESI+): m / z = 700.2[M+H] +
[0242] 1 H NMR (400MHz, CDCl3-d) δ: 8.35 (s, 1H), 7.49 (t, J = 60.4Hz, 1H), 7.38-7.30 (m, 7H), 7.07-7.00 (m, 2H), 6.77 (s, 1H), 6.66 (s, 1H), 5.12 (s,1H),5.02(s,2H),4.25-4.15(m,1H),4.01(s,3H),3.91(s,1H),3.75-3.65(m,3H),2.22(s,3H),2.00-1.88(m,2H),1.71(s,6H).
[0243] Step 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminoisopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(difluoromethyl)-7-methoxy-2H-indazol-5-yl)methyl ketone (2)
[0244] Compound 2d (40 mg, 0.06 mmol) was dissolved in concentrated hydrochloric acid (1 mL) and stirred at 80 °C for 0.5 h. The pH was adjusted to 9 with sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 2 (21.4 mg) was purified by Prep-TLC (evolving solvent: dichloromethane / methanol = 10 / 1) to obtain compound 2.
[0245] LCMS(ESI+): m / z = 566.3 [M+H] +
[0246] 1 H NMR(400MHz, DMSO-d6)δ:8.90(s,1H),8.14(t,J=58.8Hz,1H),7.54-7.47(m,2H),7.45(d,J=0.8Hz,1H),7.23-7.16(m,2H),7.00(s,1H),6.74 (d,J=0.8Hz,1H),4.03-3.98(m,1H),3.91(s,3H),3.81(s,1H),3.78-3 .70(m,1H),3.62-3.50(m,2H),2.42(s,3H),1.94(s,2H),1.47(s,6H).
[0247] Example 3: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (3)
[0248] Step 1: Preparation of 5-bromo-7-methoxy-2-methyl-2H-indazole (3a)
[0249] 5-Bromo-7-methoxy-2H-indazole (2.0 g, 8.85 mmol) was dissolved in ethyl acetate (20 mL), and trimethyloxonium tetrafluoroboric acid (1.3 g, 8.85 mmol) was added. The mixture was stirred at 25 °C for 15 hours. The solution was quenched with saturated sodium bicarbonate solution and extracted with ethyl acetate (60 mL * 2). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1-5 / 1) gave compound 3a (1.8 g).
[0250] LCMS(ESI+):m / z=241.1 / 243.0[M+H] +
[0251] 1 H NMR (400MHz, CDCl3-d) δ: 7.79 (s, 1H), 7.37 (d, J = 1.6Hz, 1H), 6.63 (d, J = 1.2Hz, 1H), 4.20 (s, 3H), 4.00 (s, 3H).
[0252] Step 2: Preparation of ethyl 7-methoxy-2-methyl-2H-indazole-5-carboxylic acid ester (3b)
[0253] Compound 3a (1.8 g, 7.5 mmol), sodium acetate (1.2 g, 14.3 mmol), 1,1'-bis(diphenylphosphine)ferrocene (416 mg, 0.75 mmol), and palladium acetate (84 mg, 0.38 mmol) were dissolved in anhydrous ethanol (36 mL) and stirred at 80 °C for 15 hours under carbon monoxide. The solution was evaporated to dryness, diluted with water, and extracted with ethyl acetate (60 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1-3 / 1) yielded compound 3b (1.3 g).
[0254] LCMS(ESI+): m / z = 235.2[M+H] +
[0255] 1 H NMR(400MHz, CDCl3-d)δ:8.09(d,J=1.2Hz,1H),7.99(s,1H),7.18(d,J=1.2Hz ,1H),4.40(q,J=7.2Hz,2H),4.24(s,3H),4.07(s,3H),1.42(t,J=7.2Hz,3H).
[0256] Step 3: Preparation of 7-methoxy-2-methyl-2H-indolezol-5-carboxylic acid (3c)
[0257] Compound 3b (500 mg, 2.14 mmol) and lithium hydroxide (511 mg, 21.4 mmol) were dissolved in tetrahydrofuran (10 mL) and water (2 mL), and reacted at 45 °C for 15 hours. The pH was adjusted to 3 with 1 N hydrochloric acid, filtered, and the filter cake was dried under reduced pressure to give compound 3c (370 mg).
[0258] LCMS(ESI+): m / z = 207.1 [M+H] +
[0259] Step 4: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-methoxy-2-methyl-2H-indolezol-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (3d)
[0260] Compound 3c (16 mg, 0.076 mmol), compound 1o (30 mg, 0.063 mmol), HATU (36 mg, 0.095 mmol), and N,N-diisopropylethylamine (24 mg, 0.19 mmol) were dissolved in N,N-dimethylformamide (16 mL) and reacted at 25 °C for 3 h. The reaction was quenched with water and extracted with ethyl acetate (30 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (eluent: dichloromethane / methanol = 15 / 1) yielded compound 3 (24 mg).
[0261] LCMS(ESI+): m / z = 664.2[M+H] +
[0262] 1 H NMR(400MHz, CDCl3-d)δ:7.87(s,1H),7.40-7.28(m,7H),7.06-6.98(m,2H),6.90-6.65(m,2H),6.62(s,1H),5.13(s,1H),5.02(s ,2H),4.24(s,3H),4.23-4.15(m,1H),3.99(s,3H),3.90(s,1H),3.81-3.62(m,3H),2.22(s,3H),2.00-1.85(m,2H),1.71(s,6H).
[0263] Step 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (3)
[0264] Compound 3d (40 mg, 0.06 mmol) was dissolved in concentrated hydrochloric acid (1 mL) and stirred at 80 °C for 0.5 h. The pH was adjusted to 9 with sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (eluent: dichloromethane / methanol = 10 / 1) yielded compound 3 (12.6 mg).
[0265] LCMS(ESI+): m / z = 530.3 [M+H] +
[0266] 1 H NMR(400MHz, DMSO-d6)δ:8.34(s,1H),7.49(dd,J=8.4,5.6Hz,2H),7.37(s,1H),7.19(t,J=8.8Hz,2H),7.00(s,1H),6.62(s,1 H),4.16(s,3H),4.07-3.96(m,1H),3.87(s,3H),3.82-3.71(m,2H),3.64-3.50(m,2H),2.42(s,3H),1.92(s,2H),1.47(s,6H).
[0267] Example 4: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(1-fluorocyclopropyl)-7-methoxy-2H-indazol-5-yl) methyl ketone (4)
[0268] The preparation of compound 4 is described in Example 1.
[0269] LCMS(ESI+): m / z = 574.2 [M+H] +
[0270] Example 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-(methoxy-d3)-2H-indazol-5-yl) methyl ketone (5)
[0271] Compound 5 was prepared according to Examples 1 and 23.
[0272] LCMS(ESI+): m / z = 559.2 [M+H] +
[0273] Example 6: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-(methyl-d3)-2H-indazol-5-yl) methyl ketone (6)
[0274] Step 1: Preparation of methyl 3-methoxy-5-(((methyl-d3)amino)methyl)-4-nitrobenzoate (6a)
[0275] Compound 1d (2.0 g, 8.36 mmol), deuterated methylamine hydrochloride (1.77 g, 25.1 mmol), and sodium acetate (3.43 g, 41.8 mmol) were added to methanol (20 mL) and stirred at 25 °C for 2 hours. The mixture was quenched with water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and dissolved in methanol (20 mL). Sodium cyanoborohydride (739 mg, 11.8 mmol) was added, and the mixture was stirred at 25 °C for half an hour. The solution was poured into water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 6a (0.700 g).
[0276] LCMS(ESI+): m / z = 258.1 [M+H] +
[0277] Step 2: Preparation of 7-methoxy-2-(methyl-d3)-2H-indazole-5-carboxylic acid (6b)
[0278] Compound 6a (640 mg, 2.49 mmol) and zinc powder (647 mg, 9.95 mmol) were added to dioxane (23.5 mL), and the mixture was cooled to 0 °C. Sodium hydroxide aqueous solution (1.07 M, 23.25 mL) was added dropwise. After addition, the mixture was stirred at 25 °C for 16 hours. The pH was adjusted to 2 with 2N hydrochloric acid, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 6b (300 mg).
[0279] LCMS(ESI+): m / z = 210.1[M+H] +
[0280] Step 3: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-methoxy-2-(methyl-d3)-2H-indazole-5-formyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (6c)
[0281] Compound 6b (65 mg, 0.31 mmol) was added to DMF (3 mL), followed by DIEA (120 mg, 0.93 mmol), HATU (7.2 mg, 0.46 mmol), and compound 1o (148 mg, 0.31 mmol). The mixture was stirred at 25 °C for 2 h, then water (5 mL) was added. The mixture was extracted with ethyl acetate, washed with brine, and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. Thin-layer chromatography was used to purify compound 6c (98.00 mg).
[0282] LCMS(ESI+): m / z = 667.3 [M+H] +
[0283] Step 4: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-(methyl-d3)-2H-indazol-5-yl)methyl ketone (6)
[0284] Concentrated hydrochloric acid (2 mL) was added to compound 6c (98 mg, 0.15 mmol), stirred at 80 °C for 0.5 h, ice water was added, ethyl acetate was used for extraction, brine was washed, the organic phases were combined, dried over anhydrous sodium sulfate and filtered, the filtrate was concentrated under reduced pressure and purified by pre-chromatographic chromatography under high pressure to obtain compound 6 (26.97 mg).
[0285] LCMS(ESI+): m / z = 533.1 [M+H] +
[0286] 1H NMR(400MHz, DMSO-d6)δ:8.34(s,1H),7.55-7.46(m,2H),7.37(s,1H),7.20(t,J=8.9Hz,2H),6.98(s,1H),6.62(s,1H ),4.06-3.98(m,1H),3.90-3.85(m,3H),3.82-3.74(m,2H),3.64-3.53(m,2H),2.41(s,3H),1.93(s,2H),1.49(s,6H).
[0287] Example 7: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-cyclopropoxy-2-methyl-2H-indole-5-yl) methyl ketone (7)
[0288] Step 1: Preparation of 7-hydroxy-2-methyl-2H-indolezol-5-carboxylic acid (7a)
[0289] Compound 3b (100 mg, 0.43 mmol) was dissolved in dichloromethane (0.5 mL), and boron tribromide (1.5 mL) was added at 0 °C. The reaction was carried out at 25 °C for 16 hours. Five batches were processed simultaneously. The reaction was quenched by adding methanol (15 mL) at 0 °C, and the mixture was concentrated under reduced pressure to give compound 7a (500 mg), which was used directly in the next step of the reaction.
[0290] LCMS(ESI+): m / z = 193.1 [M+H] +
[0291] Step 2: Preparation of methyl 7-hydroxy-2-methyl-2H-indazole-5-carboxylic acid ester (7b)
[0292] Compound 7a (500 mg) was dissolved in methanol (2 mL), and concentrated sulfuric acid (0.2 mL) was added at 0 °C. The reaction was carried out at 68 °C for 8 hours. The reaction was quenched by adding sodium bicarbonate aqueous solution (20 mL) at 0 °C, and extracted with dichloromethane (30 mL * 3). The organic phases were combined, washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 3 / 1) to obtain compound 7b (350 mg).
[0293] LCMS(ESI+): m / z = 207.1 [M+H] +
[0294] 1H NMR (400MHz, CDCl3-d) δ: 8.06 (d, J = 1.2 Hz, 1H), 8.03 (s, 1H), 7.88 (s, 1H), 7.35 (d, J = 1.2 Hz, 1H), 4.27 (s, 3H), 3.92 (s, 3H).
[0295] Step 3: Preparation of methyl 7-cyclopropoxy-2-methyl-2H-indazole-5-carboxylic acid ester (7c)
[0296] Compound 7b (50 mg, 0.24 mmol), cyclopropylboronic acid (63 mg, 0.73 mmol), and cesium carbonate (237 mg, 0.73 mmol) were dissolved in 1,2-dichloroethane (1 mL), and copper acetate (132 mg, 0.73 mmol) and 1,10-phenanthroline (87 mg, 0.50 mmol) were added. The reaction was carried out at 70 °C for 16 hours under nitrogen. Five batches were processed simultaneously. The filtrate was filtered, concentrated under reduced pressure, and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 1 / 1) to give compound 7c (100 mg).
[0297] LCMS(ESI+): m / z = 247.1 [M+H] +
[0298] Step 4: Preparation of 7-cyclopropoxy-2-methyl-2H-indazole-5-carboxylic acid (7d)
[0299] Compound 7c (100 mg, 0.41 mmol) was dissolved in a methanol / water mixture (1:1, 2 mL), and solid lithium hydroxide (97 mg, 4.06 mmol) was added at 0 °C. The reaction was carried out at 25 °C for 3 hours. Methanol was removed by vacuum concentration, and the mixture was washed twice with methyl tert-butyl ether (1 mL * 2) in the aqueous phase. The pH was adjusted to 5 with hydrochloric acid (1 N), and the mixture was extracted with a dichloromethane / methanol mixture (10:1, 20 mL * 3). The organic phase was concentrated under vacuum, and the mixture was purified by high pressure to obtain compound 7d (30 mg).
[0300] LCMS(ESI+): m / z = 233.1 [M+H] +
[0301] 8.33(s,1H),8.12(d,J=1.2Hz,1H),7.55(d,J=0.8Hz,1H),4.20(s,3H),4.05-3.99(m,1H),0.91-0.88(m,2H),0.86-0.84(m,2H).
[0302] Step 5: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-methoxy-2-methyl-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (7e)
[0303] Compound 7d (30 mg, 0.13 mmol), N,N-diisopropylethylamine (42 mg, 0.32 mmol), and HATU (74 mg, 0.20 mmol) were dissolved in dichloromethane (5 mL). The mixture was stirred at 0 °C under nitrogen for 2 hours. Compound 1o (31 mg, 0.07 mmol) was added, and the mixture was stirred for 16 hours. Water (10 mL) was added, and the mixture was extracted with dichloromethane / methanol (10:1, 20 mL * 3). The organic phases were combined, washed with water and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 7e (60 mg) was purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 1 / 2).
[0304] LCMS(ESI+): m / z = 690.3[M+H] +
[0305] Step 6: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-cyclopropoxy-2-methyl-2H-indole-5-yl) methyl ketone (7)
[0306] Compound 7e (50 mg, 0.07 mmol) was dissolved in concentrated hydrochloric acid (0.1 mL) and stirred at 30 °C for 2 hours under nitrogen. Saturated sodium bicarbonate (20 mL) was added, followed by extraction with a dichloromethane / methanol mixture (10:1, 20 mL x 5). The organic phases were combined, washed with water and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 7 (10 mg) was purified by preparative chromatography under high pressure.
[0307] LCMS(ESI+): m / z = 556.3 [M+H] +
[0308] 1H NMR(400MHz,CD3OD-d4)δ:8.22(s,1H),7.49–7.42(m,2H),7.39(d,J=1.2Hz ,1H),7.09(t,J=8.8Hz,2H),7.00(d,J=1.2Hz,1H),6.67(s,1H),4.20(s,4H ),3.97–3.91(m,1H),3.86–3.83(m,2H),3.74–3.72(m,1H),3.66–3.63(m,1 H),2.36(s,3H),2.02(s,1H),1.94–1.92(m,1H),1.81(s,6H),0.80(s,4H).
[0309] Example 8: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-6,7-dihydro-2H-furan[3,2-g]indazole-5-yl)formyl (8)
[0310] The preparation of compound 8 is described in Example 1.
[0311] LCMS(ESI+): m / z = 568.2 [M+H] +
[0312] Example 9: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-8-methoxyimidazol[1,2-a]pyridin-6-yl) methyl ketone (9)
[0313] Step 1: Preparation of 6-bromo-2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridine (9a)
[0314] 5-Bromo-3-methoxypyridine-2-amine (1 g, 4.9 mmol) and 2-bromo-1-cyclopropyl ethyl ketone (0.96 g, 5.88 mmol) were added to EtOH (10 mL) and reacted at 80 °C for 16 h. The mixture was evaporated to dryness and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1-1 / 1) to give compound 9a (700 mg).
[0315] LCMS(ESI+):m / z=267.0 / 269.0[M+H] +
[0316] Step 2: Preparation of ethyl 2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridine-6-carboxylic acid ester (9b)
[0317] Compound 9a (700 mg, 2.62 mmol), sodium acetate (408.1 mg, 4.97 mmol), 1,1'-bis(diphenylphosphine)ferrocene (145.4 mg, 0.26 mmol), and palladium acetate (29.8 mg, 0.126 mmol) were dissolved in anhydrous ethanol (10 mL) and stirred at 80 °C for 16 hours. The solution was evaporated to dryness, diluted with water, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1-3 / 1) yielded compound 9b (100 mg).
[0318] LCMS(ESI+): m / z = 261.1[M+H] +
[0319] 1 H NMR (400MHz, DMSO-d6) δ: 8.46 (d, J=1.2Hz, 1H), 7.37 (s, 1H), 6.96 (s, 1H), 4.40 (q, J= 7.1Hz,2H),4.04(s,3H),2.09-2.00(m,1H),1.41(t,J=7.2Hz,3H),1.03-0.94(m,4H).
[0320] Step 3: Preparation of 2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridine-6-carboxylic acid (9c)
[0321] Compound 9b (100 mg, 0.38 mmol) and lithium hydroxide monohydrate (161.3 mg, 3.84 mmol) were dissolved in methanol (5 mL) and water (1 mL), and reacted at 25 °C for 16 hours. The pH was adjusted to 5 with 1 N hydrochloric acid, filtered, and the filter cake was dried under reduced pressure to give compound 9c (80 mg).
[0322] LCMS(ESI+): m / z = 233.1 [M+H] +
[0323] 1 H NMR(400MHz, DMSO-d6)δ:8.86(s,1H),7.97(s,1H),7.13(s,1H),3.75(s,3H),2.10(s,1H),1.30-1.20(m,2H),1.15-1.10(m,2H).
[0324] Step 4: Preparation of benzyl (2-(6-(((1R,5S,6S)-3-(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridine-6-carboxyl)-3-azatricyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)isopropyl)carbamate (9d)
[0325] Compound 9c (80.0 mg, 0.34 mmol) was added to DMF (3 mL), followed by the addition of compound 1o (163.8 mg, 0.34 mmol), HATU (196.5 mg, 0.52 mmol), and DIEA (133.6 mg, 1.03 mmol) at 25 °C. The reaction was carried out at 25 °C for 16 hours. The reaction was quenched with ice water (10 mL), extracted with ethyl acetate (10 mL x 3), and the organic phases were combined. The organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 9d (30.0 mg).
[0326] LCMS(ESI+): m / z = 690.3[M+H] +
[0327] Step 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-8-methoxyimidazol[1,2-a]pyridin-6-yl) methyl ketone (9)
[0328] Compound 9d (30.0 mg, 0.042 mmol) was dissolved in concentrated hydrochloric acid (1 mL) and reacted at 80 °C for 0.5 h. The solution was then poured into a saturated sodium carbonate aqueous solution (10 mL), and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 9 (10.0 mg) was purified by silica gel plate preparation (eluent: dichloromethane / methanol = 10 / 1).
[0329] LCMS(ESI+): m / z = 556.3 [M+H] +
[0330] 1H NMR(400MHz, CD3OD-d4)δ:8.16(d,J=1.2Hz,1H),7.55(s,1H),7.44-7.40(m,2H),7.12(t,J=8.8Hz,2H),7.01(s,1H),6.69(d,J=0.8Hz,1H),4.17-4 .16(m,1H),3.97(s,3H),3.86-3.82(m,3H),3.68-3.67(m,1H),2.36(s,3 H),2.04-1.99(m,3H),1.60(s,6H),1.00-0.95(m,2H),0.90-0.85(m,2H).
[0331] Example 10: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(difluoromethyl)-8-methoxyimidazol[1,2-a]pyridin-6-yl) methyl ketone (10)
[0332] The preparation of compound 10 is described in Example 1.
[0333] LCMS(ESI+): m / z = 566.2 [M+H] +
[0334] Example 11: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-methoxy-2-methylimidazol[1,2-a]pyridin-6-yl) methyl ketone (11)
[0335] The preparation of compound 11 is described in Example 1.
[0336] LCMS(ESI+): m / z = 530.2[M+H] +
[0337] Example 12: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxypyrazole[1,5-a]pyridin-5-yl) methyl ketone (12)
[0338] The preparation of compound 12 is described in Example 1.
[0339] LCMS(ESI+): m / z = 556.2 [M+H] +
[0340] Example 13: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-5-chloro-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indole-5-yl)methyl ketone (13)
[0341] Referring to Example 1, except that 2,3-dichloroisononiazolinone was used instead of 2-chloro-3-methylisononiazolinone (1h) in step 8 of Example 1, steps 8 to 16 were the same, to obtain compound 13.
[0342] LCMS(ESI+): m / z = 288.6[M / 2+H] +
[0343] 1 H NMR(400MHz, DMSO-d6)δ:8.47(s,1H),7.62(t,J=3.2Hz,2H),7.32(s,1H),7.25(s,1H),7.21(t,J=8.8Hz,2H),6.61(s,1H),4.15–4.12(m,1H),4.0 0(s,1H),3.85(s,3H),3.83(s,1H),3.73(s,1H),3.58(br.s,2H),2.32(b r.s,2H),1.97(s,2H),1.53(s,6H),1.26–1.23(m,2H),1.13–1.08(m,2H).
[0344] Example 14: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-5-cyclopropyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(difluoromethyl)-7-methoxy-2H-indole-5-yl)methyl ketone (14)
[0345] The preparation of compound 14 is described in Example 1.
[0346] LCMS(ESI+): m / z = 592.2 [M+H] +
[0347] Example 15: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-5-(difluoromethyl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indole-5-yl)methyl ketone (15)
[0348] The preparation of compound 15 is described in Example 1.
[0349] LCMS(ESI+): m / z = 592.2 [M+H] +
[0350] Example 16: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methoxypyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indole-5-yl)methyl ketone (16)
[0351] The preparation of compound 16 is described in Example 1.
[0352] LCMS(ESI+): m / z = 572.2 [M+H] +
[0353] Example 17: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-methyl-8-(trifluoromethyl)imidazolium[1,2-a]pyridin-6-yl) methyl ketone (17)
[0354] The preparation of compound 17 is described in Example 1.
[0355] LCMS(ESI+): m / z = 568.2 [M+H] +
[0356] Example 18: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-5-ethyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indazol-5-yl) methyl ketone (18)
[0357] Compound 18 was prepared according to Examples 46 and 1.
[0358] LCMS(ESI+): m / z = 570.2[M+H] +
[0359] Example 19: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-4-methoxybenzo[d]oxazol-6-yl) methyl ketone (19)
[0360] The preparation of compound 19 is described in Example 1.
[0361] LCMS(ESI+): m / z = 557.2 [M+H] +
[0362] Example 20: Preparation of ((1R,5S,6S)-6-((5-chloro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indole-5-yl)methyl ketone (20)
[0363] Step 1: Preparation of methyl 3-chloro-6-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indazole-5-formyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)isonicotinic acid ester (20a)
[0364] Referring to Example 1, except that methyl 2,3-dichloropyridine-4-carboxylate was used instead of 2-chloro-3-methylisonicotinamide (1h) in step 8 of Example 1, steps 8 to 10 and steps 13 to 15 were the same, to obtain compound 20a.
[0365] Step 2: Preparation of ((1R,5S,6S)-6-((5-chloro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indole-5-yl)methyl ketone (20)
[0366] Compound 20a (30 mg, 0.052 mmol) was dissolved in anhydrous tetrahydrofuran (0.5 mL), and a solution of methyl magnesium bromide in tetrahydrofuran (3 M, 0.1 mL, 0.3 mmol) was slowly added dropwise at -78 °C. The temperature was slowly raised to 25 °C, and the reaction was allowed to proceed for 1 hour. The solution was poured into a saturated ammonium chloride aqueous solution (20 mL), and extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The solution was purified by TLC (eluent: ethyl acetate) to give compound 20 (10 mg).
[0367] LCMS(ESI+): m / z = 577.0 [M+H] +
[0368] 1 H NMR(400MHz, CDCl3)δ:7.97(s,1H),7.61(t,2H),7.33(s,1H),7.11(s,1H),7.05(t,2H),6.60(s,1H),4.23(br,1H),3.98(s,3 H),3.93-3.97(m,2H),3.68-3.79(m,3H),2.52(br,1H),1.87-2.01(m,2H),1.75(s,6H),1.36-1.38(m,2H),1.16-1.18(m,2H).
[0369] Example 21: Preparation of (2-cyclopropyl-7-methoxy-2H-indazole-5-yl)((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxyisopropyl)pyridin-2-oxy)-3-azabicyclo[3.1.0]hexane-3-yl) methyl ketone (21)
[0370] Step 1: Preparation of methyl 6-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-fluoro-2-(4-fluorophenyl)isonicotinic acid ester (21a)
[0371] Referring to Example 1, except that methyl 2-chloro-3-fluoroisonicotinic acid ester was used instead of 2-chloro-3-methylisonicotinic acid nitrile (1h) in step 8 of Example 1, steps 8 to 10 and steps 13 to 15 were the same, to obtain compound 21a.
[0372] Step 2: Preparation of (2-cyclopropyl-7-methoxy-2H-indazole-5-yl)((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxyisopropyl)pyridin-2-oxy)-3-azabicyclo[3.1.0]hexane-3-yl) methyl ketone (21)
[0373] Compound 21a (30 mg, 0.053 mmol) was dissolved in anhydrous tetrahydrofuran (0.5 mL). A solution of methyl magnesium bromide in tetrahydrofuran (3 M, 0.1 mL, 0.3 mmol) was slowly added dropwise at -78 °C, and the temperature was slowly raised to 25 °C for 1 hour. The solution was then poured into a saturated ammonium chloride aqueous solution (20 mL), and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The solution was purified by TLC (eluent: ethyl acetate) to give compound 21 (10 mg).
[0374] LCMS(ESI+): m / z = 281.1[M / 2+H] +
[0375] 1 H NMR(400MHz, DMSO-d6)δ:8.50(s,1H),7.89(t,J=8.0Hz,2H),7.36(s,1H),7.19(t,J=8.8Hz,2H),6.99(d,J=4.0Hz,1H),6.65(s,1H),5.56 (s,1H),4.16–4.13(m,2H),3.88(s,3H),3.83(s,1H),3.75–3.56(m,3H),1.99(s,2H),1.50(s,6H),1.27–1.19(m,2H),1.15–1.09(m,2H).
[0376] Example 22: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl)-5-ethyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (22)
[0377] The preparation of compound 22 is described in Examples 46 and 3.
[0378] LCMS(ESI+): m / z = 544.2 [M+H] +
[0379] Example 23: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(7-(methoxy-d3)-2-methyl-2H-indazol-5-yl) methyl ketone (23)
[0380] Step 1: Preparation of ethyl 7-hydroxy-2-methyl-2H-indazole-5-carboxylic acid ester (23a)
[0381] Compound 7a (1.75 g) was dissolved in anhydrous ethanol (20 mL), and concentrated sulfuric acid (2 mL) was slowly added. The mixture was stirred at 85 °C for 16 hours. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate = 5:1-1:1) to give compound 23a (1.1 g).
[0382] LCMS(ESI+): m / z = 221.1[M+H] +
[0383] 1 H NMR(400MHz,DMSO-d6)δ:10.12(s,1H),8.46(s,1H),7.91(d,J=1.2Hz,1H),7 .02(d,J=1.2Hz,1H),4.31-4.24(m,2H),4.17(s,3H),1.32(t,J=7.2Hz,3H).
[0384] Step 2: Preparation of ethyl 7-(methoxy-d3)-2-methyl-2H-indazole-5-carboxylic acid ester (23b)
[0385] Compound 23a (90 mg, 0.409 mmol), potassium carbonate (113 mg, 0.817 mmol), and deuterated iodomethane (65 mg, 0.450 mmol) were added to DMF (130 mL) and stirred at 25 °C for 16 hours. The mixture was then poured into water (5 mL) and extracted with ethyl acetate (5 mL x 3). The combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified using a preparative method (petroleum ether: ethyl acetate = 0 / 1) to give compound 23b (70 mg).
[0386] LCMS(ESI+): m / z = 238.1 [M+H] +
[0387] 1H NMR (400MHz, CDCl3-d) δ: 8.09 (s, 1H), 7.99 (s, 1H), 7.18 (s, 1H), 4.43-4.36 (m, 2H), 4.24 (s, 3H), 1.42 (t, J = 7.2Hz, 3H).
[0388] Step 3: Preparation of 7-(methoxy-d3)-2-methyl-2H-indazole-5-carboxylic acid (23c)
[0389] Compound 23b (90 mg, 0.379 mmol) and lithium hydroxide (27.3 mg, 1.14 mmol) were added to a tetrahydrofuran / methanol / water mixture (3:2:1, 0.5 mL) and stirred at 25 °C for 16 hours. The mixture was then extracted with water (2 mL) and ethyl acetate (2 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 23c (70 mg).
[0390] LCMS(ESI+): m / z = 210.1[M+H] +
[0391] 1 H NMR (400MHz, CD3OD-d4) δ: 8.34 (s, 1H), 8.11 (d, J = 1.2Hz, 1H), 7.22 (d, 1H), 4.21 (s, 3H).
[0392] Step 4: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-(methoxy-d3)-2-methyl-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (23d)
[0393] Compound 3c (100 mg, 0.210 mmol), compound 23c (52.8 mg, 0.252 mmol), N,N-diisopropylethylamine (81.5 mg, 0.631 mmol), and HATU (104 mg, 0.273 mmol) were added to DMF (2 mL) and stirred at 25 °C for 16 hours. The mixture was then poured into water (5 mL) and extracted with ethyl acetate (5 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by preparative plate (petroleum ether:ethyl acetate = 0 / 1) to give compound 23d (80 mg).
[0394] LCMS(ESI+): m / z = 667.2[M+H] +
[0395] 1H NMR(400MHz, CDCl3-d)δ:7.86(s,1H),7.45–7.26(m,7H),7.03(t,J=8.6Hz,2H),6.77(s,1H),6.61(s,1H),5.12(s, 1H),5.02(s,2H),4.29–4.10(m,4H),3.90(s,1H),3.83–3.63(m,3H),2.22(s,3H),2.00–1.85(m,2H),1.71(s,6H).
[0396] Step 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(7-(methoxy-d3)-2-methyl-2H-indazol-5-yl)methyl ketone (23)
[0397] Compound 23d (75 mg, 0.113 mmol) was added to concentrated hydrochloric acid (2 mL) and stirred at 80 °C for 1 hour. The mixture was evaporated to dryness under reduced pressure, and extracted with saturated sodium carbonate solution (2 mL) and ethyl acetate (2 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was then separated by preparative high-performance chromatography (HPLC) (column: Excsep C18 21.2-150 mm; detector: 254 nm; mobile phase: ACN-H2O (0.1% FA); elution gradient: 15%-45%; retention time: 9 min). The preparative solution was lyophilized to obtain compound 23 (33.86 mg).
[0398] LCMS(ESI+): m / z = 533.1 [M+H] +
[0399] 1 H NMR(400MHz,DMSO-d6)δ:8.34(s,1H),8.33-8.11(m,0.59H,FA),7.56-7.45(m,2H),7.37(s,1H),7.20(t,J=8.6Hz,2H) ,6.95(s,1H),6.62(s,1H),4.16(s,3H),4.08-3.97(m,1H),3.80-3.45(m,4H),2.40(s,3H),1.93(s,2H),1.52(s,6H).
[0400] Example 24: Preparation of ((1R,5S,6S)-6-((4-(2-aminoisopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(4-methyl-2-(pyrimidin-2-yl)thiazolyl-5-yl)methyl ketone (24)
[0401] Compound 24 was prepared according to Example 25, except that 2-bromopyrimidine was used instead of 2-bromo-5-fluoropyrimidine in step 1 of Example 25, and the other steps were the same to obtain compound 24.
[0402] LCMS(ESI+): m / z = 545.1 [M+H] +
[0403] 1 H NMR(400MHz, DMSO-d6)δ:8.96(d,J=4.9Hz,2H),7.62(t,J=4.9Hz,1H),7.55–7.51(m,2H),7.23(t,J=8.9Hz,2H) ,7.00(s,1H),3.93–3.89(m,2H),3.68–3.60(m,3H),2.44(s,3H),2.41(s,3H),2.07–1.93(m,2H),1.48(s,6H).
[0404] Example 25: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(5-fluoropyrimidin-2-yl)-4-methylthiazolyl-5-yl) methyl ketone (25)
[0405] Step 1: Preparation of 5-fluoro-2-(tributyltin)pyrimidine (25a)
[0406] 2-Bromo-5-fluoropyrimidine (3 g, 17 mmol), hexabutyltin (14.79 g, 25.5 mmol), and tetrakis(triphenylphosphine)palladium (1.24 g, 1.7 mmol) were dissolved in toluene (30 mL), purged three times with nitrogen, and reacted at 110 °C for 16 hours. The reaction was quenched with water (100 mL) and extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 50 / 1) to give compound 25a (2 g).
[0407] LCMS(ESI+): m / z = 389.1 [M+H] +
[0408] Step 2: Preparation of ethyl 2-(5-fluoropyrimidin-2-yl)-4-methylthiazol-5-carboxylic acid ester (25b)
[0409] Compound 25a (1.1 g, 2.99 mmol), ethyl 2-bromo-4-methylthiazol-5-carboxylate (500 mg, 1.99 mmol), and cuprous iodide (190.4 mg, 0.99 mmol) were dissolved in dioxane (10 mL). 2-Dicyclohexylphospho-2',4',6'-triisopropylbiphenyl (381.2 mg, 0.79 mmol) and tris(dibenzylacetone)palladium (366.1 mg, 0.39 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen atmosphere. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 25b (300 mg).
[0410] LCMS(ESI+): m / z = 268.2[M+H] +
[0411] 1 H NMR (400MHz, DMSO-d6) δ: 9.07 (s, 2H), 4.33 (q, J = 7.2Hz, 2H), 2.73 (s, 3H), 1.32 (t, J = 7.2Hz, 3H).
[0412] Step 3: Preparation of 2-(5-fluoropyrimidin-2-yl)-4-methylthiazol-5-carboxylic acid (25c)
[0413] Compound 25b (100 mg, 0.37 mmol) was dissolved in tetrahydrofuran (4 mL) and water (2 mL), and lithium hydroxide (26.9 mg, 1.12 mmol) was added. The mixture was reacted at 25 °C for 2 hours. The solution was concentrated under reduced pressure. Water (5 mL) was added, and the pH was adjusted to 5 with HCl (2N). The mixture was filtered, and the filter cake was dried to give compound 25c (50 mg).
[0414] LCMS(ESI+): m / z = 240.1[M+H] +
[0415] 1 H NMR(400MHz,DMSO-d6)δ:9.06(s,2H),2.70(s,3H).
[0416] Step 4: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(2-(5-fluoropyrimidin-2-yl)-4-methylthiazolyl-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-methylpyridin-4-yl)propane-2-yl)carbamate (25d)
[0417] Compound 25c (50 mg, 0.21 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (119.9 mg, 0.32 mmol), and compound 1o (50 mg, 0.11 mmol) were dissolved in dichloromethane (5 mL), and N,N-diisopropylethylamine (67.9 mg, 0.53 mmol) was added. The reaction was carried out at 25 °C for 16 hours. The mixture was diluted with water (10 mL) and extracted with dichloromethane (10 mL * 3). The organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 25d (50 mg) was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 10 / 1).
[0418] LCMS(ESI+): m / z = 697.2 [M+H] +
[0419] 1 H NMR (400MHz, DMSO-d6) δ: 9.05 (s, 2H), 7.94 (s, 1H), 7.45-7.28 (m, 6H), 7.22 (t, J = 8.8Hz, 2H), 6.73 (s, 1H), 4 .95(s,2H),3.95-3.83(m,2H),3.72-3.53(m,3H),2.40(s,3H),2.15(s,3H),2.08-1.92(m,2H),1.58(s,6H).
[0420] Step 5: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-(5-fluoropyrimidin-2-yl)-4-methylthiazolyl-5-yl)methyl ketone (25)
[0421] Compound 25d (50 mg, 0.07 mmol) was suspended in concentrated hydrochloric acid (2 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7–8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (20 mL * 3). The combined organic phases were washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 25 (16.8 mg) was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 10 / 1) to give compound 25.
[0422] LCMS(ESI+): m / z = 563.3 [M+H] +
[0423] 1 H NMR (400MHz, DMSO-d6) δ: 9.06 (s, 2H), 7.55-7.51 (m, 2H), 7.23 (t, J = 8.8Hz, 2H), 7.00 (s, 1H), 3.95-3.85 (m,2H),3.71-3.55(m,3H),2.44(s,3H),2.40(s,3H),2.05-1.97(m,1H),1.95-1.88(m,1H),1.48(s,6H).
[0424] Example 26: Preparation of (R)-5-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxamide (26)
[0425] Step 1: Preparation of (R)-6-chloro-2-iodo-3-((2-methylepoxypropyl)methoxy)pyridine (26a)
[0426] 2-Iodo-3-hydroxy-6-chloropyridine (4.0 g, 15.7 mmol) and diphenyl-2-pyridinium phosphine (4.6 g, 17.2 mmol) were dissolved in anhydrous tetrahydrofuran (40 mL), purged three times with nitrogen, cooled to 0 °C, and (2S)-(+)-2-methyl-2,3-epoxy-1-propanol (1.4 g, 15.7 mmol) and diisopropyl azodicarbonate (3.5 g, 17.2 mmol) were added dropwise. The mixture was slowly brought back to room temperature and stirred at 25 °C for 16 hours. The mixture was diluted with water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The solution was purified by medium-pressure flash (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1) to give compound 26a (4.0 g).
[0427] LCMS(ESI+): m / z = 326.0 [M+H] +
[0428] 1H NMR (400MHz, CDCl3-d) δ: 7.20 (d, J = 8.4Hz, 1H), 7.03 (d, J = 8.4Hz, 1H), 4.17 (d, J = 10.8Hz ,1H),3.97(d,J=10.8Hz,1H),2.95(d,J=4.8Hz,1H),2.78(d,J=4.8Hz,1H),1.53(s,3H).
[0429] Step 2: Preparation of (S)-(5-chloro-7-iodo-3-methyl-2,3-dihydrofurano[2,3-c]pyridin-3-yl)methanol (26b)
[0430] Compound 26a (4.8 g, 14.8 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), purged three times with nitrogen, and cooled to 0 °C. Diisopropylaminolithium (8.8 mL, 17.7 mmol) was then added dropwise, and the mixture was stirred at 0 °C for 1 hour. The mixture was quenched with ice water and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 26b (2.2 g) was purified by medium-pressure flash (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1).
[0431] LCMS(ESI+): m / z = 325.8 [M+H] +
[0432] 1 H NMR (400MHz, CDCl3-d) δ: 7.06 (s, 1H), 4.69 (d, J = 8.4Hz, 1H), 4.37 (d, J = 8.4Hz, 1H), 3.73-3.70 (m, 1H), 3.67-3.63 (m, 1H), 1.40 (s, 3H).
[0433] Step 3: Preparation of (S)-(5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridin-3-yl)methanol (26c)
[0434] Compound 26b (1.64 g, 5.04 mmol), 4-fluorophenylboronic acid (0.85 g, 6.05 mmol), palladium dichloride (0.35 g, 0.50 mmol), and sodium carbonate (1.33 g, 12.6 mmol) were dissolved in tetrahydrofuran (15 mL) and water (3 mL). The mixture was purged with nitrogen three times and reacted at 70 °C for 1 hour under nitrogen atmosphere. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 26c (1.1 g) was purified by flash extraction under medium pressure (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1).
[0435] LCMS(ESI+): m / z = 294.1 [M+H] +
[0436] 1 H NMR(400MHz, DMSO-d6)δ:8.18(dd,J=8.8,5.6Hz,2H),7.52-7.47(m,1H),7.39(s,1H),7.32(t,J=8.8Hz,2H),5.16 (t,J=5.6Hz,1H),4.73(d,J=8.8Hz,1H),4.38(d,J=8.8Hz,1H),3.63-3.52(m,1H),3.50-3.45(m,1H),1.33(s,2H).
[0437] Step 4: Preparation of (R)-5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridine-3-carboxylic acid (26d)
[0438] Compound 26c (1.20 g, 4.09 mmol) was dissolved in acetone (15 mL), and Jones' reagent (5 mL, 12.27 mmol) was added dropwise at 0 °C. The reaction was carried out at 25 °C for 16 hours. The reaction was quenched with isopropanol and water, and extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 26d (1.30 g).
[0439] LCMS(ESI+): m / z = 308.1 [M+H] +
[0440] Step 5: Preparation of methyl(R)-5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridine-3-carboxylic acid ester (26e)
[0441] Compound 26d (1.30 g) was dissolved in anhydrous methanol (13 mL), and sulfuric acid (1.20 g, 12.69 mmol) was added. The reaction was carried out at 50 °C for 16 hours. After cooling to room temperature, the pH was adjusted to 7–8 with saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 26e (0.46 g) was purified by medium-pressure flash (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 2 / 1).
[0442] LCMS(ESI+): m / z = 322.1[M+H] +
[0443] 1 H NMR(400MHz, CDCl3-d)δ:8.24-8.20(m,2H),7.24(s,1H),7.13(t,J=8.8Hz, 2H), 5.21 (d, J = 9.2Hz, 1H), 4.44 (d, J = 9.2Hz, 1H), 3.80 (s, 3H), 1.67 (s, 3H).
[0444] Step 6: Preparation of methyl(R)-5-(((1R,5S,6S)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridine-3-carboxylic acid ester (26f)
[0445] Compound 26e (460 mg, 1.43 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (2851 mg, 1.43 mmol), potassium phosphate (910 mg, 4.29 mmol), 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (192 mg, 0.29 mmol), and palladium acetate (32 mg, 0.14 mmol) were dissolved in trifluorotoluene (3 mL) and methoxycyclopentane (3 mL), purged three times with nitrogen, and reacted at 90 °C for 16 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (developing solvent: petroleum ether / ethyl acetate = 2 / 1) yielded compound 26f (280 mg).
[0446] LCMS(ESI+): m / z = 485.3 [M+H] +
[0447] 1 H NMR(400MHz, CDCl3-d)δ:8.30-8.26(m,2H),7.13(t,J=8.8Hz,2H),6.69(s,1H),5.14(d,J=9.2Hz,1H),4.38(d,J=9.2Hz,1 H),3.88(s,1H),3.80-3.77(m,4H),3.70(d,J=10.0Hz,1H),3.51(t,J=12.0Hz,2H),1.88(s,2H),1.65(s,3H),1.48(s,9H).
[0448] Step 7: Preparation of (R)-5-(((1R,5S,6S)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxylic acid (26g)
[0449] Compound 26f (280 mg, 0.58 mmol) and lithium hydroxide (28 mg, 1.16 mmol) were added to a mixture of anhydrous methanol / tetrahydrofuran / water (1 / 1 / 1, 3 mL), and stirred at 25 °C for 2 hours. The pH was adjusted to 5–6 with dilute hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 26 g (300 mg).
[0450] LCMS(ESI+): m / z = 471.3[M+H] +
[0451] Step 8: Preparation of tert-butyl(1R,5S,6S)-6-(((R)-3-aminoacyl-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuranopyridin-5-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (26h)
[0452] Compound 26 g (300 mg, 0.64 mmol), ammonium chloride (51 mg, 0.96 mmol), and N,N-diisopropylethylamine (413 mg, 3.20 mmol) were dissolved in N,N-dimethylformamide (3 mL). HATU (486 mg, 1.28 mmol) was added at 0 °C, and the mixture was stirred at 25 °C for 16 hours. The mixture was extracted dropwise into ice water with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC (electrolyte: petroleum ether / ethyl acetate = 1 / 1) was used to purify compound 26 h (240 mg).
[0453] LCMS(ESI+): m / z = 470.3[M+H] +
[0454] 1 H NMR(400MHz, DMSO-d6)δ:8.24-8.21(m,2H),7.43(s,1H),7.34-7.28(m,3H),6.95(s,1H),5.12(d,J=8.8Hz,1H), 4.35(d,J=8.8Hz,1H),3.78(s,1H),3.63-3.58(m,2H),3.46-3.40(m,2H),1.91(s,2H),1.57(s,3H),1.41(s,9H).
[0455] Step 9: Preparation of (R)-5-(((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxamide (26i)
[0456] Compound 26h (200 mg, 0.42 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1.5 mL) was added. The mixture was stirred at 25 °C for 2 hours and then evaporated to dryness to obtain compound 26i (130 mg).
[0457] LCMS(ESI+): m / z = 370.2[M+H] +
[0458] Step 10: Preparation of (R)-5-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxamide (26)
[0459] Compound 26i (40 mg, 0.11 mmol), compound 1f (38 mg, 0.16 mmol), HATU (84 mg, 0.22 mmol), and N,N-diisopropylethylamine (71 mg, 0.55 mmol) were dissolved in N,N-dimethylformamide (1 mL) and stirred at 25 °C for 16 hours. The solution was diluted with water and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC (electrolyte: dichloromethane / methanol = 20 / 1) was used to purify compound 26 (28.8 mg).
[0460] LCMS(ESI+): m / z = 584.1 [M+H] +
[0461] 1 H NMR(400MHz, DMSO-d6)δ:8.52(s,1H),8.16-8.12(m,2H),7.43-7.34(m,3H),7.06(t,J=8.8Hz,2H),6.93(s,1H),6.68(s,1H),5.11(d,J=8.8Hz,1H ),4.34(d,J=8.8Hz,1H),4.17-4.12(m,2H),3.89(s,3H),3.82-3.58(m,4 H),2.00-1.90(m,2H),1.56(s,3H),1.30-1.23(m,2H),1.14-1.09(m,2H).
[0462] Example 27: Preparation of (R)-7-(4-fluorophenyl)-3-methyl-5-(((1R,5S,6S)-3-(4-methyl-2-(2-pyrimidazolyl)thiazolyl-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2,3-dihydrofurano[2,3-c]pyridine-3-carboxamide (27)
[0463] Step 1: Preparation of (R)-7-(4-fluorophenyl)-3-methyl-5-(((1R,5S,6S)-3-(4-methyl-2-(2-pyrimidazolyl)thiazolyl-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2,3-dihydrofurano[2,3-c]pyridine-3-carboxamide (27)
[0464] Compound 26i (40 mg, 0.11 mmol), 4-methyl-2-(2-pyrimidinyl)thiazol-5-carboxylic acid (35 mg, 0.16 mmol), HATU (84 mg, 0.22 mmol), and N,N-diisopropylethylamine (71 mg, 0.55 mmol) were dissolved in N,N-dimethylformamide (1 mL) and stirred at 25 °C for 16 hours. The solution was diluted with water and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (eluent: dichloromethane / anhydrous methanol = 20 / 1) yielded compound 27 (19.80 mg).
[0465] LCMS(ESI+): m / z = 573.2 [M+H] +
[0466] 1H NMR(400MHz, DMSO-d6)δ:8.97(d,J=4.8Hz,2H),8.25–8.21(m,2H),7.64(t,J=4.8Hz,1H),7.45(s,1H),7.35(s,1H),7.27(t,J=8.8Hz,2H),6.95 (s,1H),5.12(d,J=8.8Hz,1H),4.35(d,J=8.8Hz,1H),4.05(s,1H),3.97 (s,1H),3.79-3.61(m,3H),3.32(s,3H),2.11-1.92(m,2H),1.57(s,3H).
[0467] Example 28: Preparation of ((1R,5S,6S)-6-((4-(1-aminocyclopropyl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (28)
[0468] Step 1: Preparation of 1,3-dioxoisoindoline-2-yl 1-(((benzyloxycarbonyl)amino)cyclopropane-1-carboxylic acid ester (28a)
[0469] 1-Cbz-aminocyclopropanecarboxylic acid (4 g, 17 mmol) and N-hydroxyphthalimide (3.05 g, 18.7 mmol) were dissolved in anhydrous dichloromethane (50 mL), and DMAP (0.21 g, 1.7 mmol) and EDCI (3.58 g, 18.7 mmol) were added at 0 °C. The mixture was stirred at room temperature for 5 hours. The solution was slowly poured into water and extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to give compound 28a (6 g).
[0470] 1 H NMR(400MHz, CDCl3-d)δ:7.93-7.86(m,2H),7.82-7.76(m,2H),7.41-7.29(m,5H),5.56-5.34(m,1H),5.29-5.11(m,2H),1.90(s,2H),1.50(s,2H).
[0471] Step 2: Preparation of benzyl (1-(2,6-dichloropyridin-4-yl)cyclopropyl)carbamate (28b)
[0472] Compound 28a (6 g, 15.8 mmol) and 4-bromo-2,6-dichloropyridine (3.62 g, 15.9 mmol) were dissolved in DMA (60 mL), and di(2,2′-bipyridine-)-dihydrate was added at 0 °C. K N 1 , K N 1′ Di-M-chlorodichlorodinickel stereoisomer (0.48 g, 0.79 mmol), zinc powder (8.27 g, 126.4 mmol), and trimethylchlorosilane (5.15 g, 47.4 mmol). Stirred at 0°C for 2 hours under N2 protection. Pour into water and extract with ethyl acetate (20 mL * 3). Combine organic phases, wash with brine, dry to dryness with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 28b (3.5 g).
[0473] LCMS(ESI+): m / z = 336.8 [M+H] +
[0474] 1 H NMR(400MHz, CDCl3-d)δ:7.38(br.s,5H),6.96(s,2H),5.14(s,2H),1.52-1.46(m,2H),1.41-1.35(m,2H).
[0475] Step 3: Preparation of phenyl (1-(2-chloro-6-(4-fluorophenyl)pyridin-4-yl)cyclopropyl)carbamate (28c)
[0476] Compound 28b (1 g, 3 mmol) and 4-fluorophenylboronic acid (0.38 g, 2.7 mmol) were dissolved in 1,4-dioxane (15 mL) and water (3 mL). Potassium carbonate (0.83 g, 6 mmol) and Pd(dppf)Cl2 (0.22 g, 0.3 mmol) were added at room temperature, and the mixture was purged three times with nitrogen and reacted overnight at 80 °C. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Compound 28c (0.5 g) was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1).
[0477] LCMS(ESI+): m / z = 396.8 [M+H] +
[0478] Step 4: Preparation of tert-butyl(1R,5S,6S)-6-((4-(1-(((benzyloxycarbonyl)amino)cyclopropyl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (28d)
[0479] Compound 28c (500 mg, 1.26 mmol) and (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (505 mg, 2.52 mmol), anhydrous potassium phosphate (535 mg, 2.52 mmol) were dissolved in 1,4-dioxane (10 mL). 5-(bis(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (167 mg, 0.25 mmol) and Pd2(dba)3 (115 mg, 0.13 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 28d (380 mg).
[0480] LCMS(ESI+): m / z = 559.8 [M+H] +
[0481] 1 H NMR(400MHz, CDCl3-d)δ:7.92(dd,J=8.1,5.7Hz,2H),7.45–7.32(m,4H),7.22–6.96(m,4H),6.44(s,1H),5.50(s, 1H),5.13(s,2H),3.90(s,1H),3.84–3.63(m,2H),3.59–3.43(m,2H),1.87(s,2H),1.47(s,9H),1.44–1.37(m,4H).
[0482] Step 5: Preparation of benzyl(1-(2-(((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-6-(4-fluorophenyl)pyridin-4-yl)cyclopropyl)carbamate (28e)
[0483] Compound 28d (100 mg, 0.18 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added. The reaction was carried out at 25 °C for 2 hours. The solution was concentrated under reduced pressure. The solution was then dissolved in dichloromethane (10 mL), washed with saturated sodium bicarbonate solution and saturated saline solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 28e (70 mg).
[0484] LCMS(ESI+): m / z = 460.3[M+H] +
[0485] Step 6: Preparation of benzyl (1-(2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-methoxy-2-methyl-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)pyridin-4-yl)cyclopropyl)carbamate (28f)
[0486] Compound 28e (40 mg, 0.087 mmol), 7-methoxy-2-methylindazole-5-carboxylic acid (20 mg, 0.096 mmol), and N,N-diisopropylethylamine (22 mg, 0.174 mmol) were dissolved in DMF (2 mL), and HATU (50 mg, 0.13 mmol) was added. The mixture was reacted at 25 °C for 2 hours. Water (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 28f (40 mg) was purified by Prep-TLC (electrolyte: dichloromethane / methanol = 20:1).
[0487] LCMS(ESI+): m / z = 648.3 [M+H] +
[0488] Step 7: Preparation of ((1R,5S,6S)-6-((4-(1-aminocyclopropyl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (28)
[0489] Compound 28f (40 mg, 0.062 mmol) was suspended in concentrated hydrochloric acid (1 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7–8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 10 / 1) to give compound 28 (22.18 mg).
[0490] LCMS(ESI+): m / z = 514.3[M+H] +
[0491] 1H NMR (400MHz, CDCl3-d) δ: 8.37 (s, 1H), 8.07 (dd, J = 8.1, 5.8Hz, 2H), 7.40 (d, J = 16.3Hz, 2H), 7.12 (t, J = 8.7Hz, 2H), 6. 70(d,J=16.3Hz,2H),4.25-4.06(m,4H),3.99-3.85(m,4H),3.83-3.55(m,3H),2.10-1.85(m,2H),1.15-1.01(m,4H).
[0492] Example 29: Preparation of ((1R,5S,6S)-6-((4-(1-aminocyclopropyl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indazol-5-yl) methyl ketone (29)
[0493] The preparation of compound 29 is described in Example 28.
[0494] LCMS(ESI+): m / z = 540.4 [M+H] +
[0495] 1 H NMR(400MHz, DMSO-d6)δ:8.51(s,1H),8.08-8.05(m,2H),7.38(s,2H),7.11(t,J=8.8Hz,2H),6.70(d,J=17.9Hz,2H),4.18-4.1 2(m,2H),3.89(s,4H),3.81-3.51(m,3H),2.91(br.s,1H),2.08-1.52(d,J=30.8Hz,2H),1.40-1.19(m,3H),1.18-1.02(m,6H).
[0496] Example 30: Preparation of ((1R,5S,6S)-6-((4-(1-aminocyclopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-methoxy-2-methyl-2H-indazol-5-yl) methyl ketone (30)
[0497] The preparation of compound 30 is described in Example 28.
[0498] LCMS(ESI+): m / z = 528.3 [M+H] +
[0499] Example 31: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-methoxy-3-methylcenolin-6-yl) methyl ketone (31)
[0500] Step 1: Preparation of methyl (E)-4-(3,3-diethyltriaza-1-en-1-yl)-3-iodo-5-methoxybenzoate (31a)
[0501] Methyl 4-amino-3-iodo-5-methoxybenzoate (9.6 g, 0.031 mol) was dissolved in hydrochloric acid (6 M, 39 mL, 0.229 mol), cooled to 0 °C, and an aqueous solution of sodium nitrite (2.6 g, 0.037 mol) was added dropwise. The reaction was carried out at 0 °C for 30 minutes. Diethylamine (8.3 mL, 0.080 mol) and potassium carbonate (22 g, 0.16 mol) were dissolved in acetonitrile (26 mL) and water (52 mL) and added dropwise. The reaction was carried out at 0 °C for 30 minutes. The mixture was diluted with water and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was then subjected to column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give compound 31a (11 g).
[0502] LCMS(ESI+): m / z = 391.9 [M+H] +
[0503] 1 H NMR (400MHz, CDCl3) δ: 8.15 (d, J = 1.6Hz, 1H), 7.56 (d, J = 1.6Hz, 1H), 3.90 (s, 3H), 3.85-3.73 (m, 7H), 1.34 (t, J = 6.9Hz, 6H).
[0504] Step 2: Preparation of methyl (E)-4-(3,3-diethyltriaza-1-en-1-yl)-3-methoxy-5-(prop-1-yn-1-yl)benzoate (31b)
[0505] Compound 31a (11 g, 0.029 mol), 1-(trimethylsilyl)propyne (26 g, 0.23 mol), cuprous iodide (1.1 g, 5.8 mmol), and cesium fluoride (22 g, 0.15 mol) were added to a mixed solution of N,N-dimethylformamide (110 mL) and methanol (22 mL). Under nitrogen atmosphere, palladium dichloride dichloride (1.1 g, 1.5 mmol) was added, and the reaction was carried out at room temperature for 2 h. The mixture was poured into ice water (400 mL) and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) yielded compound 31b (8.0 g).
[0506] LCMS(ESI+): m / z = 304.2[M+H] +
[0507] 1 H NMR (400MHz, CDCl3) δ: 7.74 (d, J = 1.7Hz, 1H), 7.48 (d, J = 1.7Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.80 (q, J = 7.1Hz, 4H), 1.99 (s, 3H), 1.31 (t, J = 7.0Hz, 6H).
[0508] Step 3: Preparation of methyl 4-bromo-8-methoxy-3-methylcenline-6-carboxylic acid (31c)
[0509] Compound 31b (8.0 g, 0.026 mol) was dissolved in acetone (80 mL), and after cooling to 0 °C, 48% hydrogen bromide aqueous solution (24 mL, 0.21 mol) was added dropwise. The mixture was slowly brought back to room temperature and reacted for 1.5 hours. The solution was concentrated under reduced pressure, dissolved in dichloromethane, adjusted to alkaline with sodium bicarbonate aqueous solution, and extracted with dichloromethane (50 mL * 3). The organic phases were combined. The organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 31c (7.3 g), which was used directly in the next reaction without purification.
[0510] LCMS (ESI+): m / z=310.8, 312.9[M+H] +
[0511] Step 4: Preparation of methyl 8-methoxy-3-methyl-3,4-dihydrocenline-6-carboxylic acid (31d)
[0512] Compound 31c (7.3 g, 24 mmol) was dissolved in methanol (70 mL), and palladium / carbon (1.8 g) was added. The mixture was purged three times with hydrogen and reacted overnight at room temperature under hydrogen atmosphere (25 psi). The mixture was filtered, and the filtrate was concentrated under reduced pressure to give compound 31d (6.2 g), which could be used directly in the next reaction without purification.
[0513] LCMS(ESI+): m / z = 235.0 [M+H] +
[0514] Step 5: Preparation of methyl 8-methoxy-3-methylcenline-6-carboxylic acid (31e)
[0515] Compound 31d (6.2 g, 0.026 mol) was dissolved in dichloromethane (60 mL), and manganese dioxide (6.0 g, 0.067 mol) was added. The mixture was reacted at 40 °C for 2 hours. The solution was filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: dichloromethane / methanol = 20 / 1) yielded compound 31e (2.0 g).
[0516] LCMS(ESI+): m / z = 233.0 [M+H] +
[0517] Step 6: Preparation of 8-methoxy-3-methylcenline-6-carboxylic acid (31f)
[0518] Compound 31e (2.0 g, 8.4 mmol) and sodium hydroxide (550 mg, 13 mmol) were added to a mixed solution of methanol (20 mL) and water (4.0 mL), and stirred at room temperature for 1 hour. The solvent was removed, and dichloromethane (5.0 mL) and water (6.0 mL) were added. The aqueous phase was separated, and the pH of the aqueous phase was adjusted to 2 with hydrochloric acid. The mixture was then filtered to obtain compound 31f (1.8 g).
[0519] LCMS(ESI+): m / z = 219.0 [M+H] +
[0520] 1 H NMR (400MHz, DMSO-d6) δ8.36(s,1H),8.18(d,J=1.1Hz,1H),7.58(d,J=1.1Hz,1H),4.13(s,3H),2.91(s,3H).
[0521] Step 7: Preparation of 2-chloro-6-(4-fluorophenyl)isocyanate (31g)
[0522] 2,6-Dichloroisononiazolinone (5.0 g, 29 mmol), 4-fluorophenylboronic acid (4.9 g, 35 mmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (0.47 g, 0.58 mmol) were dissolved in dichloromethane (70 mL), purged with nitrogen three times, and cooled to 0 °C. A tetrabutylammonium fluoride solution in tetrahydrofuran (43 mL, 43 mmol) was slowly added dropwise. After the addition was complete, the mixture was heated to 25 °C and reacted for 6 hours. Water (100 mL) was added, and the mixture was extracted with dichloromethane (100 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give 31 g (5.0 g) of the compound.
[0523] LCMS(ESI+): m / z = 232.9[M+H] +
[0524] 1 H NMR (400MHz, CDCl3) δ8.06 -7.96 (m, 2H), 7.82 (s, 1H), 7.48 (s, 1H), 7.20 (t, J = 8.6Hz, 2H).
[0525] Step 8: Preparation of 2-(2-chloro-6-(4-fluorophenyl)pyridin-4-yl)propyl-2-amine (31h)
[0526] 31 g (5.0 g, 22 mmol) of compound was dissolved in tetrahydrofuran (100 mL), and the temperature was lowered to -10 °C under nitrogen atmosphere. A tetrahydrofuran solution of methyl magnesium bromide (22 mL, 65 mmol) was slowly added dropwise. After the addition was complete, the reaction proceeded for 1 hour. The temperature was then raised to 0 °C, and tetraisopropyl titanate (6.1 g, 22 mmol) was slowly added dropwise. After the addition was complete, the temperature was raised to 25 °C, and the reaction proceeded for 16 hours. The solution was poured into a saturated sodium carbonate aqueous solution (200 mL), and the solid was filtered off. The filter cake was washed with ethyl acetate (100 mL), and the aqueous phase was extracted with ethyl acetate (100 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 31h (5.0 g). No purification was required; it was used directly in the next reaction.
[0527] LCMS (ESI+): m / z=265.1, 267.1[M+H] +
[0528] Step 9: Preparation of (2-(2-chloro-6-(4-fluorophenyl)pyridin-4-yl)propyl-2-yl)carbamate (31i)
[0529] Compound 31h (5.0 g, 15 mmol) and N,N-diisopropylethylamine (3.9 g, 30 mmol) were dissolved in dichloromethane (50 mL). The mixture was cooled to 10 °C, and benzyl chloroformate (2.6 g, 15 mmol) was added dropwise. After the addition was complete, the mixture was heated to 25 °C and reacted for 16 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (50 mL), and extracted with dichloromethane (50 mL x 2). The organic phases were combined. The organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and slurried in a methyl tert-butyl ether / dichloromethane / acetonitrile ratio of 1 / 0.2 / 1 (25 mL) and filtered to obtain compound 31i (4.0 g).
[0530] LCMS (ESI+): m / z=399.0, 401.1[M+H] +
[0531] 1 H NMR (400MHz, CDCl3) δ8.11-7.99(m,2H),7.93(s,1H),7.82(s,1H),7.39-7.26(m,7H),4.99(s,2H),1.58(s,6H).
[0532] Step 10: Preparation of tert-butyl(1R,5S,6S)-6-((4-(2-(((benzyloxy)carbonyl)amino)prop-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (31j)
[0533] Compound 31i (1.0 g, 2.5 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (0.50 g, 2.5 mmol), and anhydrous potassium phosphate (1.6 g, 7.5 mmol) were dissolved in cyclopentyl methyl ether (15 mL) and trifluorotoluene (15 mL). 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (0.17 g, 0.25 mmol) and palladium acetate (0.060 g, 0.25 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 31j (0.50 g).
[0534] LCMS(ESI+): m / z = 562.3 [M+H] + .
[0535] Step 11: Preparation of benzyl(2-(2-((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-6-(4-fluorophenyl)pyridin-4-yl)prop-2-yl)carbamate (31k)
[0536] Compound 31j (0.5 g, 0.89 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (2.0 mL) was added. The reaction was carried out at 25 °C for 1 hour. The solution was concentrated under reduced pressure. The solution was then dissolved in dichloromethane (30 mL), washed with saturated sodium bicarbonate solution and saturated saline solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 31k (0.35 g), which could be used directly in the next reaction without further purification.
[0537] LCMS(ESI+): m / z = 462.2[M+H] +
[0538] Step 12: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-((1R,5S,6S)-3-(8-methoxy-3-methylcenolin-6-carbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)pyridin-4-yl)prop-2-yl)carbamate (31l)
[0539] Compound 31k (350 mg, 0.76 mmol), compound 31f (8-methoxy-3-methylcenline-6-carboxylic acid) (170 mg, 0.76 mmol), and N,N-diisopropylethylamine (290 mg, 2.3 mmol) were dissolved in dichloromethane (10 mL), and HATU (430 mg, 1.1 mmol) was added. The mixture was reacted at 25 °C for 16 hours. Water (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give compound 1l (300 mg), which was used directly in the next reaction without further purification.
[0540] LCMS(ESI+): m / z = 662.3[M+H] +
[0541] 1H NMR(400MHz,DMSO-d6)δ8.06-7.94(m,3H),7.84(s,1H),7.57(s,1H),7.52-7.47(m,1H), 7.39-7.23(m,6H),7.17(t,J=8.7Hz,2H),6.69(s,1H),4.95(s,2H),4.14(d,J=12.1Hz,1 H),4.09-3.99(m,4H),3.77(dd,J=10.4,4.6Hz,1H),3.67(dd,J=12.2,4.7Hz,1H),3.58( d,J=10.5Hz,1H),2.89-2.86(m,3H),2.10-2.02(m,1H),1.99-1.98(m,1H),1.55(s,6H).
[0542] Step 13: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-methoxy-3-methylcenolin-6-yl)methyl ketone (31)
[0543] Compound 31 (100 mg, 0.15 mmol) was suspended in concentrated hydrochloric acid (5.0 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7-8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (eluent: dichloromethane / methanol = 15 / 1) to give compound 31 (10 mg).
[0544] LCMS(ESI+): m / z = 528.2 [M+H] +
[0545] 1H NMR(400MHz,DMSO-d6)δ8.12(dd,J=8.6,5.7Hz,2H),8.00(s,1H),7.74(s,1H),7.58(s,1 H),7.28(s,1H),7.17(t,J=8.8Hz,2H),6.89(s,1H),4.15(d,J=12.2Hz,1H),4.08(s,3H) ,4.02(s,1H),3.81-3.73(m,1H),3.67(dd,J=12.0,4.8Hz,1H),3.59(d,J=10.8Hz,1H),3 .29-2.99(m,2H),2.87(s,3H),2.05(d,J=4.2Hz,1H),1.98(d,J=4.4Hz,1H),1.40(s,6H).
[0546] Example 32: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-methoxy-3-(deuterated methyl-d3) cinnamyl-6-yl) methyl ketone (32)
[0547] Step 1: Preparation of methyl 4-amino-3-methoxy-5-(prop-1-yn-1-yl-d3)benzoate (32a)
[0548] Methyl 4-amino-3-iodo-5-methoxybenzoate (5.0 g, 16 mmol), trimethyl(prop-1-yn-1-yl-d3)silane (3.8 g, 33 mmol), cuprous iodide (0.62 g, 3.3 mmol), and cesium fluoride (7.4 g, 49 mol) were added to a mixed solution of N,N-dimethylformamide (50 mL) and methanol (12 mL). Palladium dichloride bis(triphenylphosphine) (0.57 g, 0.82 mmol) was added under nitrogen atmosphere, and the reaction was carried out at room temperature for 2 h. The mixture was then poured into ice water (200 mL) and extracted with ethyl acetate (80 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and dried under vacuum to give compound 32a (2.8 g).
[0549] LCMS(ESI+): m / z = 223.2[M+H] +
[0550] Step 2: Preparation of methyl 7-methoxy-1-methyl-2-(methyl-d3)-1H-indole-5-carboxylic acid (32b)
[0551] Compound 32a (2.8 g, 13 mmol) was dissolved in NMP (60 mL) under nitrogen atmosphere, and potassium tert-butoxide (3.5 g, 32 mmol) was added. After the addition was complete, the reaction mixture was heated to 30 °C for 4 hours under nitrogen protection. The solution was poured into a saturated ammonium chloride aqueous solution (300 mL) and extracted with ethyl acetate (80 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 7 / 1) yielded compound 32b (1.6 g).
[0552] LCMS(ESI+): m / z = 237.2[M+H] +
[0553] Step 3: Preparation of methyl 1-amino-7-methoxy-2-(methyl-d3)-1H-indole-5-carboxylic acid (32c)
[0554] Compound 32b (1.6 g, 6.8 mmol) was dissolved in DMF (50 mL), and potassium tert-butoxide (1.5 g, 14 mmol) and O-(4-nitrobenzoyl)hydroxylamine (2.5 g, 13 mmol) were added under nitrogen. The reaction was carried out at room temperature for 5 hours under nitrogen. The mixture was poured into a saturated ammonium chloride aqueous solution (300 mL) and extracted with ethyl acetate (80 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) was used to give compound 32c (1.0 g).
[0555] LCMS(ESI+): m / z = 238.2[M+H] +
[0556] Step 4: Preparation of methyl 8-methoxy-3-(methyl-d3)-cenline-6-carboxylic acid (32d)
[0557] Compound 2c (1.0 g, 4.2 mmol) was dissolved in methanol (15 mL), and hydrogen chloride methanol solution (6.0 M, 6.0 mL) was added under nitrogen atmosphere. After the addition was complete, the mixture was heated to 80 °C and reacted for 12 hours. The mixture was cooled to room temperature, concentrated under reduced pressure, dissolved in dichloromethane (30 mL), washed with saturated sodium bicarbonate aqueous solution (50 mL x 3), washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) yielded compound 32d (710 mg).
[0558] LCMS(ESI+): m / z = 236.2[M+H] +
[0559] Step 5: Preparation of 8-methoxy-3-(methyl-d3)-cenline-6-carboxylic acid (32e)
[0560] Compound 32d (0.70 g, 3.0 mmol) and sodium hydroxide (240 mg, 6.0 mmol) were added to a mixed solution of methanol (10 mL) and D₂O (2.0 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by reverse-phase column chromatography to give compound 32e (0.41 g).
[0561] LCMS(ESI+): m / z = 222.1[M+H] +
[0562] 1 H NMR (400MHz, DMSO-d6) δ8.38 (s, 1H), 8.20 (d, J = 1.1Hz, 1H), 7.60 (d, J = 1.1Hz, 1H), 4.16 (s, 3H).
[0563] Step 6: Preparation of benzyl (2-(2-(4-fluorophenyl)-6-((1R,5S,6S)-3-(8-methoxy-3-(methyl-d3)cenline-6-carbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)pyridin-4-yl)prop-2-yl)carbamate (32f)
[0564] Compound 31k (210 mg, 0.45 mmol), compound 32e (100 mg, 0.45 mmol), and N,N-diisopropylethylamine (180 mg, 1.4 mmol) were dissolved in dichloromethane (10 mL), and HATU (260 mg, 0.68 mmol) was added. The reaction was carried out at 25 °C for 16 hours. Water (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give compound 32f (180 mg), which could be used directly in the next reaction without further purification.
[0565] LCMS(ESI+): m / z = 665.3 [M+H] +
[0566] Step 7: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-methoxy-3-(methyl-d3)cenline-6-yl)methyl ketone (32)
[0567] Compound 32f (100 mg, 0.15 mmol) was suspended in concentrated hydrochloric acid (5.0 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7-8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound 32 (18 mg) was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 15 / 1) to give compound 32.
[0568] LCMS(ESI+): m / z = 531.2[M+H] +
[0569] 1 H NMR(400MHz,DMSO-d6)δ8.15(dd,J=8.6,5.7Hz,2H),8.02(s,1H),7.77(s,1H),7.60( s,1H),7.30(s,1H),7.19(t,J=8.8Hz,2H),6.91(s,1H),4.16(d,J=12.2Hz,1H),4.10( s,3H),4.04(s,1H),3.83-3.75(m,1H),3.69(dd,J=12.0,4.8Hz,1H),3.61(d,J=10.8 Hz,1H),3.31-3.02(m,2H),2.07(d,J=4.2Hz,1H),2.00(d,J=4.4Hz,1H),1.42(s,6H).
[0570] Example 33: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-methoxy-3-methylcenolin-6-yl) methyl ketone (33)
[0571] Step 1: Preparation of methyl 3-fluoro-2-(4-fluorophenyl)isonicotinic acid ester (33a)
[0572] Methyl 2-chloro-3-fluoroisonicotinic acid (6.0 g, 0.03 mol) was dissolved in tetrahydrofuran / water = 6 / 1 (100 mL), and p-fluorophenylboronic acid (5.8 g, 0.04 mol), potassium phosphate (20.2 g, 0.1 mol), and XPhos Pd G2 (2.5 g, 0.003 mol) were added. The reaction was carried out at 80 °C under nitrogen for 16 hours. The mixture was filtered, and the filtrate was extracted with water (100 mL) and ethyl acetate (50 mL * 3). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE / EA = 20 / 1 ~ 3 / 1) to give compound 33a (6.0 g).
[0573] LCMS(ESI+): m / z = 250.1 [M+H] +
[0574] 1 H NMR (400MHz, CDCl3) δ: 8.59 (d, J = 4.8Hz, 1H), 7.97 (dd, J = 7.7, 6.2Hz, 2H), 7.69 (t, J = 4.9Hz, 1H), 7.18 (t, J = 8.7Hz, 2H), 4.00 (s, 3H).
[0575] Step 2: Preparation of 1-oxide (33b) of 3-fluoro-2-(4-fluorophenyl)-4-(methoxycarbonyl)pyridine
[0576] Compound 33a (6.0 g, 0.02 mol) was dissolved in dichloromethane (100 mL), and m-chloroperoxybenzoic acid (14.7 g, w / w = 85%, 0.07 mol) was slowly added at 0 °C. The mixture was stirred at 25 °C for 16 hours. After filtration, the filtrate was poured into a saturated sodium bicarbonate aqueous solution (200 mL), extracted with dichloromethane (100 mL * 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE / EA = 50 / 1 ~ 10 / 1) to give compound 33b (6.0 g).
[0577] LCMS(ESI+): m / z = 266.1 [M+H] +
[0578] 1 H NMR (400MHz, CDCl3) δ: 8.20 (dd, J=7.0, 1.2Hz, 1H), 7.80 (dd, J=8.3, 7.1Hz, 1H), 7.62–7.55 (m, 2H), 7.24–7.18 (m, 2H), 3.97 (s, 3H).
[0579] Step 3: Preparation of methyl 6-chloro-3-fluoro-2-(4-fluorophenyl)isonicotinic acid ester (33c)
[0580] Compound 33b (3.0 g, 11.31 mmol) was dissolved in toluene (30 mL), and phosphorus oxychloride (6.9 g, 45.2 mmol) was slowly added at 0 °C. The mixture was stirred at 80 °C for 2 hours. Slowly, saturated sodium bicarbonate aqueous solution (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE / EA = 50 / 1 ~ 10 / 1) to obtain compound 33c (2.0 g).
[0581] LCMS(ESI+): m / z = 284.1 [M+H] +
[0582] 1 H NMR (400MHz, CDCl3) δ: 8.00 (dd, J = 7.4, 5.4Hz, 2H), 7.69 (d, J = 4.0Hz, 1H), 7.18 (t, J = 8.7Hz, 2H), 4.00 (s, 3H).
[0583] Step 4: Preparation of tert-butyl(1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(methoxycarbonyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (33d)
[0584] Compound 33c (400.0 mg, 1.41 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (282.4 mg, 1.41 mmol), and anhydrous potassium phosphate (898.0 mg, 4.23 mmol) were dissolved in cyclopentyl methyl ether (8 mL) and trifluorotoluene (8 mL). 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (93.5 mg, 0.14 mmol) and tris(dibenzylideneacetone)dipalladium (31.7 mg, 0.14 mmol) were added. The mixture was purged with nitrogen three times and reacted at 90 °C under nitrogen for 16 hours. The filtrate was filtered, concentrated under reduced pressure, and purified by TLC (developing solvent: petroleum ether / ethyl acetate = 3 / 1) to give compound 33d (400.0 mg).
[0585] LCMS(ESI+):m / z=391.0[M-56+H] +
[0586] 1 H NMR(400MHz, CDCl3)δ:8.04(dd,J=7.9,5.7Hz,2H),7.17(t,J=8.7Hz,2H),7.10(d,J=3.5Hz,1H),3.98(s,3H), 3.89(s,1H),3.78(d,J=11.0Hz,1H),3.67(d,J=10.8Hz,1H),3.50(q,J=11.9Hz,2H),1.89(s,2H),1.46(s,9H).
[0587] Step 5: Preparation of methyl 6-(((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-fluoro-2-(4-fluorophenyl)isonicotinic acid ester (3e)
[0588] Compound 33d (400.0 mg, 0.90 mmol) was dissolved in dichloromethane (6 mL), and trifluoroacetic acid (2 mL) was added. The reaction was carried out at 25 °C for 0.5 h. The solution was concentrated under reduced pressure, dissolved in dichloromethane (10 mL), washed with saturated sodium bicarbonate aqueous solution (10 mL), washed with saturated saline solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 33e (300 mg).
[0589] LCMS(ESI+): m / z = 347.1 [M+H] +
[0590] Step 6: Preparation of methyl 3-fluoro-2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(8-methoxy-3-methylxyquinoline-6-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)isoquinoline acid methyl ester (33f)
[0591] Compound 33e (180.0 mg, 0.52 mmol), compound 1f (113.4 mg, 0.52 mmol), and N,N-diisopropylethylamine (201.5 mg, 1.56 mmol) were dissolved in N,N-dimethylformamide (5 mL), and HATU (296.4 mg, 0.78 mmol) was added. The mixture was reacted at 25 °C for 16 hours. The solution was poured into water (30 mL), and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with water (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by TLC (eluent: petroleum ether / ethyl acetate = 2 / 1) to give compound 33f (150 mg).
[0592] LCMS(ESI+): m / z = 547.2 [M+H] +
[0593] 1 H NMR(400MHz, CDCl3)δ:7.97(dd,J=7.8,5.6Hz,2H),7.59(s,1H),7.31(s,1H),7.14–6.99(m,4H),4.33(d,J=1 2.2Hz,1H),4.16(s,3H),3.97(s,3H),3.83–3.65(m,4H),2.98(s,3H),2.10–2.03(m,1H),2.02–1.94(m,1H).
[0594] Step 7: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-methoxy-3-methylcenolin-6-yl)methyl ketone (33)
[0595] Compound 33f (150.0 mg, 0.27 mmol) was dissolved in anhydrous tetrahydrofuran (2 mL). A tetrahydrofuran solution of methyl magnesium bromide (3 M, 0.2 mL, 0.69 mmol) was slowly added dropwise at -78 °C, and the temperature was slowly raised to 25 °C for 0.5 h. The solution was poured into a saturated ammonium chloride aqueous solution (20 mL), and extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by TLC (eluent: petroleum ether / ethyl acetate = 0 / 1) to give compound 33 (13.0 mg).
[0596] LCMS(ESI+): m / z = 547.3 [M+H] +
[0597] 1 H NMR (400MHz, CDCl3) δ: 7.94 (dd, J = 7.7, 5.6Hz, 2H), 7.71 (s, 1H), 7.35 (s, 1H), 7.09 (t, J = 8.6Hz, 3H), 6.96 (d, J = 4.3Hz, 1H), 4. 32(d,J=12.4Hz,1H),4.14(s,3H),3.95(s,1H),3.82–3.70(m,3H),3.00(s,3H),2.81(s,1H),2.06-1.98(m,2H),1.66(s,6H).
[0598] Example 34: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-methoxy-3-(deuterated methyl-d3) cinnamyl-6-yl) methyl ketone (34)
[0599] Compound 34 was prepared according to Examples 31 and 33.
[0600] LCMS(ESI+): m / z = 550.2[M+H] +
[0601] Example 35: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(3-(difluoromethyl)-8-methoxyzolin-6-yl) methyl ketone (35)
[0602] The preparation of compound 35 is described in Example 31. The preparation process of intermediate 56 is described in patent WO2021214136A1 (CAS: 2721375-69-3).
[0603] LCMS(ESI+): m / z = 564.2 [M+H] +
[0604] Example 36: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(3-cyclopropyl-8-methoxy-6-yl)methyl ketone (36)
[0605] The preparation of compound 36 is described in Example 31. The preparation process of intermediate 61 is described in patent WO2021214136A1, which is based on intermediate 61 (CAS: 2721376-81-2).
[0606] LCMS(ESI+): m / z = 554.2 [M+H] +
[0607] Example 37: Preparation of ((1R,5S,6S)-6-((6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-methoxy-3-methylcenolin-6-yl) methyl ketone (37)
[0608] Compound 37 was prepared according to Example 33. Except that methyl 2-chloro-3-fluoroisonicotinic acid was replaced with methyl 2-chloro-3-methylpyridine-4-carboxylate in step 1 of Example 33, the remaining steps were the same to obtain compound 37.
[0609] LCMS(ESI+): m / z = 543.2 [M+H] +
[0610] Example 38: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(3-methyl-7,8-dihydrofurano[3,2-h]cenline-6-yl) methyl ketone (38)
[0611] The preparation of compound 38 is described in Example 33.
[0612] LCMS(ESI+): m / z = 559.2 [M+H] +
[0613] Example 9: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(3-methyl-7,8-dihydrofurano[3,2-h]cenline-6-yl) methyl ketone (39)
[0614] The preparation of compound 39 is described in Example 31.
[0615] LCMS(ESI+): m / z = 540.2[M+H] +
[0616] Example 40: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-(methoxy-d3)-3-methylcenolin-6-yl) methyl ketone (40)
[0617] The preparation of compound 40 is described in Example 31. The preparation process of intermediate (CAS: 2721375-88-6) is described in reference to patent WO2021198981A1, which describes intermediate 122-2.
[0618] LCMS(ESI+): m / z = 531.2[M+H] +
[0619] Example 41: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-(methoxy-d3)-3-methylcenolin-6-yl)methyl ketone (41)
[0620] Compound 41 was prepared according to Examples 31 and 33.
[0621] LCMS(ESI+): m / z = 550.2[M+H] +
[0622] Example 42: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azatricyclo[3.1.0]hexane-3-yl)(8-methoxy-3-methylqinidin-6-yl) methyl ketone (42)
[0623] Step 1: Preparation of 2-chloro-3-methylisonicotinic acid nitrile (42a)
[0624] 2-Chloro-4-iodo-3-methylpyridine (10 g, 39.51 mmol) and cuprous cyanide (7.03 g, 79.20 mmol) were dissolved in DMF (100 mL), and the mixture was purged with nitrogen three times and reacted at 100 °C for 16 hours. Water (300 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1) to give compound 42a (3.0 g).
[0625] LCMS(ESI+): m / z = 153.0 [M+H] +
[0626] 1 H NMR (400MHz, CDCl3) δ: 8.40 (d, J = 4.9 Hz, 1H), 7.44 (d, J = 4.9 Hz, 1H), 2.63 (s, 3H).
[0627] Step 2: Preparation of 2-(4-fluorophenyl)-3-methylisonicotinamide (42b)
[0628] Compound 42a (4 g, 26.21 mmol), 4-fluorophenylboronic acid (4.4 g, 31.41 mmol), potassium carbonate (10.86 g, 78.62 mmol), and tetrakis(triphenylphosphine)palladium (1.92 g, 2.62 mmol) were dissolved in dioxane / water (10:1, 30 mL + 3 mL), and the mixture was heated to 100 °C under nitrogen and reacted for 16 hours. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1) to give compound 42b (5.0 g).
[0629] LCMS(ESI+): m / z = 213.1[M+H]+
[0630] 1 H NMR (400MHz, CDCl3) δ: 8.66 (d, J = 4.9 Hz, 1H), 7.62–7.39 (m, 3H), 7.18 (t, J = 8.6 Hz, 2H), 2.57 (s, 3H).
[0631] Step 3: Preparation of 4-cyano-2-(4-fluorophenyl)-3-methylpyridine 1-oxide (42c)
[0632] Compound 42b (5.0 g, 23.6 mmol) and m-chloroperoxybenzoic acid (7.19 g, 35.4 mmol) were dissolved in dichloromethane (100 mL) and reacted at 40 °C for 16 hours. The reaction was quenched with saturated sodium bicarbonate aqueous solution (100 mL) and extracted with dichloromethane (100 mL * 2). The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and pulped and filtered with methyl tert-butyl ether (10 mL) to give compound 42c (4.0 g).
[0633] LCMS(ESI+): m / z = 229.1 [M+H] +
[0634] 1 H NMR (400MHz, CDCl3) δ: 8.23 (d, J = 6.8Hz, 1H), 7.47 (d, J = 6.8Hz, 1H), 7.31 (dd, J = 8.6, 5.4Hz, 2H), 7.23 (d, J = 8.7Hz, 2H), 2.32 (s, 3H).
[0635] Step 4: Preparation of 6-chloro-2-(4-fluorophenyl)-3-methylisonicotinonitrile (42d)
[0636] Compound 42c (4.0 g, 17.51 mmol) was added to toluene (100 mL), and phosphorus oxychloride (13.5 g, 87.51 mmol) was slowly added at 25 °C. The reaction was carried out at 100 °C for 2 hours under nitrogen. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give compound 42d (4.0 g).
[0637] LCMS(ESI+): m / z = 247.0 [M+H] +
[0638] 1 H NMR (400MHz, CDCl3) δ: 7.60–7.40 (m, 3H), 7.18 (t, J = 8.6Hz, 2H), 2.54 (s, 3H).
[0639] Step 5: Preparation of 2-(6-chloro-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propylamino-2-amine (42e)
[0640] Compound 42d (2.0 g, 8.1 mmol) was dissolved in tetrahydrofuran (20 mL), and the temperature was lowered to -10 °C under nitrogen. A solution of methyl magnesium bromide in tetrahydrofuran (3.0 M, 8.1 mL, 24.31 mmol) was slowly added dropwise. After the addition was complete, the reaction was allowed to proceed for 1 hour. The temperature was then raised to 0 °C, and tetraisopropyl titanate (2.3 g, 8.11 mmol) was slowly added dropwise. After the addition was complete, the temperature was raised to 50 °C, and the reaction was allowed to proceed for 4 hours. The solution was poured into a saturated sodium carbonate aqueous solution (50 mL), filtered, and the filter cake was washed with ethyl acetate (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to give compound 42e (600 mg).
[0641] LCMS(ESI+): m / z = 279.1 [M+H] +
[0642] 1 H NMR(400MHz, CDCl3)δ:7.62(s,1H),7.44–7.40(m,2H),7.21–7.17(m,2H),2.40(s,3H),1.59(s,6H).
[0643] Step 6: Preparation of benzyl (2-(6-chloro-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propane-2-yl)carbamate (42f)
[0644] Compound 42e (600 mg, 2.15 mmol) was dissolved in tetrahydrofuran (10 mL) and water (5.0 mL), sodium bicarbonate (542 mg, 6.46 mmol) was added, and the mixture was cooled to 0 °C. Benzyl chloroformate (551 mg, 3.23 mmol) was then added dropwise. After the addition was complete, the mixture was heated to 25 °C and reacted for 16 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (50 mL), and extracted with ethyl acetate (50 mL x 3). The organic phases were combined. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to give compound 42f (1.0 g).
[0645] LCMS(ESI+): m / z = 413.2[M+H] +
[0646] 1H NMR (400MHz, CDCl3) δ: 7.36–7.26 (m, 7H), 7.08 (t, J = 8.6Hz, 2H), 5.12 (s, 1H), 5.02 (s, 2H), 2.22 (s, 3H), 1.72 (s, 6H).
[0647] Step 7: Preparation of tert-butyl(1R,5S,6S)-6-((4-(2-(((benzyloxy)carboxyl)amino)propane-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (42g)
[0648] Compound 42f (500 mg, 1.21 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (243 mg, 1.21 mmol), and anhydrous potassium phosphate (771 mg, 3.63 mmol) were dissolved in cyclopentyl methyl ether (5.0 mL) and trifluorotoluene (5.0 mL). 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (161 mg, 0.242 mmol) and tris(dibenzylideneacetone)dipalladium (111 mg, 0.121 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen. The mixture was filtered, the filtrate was concentrated under reduced pressure, and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 3 / 1) to give compound 42 g (250 mg).
[0649] LCMS(ESI+): m / z = 576.0 [M+H] +
[0650] 1 H NMR (400MHz, CDCl3) δ: 7.34 (br.s, 7H), 7.08 (t, J = 8.7Hz, 3H), 5.03 (s, 2H), 3.81 (s, 1H), 3.68 (d, J = 10.6Hz ,1H),3.58(d,J=10.7Hz,1H),3.46(d,J=11.2Hz,2H),2.23(s,3H),1.79(s,2H),1.72(s,6H),1.44(s,9H).
[0651] Step 8: Preparation of benzyl (2-(6-(((1R,5S,6S)-3-azatricyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propyl-2-yl)carbamate (42h)
[0652] 42 g (250 mg, 0.43 mmol) of compound was dissolved in dichloromethane (3.0 mL), and trifluoroacetic acid (1.0 mL) was added. The mixture was reacted at 25 °C for 2 hours. The solution was concentrated under reduced pressure, dissolved in dichloromethane (10 mL), washed with saturated sodium bicarbonate aqueous solution and saturated saline solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 42h (150 mg).
[0653] LCMS(ESI+): m / z = 476.1 [M+H] +
[0654] 1 H NMR(400MHz, CDCl3)δ:7.34(br.s,7H),7.14–7.01(m,3H),6.79(s,1H),5.03(s,2H),4.04(s ,1H),3.36(d,J=11.5Hz,2H),3.25(d,J=10.6Hz,2H),2.22(s,3H),1.79(s,2H),1.72(s,6H).
[0655] Step 9: Preparation of benzyl(2-(6-(((1R,5S,6S)-3-(2-cyclopropyl-7-methoxy-2H-indole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-2-(4-fluorophenyl)-3-methylpyridin-4-yl)propionic acid-2-yl)carbamate (42i)
[0656] Compound 42h (100 mg, 0.21 mmol), compound 1f (46 mg, 0.21 mmol), and N,N-diisopropylethylamine (81 mg, 0.63 mmol) were dissolved in dichloromethane (5 mL), and HATU (120 mg, 0.32 mmol) was added. The reaction mixture was reacted at 25 °C for 16 hours. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 1 / 1) to give compound 42i (60 mg).
[0657] LCMS(ESI+): m / z = 676.2 [M+H] +
[0658] 1H NMR(400MHz, DMSO)δ:7.95–7.93(m,2H),7.52(s,1H),7.35–7.33(m,7H),7.21–7.15(m,3H),6.73(s,1H),4.94(s,2H),4.04–3.98(m,4H),3.8 8(s,1H),3.74(d,J=6.7Hz,1H),3.60(d,J=7.8Hz,1H),3.48(d,J=10.9Hz,1H),2.87(s,3H),2.14(s,3H),1.97(s,2H),1.57(d,J=8.7Hz,6H).
[0659] Step 10: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropyl-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(2-cyclopropyl-7-methoxy-2H-indazol-5-yl) methyl ketone (42)
[0660] Compound 42i (60 mg, 0.088 mmol) was suspended in concentrated hydrochloric acid (1 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7–8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (10 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (developing solvent: dichloromethane / methanol = 15 / 1) to give compound 42 (20.5 mg).
[0661] LCMS(ESI+): m / z = 542.3 [M+H] +
[0662] 1 H NMR(400MHz, CD3OD)δ:7.98(s,1H),7.49(s,1H),7.45–7.39(m,2H),7.22(s,1H),7.10(t,J=8.8Hz,2H),6.96(s,1H),4.19(d,J=12.4Hz,1H), 4.12(s,3H),3.92(s,1H),3.84–3.80(m,1H),3.75–3.62(m,2H),2.93( s,3H),2.36(s,3H),2.09–2.03(m,1H),2.00–1.92(m,1H),1.63(s,6H).
[0663] Example 43: Preparation of ((1R,5S,6S)-6-((4-(2-aminoisopropyl)-6-(3,4-difluorophenyl)pyridin-2-yl)oxy)-3-aza[3.1.0]cyclohexane-3-yl)(8-methoxy-3-methylcenline-6-yl)methyl ketone (43)
[0664] Compound 43 was prepared according to Example 31. Except that compound 3,4-difluorophenylboronic acid was used instead of 4-fluorophenylboronic acid in step 7 of Example 31, the remaining steps were the same to obtain compound 43.
[0665] LCMS(ESI+): m / z = 546.2 [M+H] +
[0666] 1 H NMR (400MHz, DMSO) δ: 8.10-7.98 (m, 1H), 7.96-7.84 (m, 2H), 7.73 (d, J = 1.2Hz, 1H), 7.51 (d, J =1.2Hz,1H),7.36(q,J=9.2Hz,1H),7.21(d,J=1.2Hz,1H),6.86(d,J=1.2Hz,1H),4.08(d,J=1 2.0Hz,1H),4.01(s,3H),3.96(s,1H),3.72(dd,J=10.8,4.8Hz,1H),3.61(dd,J=12.0,4.8Hz, 1H), 3.54 (d, J = 10.8Hz, 1H), 2.80 (s, 3H), 2.05-1.97 (m, 1H), 1.93-1.88 (m, 1H), 1.34 (s, 6H).
[0667] Example 44: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-(methoxy-d3)-3-methylcenolin-6-yl)methyl ketone (44)
[0668] Step 1: Preparation of (R)-6-chloro-2-iodo-3-((2-methylepoxypropyl)methoxy)pyridine (44a)
[0669] 2-Iodo-3-hydroxy-6-chloropyridine (4.0 g, 15.7 mmol) and diphenyl-2-pyridinium phosphine (4.6 g, 17.2 mmol) were dissolved in anhydrous tetrahydrofuran (40 mL), purged three times with nitrogen, cooled to 0 °C, and (2S)-(+)-2-methyl-2,3-epoxy-1-propanol (1.4 g, 15.7 mmol) and diisopropyl azodicarbonate (3.5 g, 17.2 mmol) were added dropwise. The mixture was slowly brought back to room temperature and stirred at 25 °C for 16 hours. The solution was diluted with water and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The solution was purified by medium-pressure flash (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1) to give compound 14a (4.0 g).
[0670] LCMS(ESI+): m / z = 326.0 [M+H] +
[0671] 1 H NMR (400MHz, CDCl3) δ: 7.20 (d, J = 8.4Hz, 1H), 7.03 (d, J = 8.4Hz, 1H), 4.17 (d, J = 10.8Hz, 1H), 3.97 (d, J = 10.8Hz, 1H), 2.95 (d, J = 4.8Hz, 1H), 2.78 (d, J = 4.8Hz, 1H), 1.53 (s, 3H).
[0672] Step 2: Preparation of (S)-(5-chloro-7-iodo-3-methyl-2,3-dihydrofurano[2,3-c]pyridin-3-yl)methanol (44b)
[0673] Compound 44a (4.8 g, 14.8 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), purged three times with nitrogen, and cooled to 0 °C. Diisopropylaminolithium (8.8 mL, 17.7 mmol) was then added dropwise, and the mixture was stirred at 0 °C for 1 hour. The mixture was quenched with ice water and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by flash filtration under medium pressure (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1) to give compound 44b (2.2 g).
[0674] LCMS(ESI+): m / z = 325.8 [M+H] +
[0675] 1H NMR (400MHz, CDCl3) δ: 7.06 (s, 1H), 4.69 (d, J = 8.4Hz, 1H), 4.37 (d, J = 8.4Hz, 1H), 3.73-3.70 (m, 1H), 3.67-3.63 (m, 1H), 1.40 (s, 3H).
[0676] Step 3: Preparation of (S)-(5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridin-3-yl)methanol (14c)
[0677] Compound 44b (1.64 g, 5.04 mmol), 4-fluorophenylboronic acid (0.85 g, 6.05 mmol), palladium dichloride (0.35 g, 0.50 mmol), and sodium carbonate (1.33 g, 12.6 mmol) were dissolved in tetrahydrofuran (15 mL) and water (3 mL), and the mixture was purged with nitrogen three times. The reaction was carried out at 70 °C for 1 hour under nitrogen atmosphere. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by flash filtration under medium pressure (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 20 / 1-5 / 1) to give compound 44c (1.1 g).
[0678] LCMS(ESI+): m / z = 294.1 [M+H] +
[0679] 1 H NMR(400MHz, DMSO)δ:8.18(dd,J=8.8,5.6Hz,2H),7.52–7.47(m,1H),7.39(s,1H),7.32(t,J=8.8Hz,2H),5.16(t ,J=5.6Hz,1H),4.73(d,J=8.8Hz,1H),4.38(d,J=8.8Hz,1H),3.63–3.52(m,1H),3.50–3.45(m,1H),1.33(s,2H).
[0680] Step 4: Preparation of (R)-5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridine-3-carboxylic acid (44d)
[0681] Compound 44c (1.20 g, 4.09 mmol) was dissolved in acetone (15 mL), and Jones' reagent (5 mL, 12.27 mmol) was added dropwise at 0 °C. The reaction was carried out at 25 °C for 16 hours. The reaction was quenched with isopropanol and water, and extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 44d (1.30 g), which was used directly in the next reaction.
[0682] LCMS(ESI+): m / z = 308.1 [M+H] +
[0683] Step 5: Preparation of methyl(R)-5-chloro-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridine-3-carboxylic acid ester (44e)
[0684] Compound 44d (1.30 g, 4.23 mmol) was dissolved in anhydrous methanol (13 mL), and sulfuric acid (1.20 g, 12.69 mmol) was added. The reaction was carried out at 50 °C for 16 hours. After cooling to room temperature, the pH was adjusted to 7–8 with saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by medium-pressure Flash (Biotage Isolera Prime 3.2, eluent: petroleum ether / ethyl acetate = 2 / 1) to give compound 44e (0.46 g).
[0685] LCMS(ESI+): m / z = 322.1[M+H] +
[0686] 1 H NMR (400MHz, CDCl3) δ: 8.24-8.20 (m, 2H), 7.24 (s, 1H), 7.13 (t, J = 8.8Hz, 2H), 5.21 (d, J = 9.2Hz, 1H), 4.44 (d, J = 9.2Hz, 1H), 3.80 (s, 3H), 1.67 (s, 3H).
[0687] Step 6: Preparation of methyl(R)-5-(((1R,5S,6S)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxylic acid ester (44f)
[0688] Compound 44e (460 mg, 1.43 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (2851 mg, 1.43 mmol), potassium phosphate (910 mg, 4.29 mmol), 5-(bis(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (192 mg, 0.29 mmol), and palladium acetate (32 mg, 0.14 mmol) were dissolved in trifluorotoluene (3 mL) and methoxycyclopentane (3 mL), purged three times with nitrogen, and reacted at 90 °C for 16 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by Prep-TLC (developing solvent: petroleum ether / ethyl acetate = 2 / 1) to give compound 44f (280 mg).
[0689] LCMS(ESI+): m / z = 485.3 [M+H] +
[0690] 1 H NMR(400MHz, CDCl3)δ:8.30-8.26(m,2H),7.13(t,J=8.8Hz,2H),6.69(s,1H),5.14(d,J=9.2Hz,1H),4.38(d,J=9.2Hz,1H ),3.88(s,1H),3.80-3.77(m,4H),3.70(d,J=10.0Hz,1H),3.51(t,J=12.0Hz,2H),1.88(s,2H),1.65(s,3H),1.48(s,9H).
[0691] Step 7: Preparation of (R)-5-(((1R,5S,6S)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxylic acid (44g)
[0692] Compound 44f (280 mg, 0.58 mmol) and lithium hydroxide (28 mg, 1.16 mmol) were added to a mixture of anhydrous methanol / tetrahydrofuran / water (1 / 1 / 1, 3 mL), and stirred at 25 °C for 2 hours. The pH was adjusted to 5–6 with dilute hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 44 g (300 mg).
[0693] LCMS(ESI+): m / z = 471.3[M+H] +
[0694] Step 8: Preparation of tert-butyl(1R,5S,6S)-6-(((R)-3-carboxamido-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofurano[2,3-c]pyridin-5-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (44h)
[0695] 44 g (300 mg, 0.64 mmol) of compound, ammonium chloride (51 mg, 0.96 mmol), and N,N-diisopropylethylamine (413 mg, 3.20 mmol) were dissolved in N,N-dimethylformamide (3 mL). HATU (486 mg, 1.28 mmol) was added at 0 °C, and the mixture was stirred at 25 °C for 16 hours. The reaction mixture was added dropwise to ice water and extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Prep-TLC purification (eluent: petroleum ether / ethyl acetate = 1 / 1) yielded compound 44 h (240 mg).
[0696] LCMS(ESI+): m / z = 470.3[M+H] +
[0697] 1 H NMR (400MHz, DMSO) δ: 8.24-8.21 (m, 2H), 7.43 (s, 1H), 7.34-7.28 (m, 3H), 6.95 (s, 1H), 5.12 (d, J = 8.8Hz, 1H), 4. 35(d,J=8.8Hz,1H),3.78(s,1H),3.63-3.58(m,2H),3.46-3.40(m,2H),1.91(s,2H),1.57(s,3H),1.41(s,9H).
[0698] Step 9: Preparation of (R)-5-(((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-7-(4-fluorophenyl)-3-methyl-2,3-dihydrofuran[2,3-c]pyridine-3-carboxamide (44i)
[0699] Compound 44h (200 mg, 0.42 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1.5 mL) was added. The mixture was stirred at 25 °C for 2 hours. The solution was then evaporated directly to dryness to give compound 44i (130 mg).
[0700] LCMS(ESI+): m / z = 370.2[M+H] +
[0701] Step 10: Preparation of ((1R,5S,6S)-6-((5-fluoro-6-(4-fluorophenyl)-4-(2-hydroxypropyl-2-yl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hex-3-yl)(8-(methoxy-d3)-3-methylcenolin-6-yl)methyl ketone (44)
[0702] Compound 44i (40 mg, 0.11 mmol), compound 31f (35 mg, 0.16 mmol), HATU (84 mg, 0.22 mmol), and N,N-diisopropylethylamine (71 mg, 0.55 mmol) were dissolved in N,N-dimethylformamide (1 mL) and stirred at 25 °C for 16 hours. The solution was diluted with water and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by TLC (evolving solvent: dichloromethane / anhydrous methanol = 20 / 1) to give compound 44 (14.70 mg).
[0703] LCMS(ESI+): m / z = 570.2[M+H] +
[0704] 1 H NMR(400MHz,DMSO)δ:8.19-8.15(m,2H),8.00(s,1H),7.58(s,1H),7.43(s,1H),7.35( s,1H),7.28(s,1H),7.12(t,J=8.8Hz,2H),6.94(s,1H),5.11(d,J=7.2Hz,1H),4.34(d ,J=6.7Hz,1H),4.15(d,J=12.1Hz,1H),4.07(s,3H),3.94(s,1H),3.79-3.75(m,1H),3 .68-3.63(m,1H),3.58(d,J=10.7Hz,1H),2.87(s,3H),2.04-1.95(m,2H),1.56(s,3H).
[0705] Example 45: Preparation of ((1R,5S,6S)-6-((4-(2-aminoisopropyl)-5-fluoro-6-(4-fluorophenyl)pyridin-2-oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(8-methoxy-3-methylcenolin-6-yl) methyl ketone (45)
[0706] Compound 45 was prepared according to steps 2 to 10 of Example 42. Except that compound 42a in step 2 of Example 42 was replaced with compound 2-chloro-3-fluoroisonicotinamide, the remaining steps were the same to obtain compound 45.
[0707] LCMS(ESI+): m / z = 546.3 [M+H] +
[0708] 1 H NMR (400MHz, DMSO) δ: 7.98 (s, 1H), 7.95-7.88 (m, 2H), 7.55 (d, J = 1.1Hz, 1H), 7.2 7-7.18(m,3H),7.04(d,J=4.4Hz,1H),4.15-4.06(m,1H),4,04(s,3H),3.95(s,1 H),3.76(dd,J=10.8,4.8Hz,1H),3.64(dd,J=12.0,4.8Hz,1H),3.55(d,J=10.8H z,1H),2.87(s,3H),2.09-2.03(m,1H),2.00-1.94(m,1H),1.44(d,J=3.2Hz,6H).
[0709] Example 46: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropane-2-yl)-5-ethyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-(methoxy-d3)-2-methyl-2H-indazol-5-yl) methyl ketone (46)
[0710] Step 1: Preparation of 2-chloro-4-iodo-3-vinylpyridine (46a)
[0711] Methyltriphenylphosphine bromide (48.08 g, 135 mmol) was dissolved in toluene (180 mL), and potassium tert-butoxide (11.33 g, 101 mmol) was added at 0 °C. The mixture was purged with nitrogen three times and reacted at 0 °C for 1 hour. 2-chloro-4-iodopyridin-3-carboxaldehyde (18.0 g, 67 mmol) was added, and the mixture was reacted at 0 °C for 2 hours. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (150 mL * 2). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1-10 / 1) to give compound 46a (6.33 g).
[0712] LCMS(ESI+): m / z = 265.9 [M+H] +
[0713] 1H NMR (400MHz, CDCl3-d) δ: 8.09-7.88 (m, 2H), 6.61 (dd, J = 17.7Hz, 11.6, 1H), 5.69 (dd, J = 38.8Hz, 14.6Hz, 2H).
[0714] Step 2: Preparation of 2-chloro-3-ethyl-4-iodopyridine (46b)
[0715] Compound 46a (7.5 g, 28.25 mmol) was dissolved in methanol (75 mL), and triphenylphosphine rhodium chloride (1.5 g, 20%) was added. Hydrogen was purged three times, and the reaction was carried out at 40 °C for 8 hours. The system was then concentrated. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to give compound 46b (2.7 g).
[0716] LCMS(ESI+): m / z = 267.9 [M+H] +
[0717] 1 H NMR (400MHz, CDCl3-d) δ: 7.80 (d, J = 5.1Hz, 1H), 7.68 (d, J = 5.1Hz, 1H), 3.00 (q, J = 7.5Hz, 2H), 1.19 (t, J = 7.5Hz, 3H).
[0718] Step 3: Preparation of 2-chloro-3-ethylisonicotinonitrile (46c)
[0719] Compound 46b (2.7 g, 10.09 mmol) and cuprous cyanide (2.33 g, 20.19 mmol) were dissolved in DMF (27 mL), purged with nitrogen three times, and reacted at 100 °C for 16 hours. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification was performed by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1–2 / 1) to give compound 46c (1.4 g).
[0720] LCMS(ESI+): m / z = 167[M+H] +
[0721] 1 H NMR (400MHz, CDCl3-d) δ: 8.40 (d, J = 4.8Hz, 1H), 7.45 (d, J = 4.9Hz, 1H), 3.02 (q, J = 7.6Hz, 2H), 1.32 (t, J = 7.6Hz, 3H).
[0722] Step 4: Preparation of 3-ethyl-2-(4-fluorophenyl)isonicotinonitrile (46d)
[0723] Compound 46c (1.4 g, 8.4 mmol), 4-fluorophenylboronic acid (1.41 g, 10.08 mmol), potassium carbonate (2.32 g, 16.81 mmol), and tetrakis(triphenylphosphine)palladium (971.02 mg, 0.84 mmol) were dissolved in dioxane:water = 7:1 (14 mL + 2 mL). The mixture was heated to 100 °C under nitrogen and reacted for 16 hours. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (50 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1) to give compound 46d (1.5 g).
[0724] LCMS(ESI+): m / z = 227.1 [M+H] +
[0725] 1 H NMR (400MHz, CDCl3-d) δ: 8.67 (d, J = 4.8Hz, 1H), 7.55-7.41 (m, 3H), 7.18 (t, J = 8.4Hz, 2H), 2.90 (q, J = 7.5Hz, 2H), 1.22 (t, J = 7.5Hz, 3H).
[0726] Step 5: Preparation of 1-oxide (46e) of 4-cyano-3-ethyl-2-(4-fluorophenyl)pyridine
[0727] Compound 46d (1.5 g, 6.63 mmol) and m-chloroperoxybenzoic acid (2.02 g, 9.94 mmol) were dissolved in dichloromethane (15 mL) and reacted at 40 °C for 16 h. The reaction was quenched with saturated sodium bicarbonate aqueous solution (20 mL), extracted with dichloromethane (20 mL * 2), and the organic phases were combined. The organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by Prep-TLC (EA) to give compound 46e (1.2 g).
[0728] LCMS(ESI+): m / z = 243.1 [M+H] +
[0729] 1 H NMR(400MHz, CDCl3-d)δ:8.26(d,J=6.8Hz,1H),7.51(d,J=6.8Hz,1H),7.34- 7.27(m,2H),7.25-7.20(m,2H),2.64(q,J=7.6Hz,2H),1.13(t,J=7.6Hz,3H).
[0730] Step 6: Preparation of 6-chloro-3-ethyl-2-(4-fluorophenyl)isonicotinamide (46f)
[0731] Compound 46e (1.2 g, 4.95 mmol) was added to toluene (12 mL), and phosphorus oxychloride (3.8 g, 24.77 mmol) was slowly added at 25 °C. The reaction was carried out at 100 °C for 2 hours under nitrogen. The mixture was concentrated under reduced pressure and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 5 / 1) to give compound 46f (810 mg).
[0732] LCMS(ESI+): m / z = 261.1[M+H] +
[0733] 1 H NMR (400MHz, CDCl3-d) δ: 7.54 (s, 1H), 7.50-7.40 (m, 2H), 7.22-7.12 (m, 2H), 2.87 (q, J = 7.5Hz, 2H), 1.22 (t, J = 7.6Hz, 3H).
[0734] Step 7: Preparation of 2-(6-chloro-3-ethyl-2-(4-fluorophenyl)pyridin-4-yl)propylamine (46g)
[0735] Compound 46f (850 mg, 3.26 mmol) was dissolved in toluene (9 mL), and the temperature was lowered to 0 °C under nitrogen. A 3M tetrahydrofuran solution of methyl magnesium bromide (3.3 mL, 9.78 mmol) was slowly added dropwise. After the addition was complete, the mixture was reacted at room temperature for 1 hour. The temperature was then lowered to 0 °C, and tetraisopropyl titanate (926 mg, 3.26 mmol) was slowly added dropwise. After the addition was complete, the temperature was raised to 50 °C and the mixture was reacted for 4 hours. The solution was poured into a saturated sodium carbonate aqueous solution (5 mL), and the aqueous phase was extracted with ethyl acetate (10 mL * 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The solution was purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 2 / 1) to give compound 46 g (227 mg).
[0736] LCMS(ESI+): m / z = 293.1 [M+H] +
[0737] 1 H NMR(400MHz, CDCl3-d)δ:7.58(s,1H),7.49-7.42(m,2H),7.28(t,J=8.9Hz, 2H), 3.05 (q, J = 7.3Hz, 2H), 1.91 (s, 2H), 1.51 (s, 6H), 0.72 (t, J = 7.3Hz, 3H).
[0738] Step 8: Preparation of benzyl (2-(6-chloro-3-ethyl-2-(4-fluorophenyl)pyridin-4-yl)propane-2-yl)carbamate (46 h)
[0739] 46 g (210 mg, 0.71 mmol) of compound was dissolved in tetrahydrofuran (4 mL) and water (2 mL), sodium bicarbonate (181 mg, 2.15 mmol) was added, the mixture was cooled to 0 °C, and benzyl chloroformate (184 mg, 1.08 mmol) was added dropwise. After the addition was complete, the mixture was heated to 25 °C and reacted for 16 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (2 mL), extracted with ethyl acetate (3 mL x 3), and the organic phases were combined. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 1 / 1) to give compound 46h (70 mg).
[0740] LCMS(ESI+): m / z = 426.9 [M+H] +
[0741] 1 H NMR (400MHz, DMSO-d6) δ: 8.11 (s, 1H), 7.46-7.21 (m, 10H), 4.91 (s, 2H), 2.98-2.82 (m, 2H), 1.62 (s, 6H), 0.56 (t, J = 7.0Hz, 3H).
[0742] Step 9: Preparation of tert-butyl(1R,5S,6S)-6-((4-(2-(((benzyloxycarbonyl)amino)propane-2-yl)-5-ethyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid ester (46i)
[0743] Compound 46h (70 mg, 0.16 mmol), (1R,5S,6S)-6-hydroxy-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (32.6 mg, 0.16 mmol), and anhydrous potassium phosphate (104.4 mg, 0.49 mmol) were dissolved in 1,4-dioxane (2 mL). 5-(di(adamantane-1-yl)phosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole (21.7 mg, 0.03 mmol) and tris(dibenzylideneacetone)dipalladium (15 mg, 0.016 mmol) were added. The mixture was purged three times with nitrogen and reacted at 90 °C for 16 hours under nitrogen. The mixture was filtered, and the filtrate was concentrated under reduced pressure and purified by thin-layer chromatography (developing solvent: petroleum ether / ethyl acetate = 3 / 1) to give compound 46i (26 mg).
[0744] LCMS(ESI+): m / z = 589.8 [M+H] +
[0745] Step 10: Preparation of benzyl (2-(6-(((1R,5S,6S)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)-3-ethyl-2-(4-fluorophenyl)pyridin-4-yl)prop-2-yl)carbamate (46j)
[0746] Compound 46i (30 mg, 0.051 mmol) was dissolved in dichloromethane (0.5 mL), and trifluoroacetic acid (0.2 mL) was added. The reaction mixture was reacted at 25 °C for 2 hours. The solution was concentrated under reduced pressure, dissolved in dichloromethane (1 mL), washed with saturated sodium bicarbonate aqueous solution and saturated saline aqueous solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 46j (20 mg).
[0747] 1 H NMR(400MHz, CDCl3-d)δ:7.33(dt,J=27.0Hz,20.6Hz,7H),7.05(t,J=8.7Hz,2H),6.81(s,1H),5.29(s,1H),4.99(s,2H) ,4.07(s,1H),3.70(s,1H),3.36(t,J=29.0Hz,4H),2.86(d,J=7.2Hz,2H),2.04(s,2H),1.72(s,6H),1.37-1.19(m,3H).
[0748] Step 11: Preparation of benzyl (2-(3-ethyl-2-(4-fluorophenyl)-6-(((1R,5S,6S)-3-(7-(deuterated methoxy)-2-methyl-2H-indazole-5-carboxyl)-3-azabicyclo[3.1.0]hexane-6-yl)oxy)pyridin-4-yl)isopropyl)carbamate (46k)
[0749] Compound 46j (20 mg, 0.041 mmol), compound 31f (8.5 mg, 0.041 mmol), and N,N-diisopropylethylamine (15.8 mg, 0.12 mmol) were dissolved in dichloromethane (1 mL), and HATU (23.3 mg, 0.06 mmol) was added. The mixture was reacted at 25 °C for 16 hours. Water (1 mL) was added, and the mixture was extracted with dichloromethane (1 mL x 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by thin-layer chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to give compound 46k (20 mg).
[0750] LCMS(ESI+): m / z = 681.4[M+H] +
[0751] Step 12: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropane-2-yl)-5-ethyl-6-(4-fluorophenyl)pyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-(methoxy-d3)-2-methyl-2H-indazol-5-yl)methyl ketone (46)
[0752] Compound 46k (20 mg, 0.029 mmol) was suspended in concentrated hydrochloric acid (1 mL) and stirred at 80 °C for 0.5 h. After cooling to room temperature, the pH was adjusted to 7–8 with sodium bicarbonate, and the mixture was extracted with dichloromethane (1 mL * 3). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was purified by thin-layer chromatography (eluent: dichloromethane / methanol = 15 / 1) to give compound 46 (5.4 mg).
[0753] LCMS(ESI+): m / z = 547.3 [M+H] +
[0754] 1 H NMR(400MHz, CD3OD-d4)δ:7.87(s,1H),7.39(dd,J=8.4,5.5Hz,2H),7.26(s,1H),7.07(t,J=8.6Hz,3H),6.58(s,1H),4.33(s,1H),4.23(s,3 H),3.90(s,1H),3.77(s,1H),3.73-3.64(m,2H),2.94(d,J=6.3Hz,2H),2.09-1.89(m,2H),1.66(s,6H),1.29(s,2H),0.76(t,J=7.2Hz,3H).
[0755] Example 47: Preparation of ((1R,5S,6S)-6-((4-(2-aminoisopropyl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azatricyclo[3.1.0]hexane-3-yl)(4-methyl-2-(5-methylpyrimidin-2-yl)thiazolyl)methyl ketone (47)
[0756] The preparation of compound 47 is described in Example 25.
[0757] LCMS(ESI+): m / z = 559.2 [M+H] +
[0758] Example 48: Preparation of ((1R,5S,6S)-6-((4-(2-aminopropane-2-yl)-6-(4-fluorophenyl)-5-methylpyridin-2-yl)oxy)-3-azabicyclo[3.1.0]hexane-3-yl)(7-(methoxy-d3)-2-(methyl-d3)-2H-indazol-5-yl) methyl ketone (48)
[0759] The preparation of compound 48 is described in Examples 6 and 23.
[0760] LCMS(ESI+): m / z = 536.2 [M+H] +
[0761] Biological Examples
[0762] 1. Virus generation and reproduction
[0763] (1) Generation and reproduction of RSV A2 virus
[0764] RSV A2 multiplies in HEp-2 cells (human cells containing HeLa-marked chromosomes and derived from HeLa contamination) with a multiplicity of infection (MOI) of 0.1. After 3-4 days of infection, when 60% of the cells have rounded and detached, all culture material is collected. The cells are centrifuged at 600g for 10 minutes at room temperature to separate the supernatant from the cell pellet. The supernatant is centrifuged at 4000g for 10 minutes at room temperature, and 2 mL of the supernatant is remixed and the cells are retained. The cells are then transferred to -80℃ and frozen overnight. After thawing at 37℃, the frozen material is centrifuged at 4000g for 2 minutes at room temperature, mixed, and then centrifuged again at 4000g for 10 minutes at room temperature. The supernatant is then aliquoted to obtain RSV A2 virus stock solution, which is stored at -80℃.
[0765] (2) Generation and reproduction of hMPV virus
[0766] hMPV multiplied in BHK-21-STD cells (a modified hamster kidney cell line) with a multiplicity of infection (MOI) of 0.01–0.1. After 60% cytopathic effect was achieved 2–3 days after infection, all culture material was collected. The cells were centrifuged at 600g for 10 minutes at room temperature to separate the supernatant from the cell pellet. The supernatant was collected, centrifuged at 4000g for 10 minutes at room temperature, and 2 mL of the supernatant was collected, mixed thoroughly by pipetting, and the cells were retained. The supernatant was then transferred to -80°C and frozen overnight. The frozen product was thawed at 37°C, centrifuged at 4000g for 2 minutes at room temperature to mix, and then centrifuged again at 4000g for 10 minutes at room temperature. The supernatant was aliquoted to obtain the hMPV virus stock solution, which was then stored at -80°C.
[0767] 2. Methods for determining viral titer
[0768] (1) Method for determining RSV A2 virus titer
[0769] Vero-E6 cells (African green monkey kidney cells) were cultured in growth medium (DMEM, 10% heat-inactivated FBS, 1% Penn / Strep) at a density of 1 × 10⁶ cells per well. 5 Cells were seeded into 24-well cell culture plates and cultured overnight at 37°C. RSV A2 virus stock solution was diluted 10-fold using pure DMEM medium, resulting in 10 dilutions. After washing the cells with PBS, 200 μL of the virus serial dilutions were added to each well, with two replicates per dilution, and the cells were gently mixed. After 2 hours of virus infection at 37°C, the virus-containing supernatant was discarded, and 2 mL of methylcellulose fixation medium (DMEM, 1.5% methylcellulose, 2% heat-inactivated FBS, 1% Penn / Strep) was added to each well. The plates were then incubated at 37°C.
[0770] Six days later, the fixation medium was discarded, and 2 mL / well of neutral paraformaldehyde fixative was added for overnight fixation. The fixative was discarded, and the cells were washed three times with PBS (shaking at room temperature, 120 rpm, 5 minutes each time). The PBS was discarded, and 500 μL / well of blocking buffer (PBS, 5% milk, 0.2% Triten-100) was added, and the cells were incubated at room temperature, 80 rpm, for 1 hour. The blocking buffer was discarded, and 200 μL / well of blocking buffer containing 1‰ anti-RSV antibody was added. After incubation overnight at 4°C, the supernatant was discarded, and the cells were washed three times with PBST (PBS, 0.5% Tween 20) (shaking at room temperature, 120 rpm, 10 minutes each time). The supernatant was discarded, and 200 μL / well of PBST containing 1 / 300 rabbit anti-goat IgG (H+L antibody) was added. After incubation at room temperature, 80 rpm, for 1 hour, the supernatant was discarded. The cells were washed three times with PBST (shaking at room temperature, 120 rpm, 4 minutes each time). Discard the supernatant, wash with 2 mL / well of ddH2O at room temperature on a shaker at 120 rpm for 10 minutes. Discard the supernatant, add 100 μL / well of DAB chromogenic reagent, and develop the solution in the dark until spots appear. Discard the chromogenic reagent, rinse the culture plate with water, and calculate the titer of the RSV A2 virus stock solution based on the chromogenic spots.
[0771] (2) Method for determining hMPV viral titer
[0772] BHK-21-STD cells were cultured in growth medium (DMEM, 10% heat-inactivated FBS, 1% Penn / Strep) at a density of 2 × 10⁶ cells per well. 4Cells were seeded into 96-well cell culture plates and cultured overnight at 37°C. The hMPV virus stock solution was diluted 10-fold using pure DMEM medium, resulting in 10 dilutions. After washing the cells twice with PBS, 100 μL of the serially diluted virus solution was added to each well, with 8 replicates for each dilution, and the cells were gently mixed. After 2 hours of virus infection at 35°C, the virus-containing supernatant was discarded, and 200 μL of maintenance medium (DMEM, 0.1% BSA, 0.5 μg / mL TPCK) was added to each well. After 6 days of culture at 35°C, the degree of cytopathic effect was observed, and the median cytotoxicity (TCID) of the virus stock solution was calculated. 50 ).
[0773] 3. In vitro pharmacological efficacy (EC) of the compound 50 Measurement
[0774] (1) In vitro pharmacological effects of compound RSV A2 (ECG) 50 Measurement
[0775] Vero-E6 cells (African green monkey kidney cells) were cultured in growth medium (DMEM, 10% heat-inactivated FBS, 1% Penn / Strep) at a density of 5 × 10⁶ cells per well. 4 Cells were seeded in 48-well cell culture plates and incubated overnight at 37°C. The DMSO solution of the test compounds was diluted with maintenance medium (DMEM, 2% heat-inactivated FBS, 1% Penn / Strep) at an initial concentration of 1 μM, followed by five-fold serial dilutions (eight gradients). A solvent control was set up with DMSO at the minimum dilution of the drug. After washing the cells twice with PBS, the serial dilutions of each test compound and maintenance medium were added sequentially to the cell culture plates, with a total volume of 100 μL, and two replicates for each concentration. Additionally, negative control wells (cells only, no virus), positive control wells (cells and virus without the compound), and solvent control wells (cells and virus with DMSO dilution) were included.
[0776] After placing the culture plate in a 37°C cell culture incubator for 1 hour, except for the negative control wells, add RSV A2 virus stock solution diluted with pure DMEM to each well at an MOI of 0.05. After gentle shaking, place in a 37°C cell culture incubator for 2 hours, discard the supernatant, and add 200 μL of serially diluted solution or maintenance medium of each test compound to each well. Shake well and incubate at 37°C for 48 hours. Then freeze the culture plate at -80°C for 1 hour, remove, and thaw at room temperature, repeating this process twice. Nucleic acid is extracted, and the virus copy number in each well is determined using RT-qPCR. The experiment is repeated at least twice, and the data are subjected to biological statistical analysis. The EC50 of each compound and JNJ-8003 (CAS: 2734047-68-6) against RSV A2 virus is calculated using GraphPad Prism 7. 50 Compared with comparative compound JNJ-8003 and comparative compound D1, the compounds of the present invention are... (WO2025006293A2, CAS No.: 3067862-04-5) RSV in vitro activity EC 50 Smaller, the results are shown in Table 1.
[0777] Table 1. RSV in vitro activity of compounds (EC) 50
[0778] Where A represents EC 50 <10nM.
[0779] (2) In vitro pharmacological efficacy of compound hMPV (EC) 50 Measurement
[0780] LLC-MK2 cells (rhesus monkey kidney cells) were cultured in growth medium (DMEM, 10% heat-inactivated FBS, 1% Penn / Strep) at a density of 5 × 10⁶ cells per well. 4 Cells were seeded in 48-well cell culture plates and incubated overnight at 37°C. The DMSO solution of the test compounds was diluted with maintenance medium (DMEM, 0.1% BSA, 0.5 μg / mL TPCK) at an initial concentration of 10 μM, followed by five-fold serial dilutions (eight gradients). A solvent control was set up with DMSO at the minimum dilution of the drug. After washing the cells twice with PBS, the serial dilutions of each test compound and maintenance medium were added sequentially to the cell culture plates, with a total volume of 100 μL, and two replicates for each concentration. Additionally, negative control wells (cells only, no virus), positive control wells (cells and virus without the compound), and solvent control wells (cells and virus with DMSO dilution) were included.
[0781] After incubating the culture plates at 35°C for 1 hour, except for the negative control wells, add pure DMEM diluted hMPV virus stock solution to each well at an MOI of 0.1. After gentle shaking, incubate at 35°C for 2 hours, discard the supernatant, and add 200 μL of serially diluted assay solution or maintenance medium for each test compound to each well. After mixing, incubate at 35°C for 48 hours. Freeze the culture plates at -80°C for 1 hour, remove, and thaw at room temperature, repeating this process twice. Extract nucleic acids and determine the virus copy number in each well using RT-qPCR. Repeat the experiment at least twice, and perform biological statistical analysis on the data. Calculate the EC50 of each compound and JNJ-8003 against hMPV virus in vitro using GraphPad Prism 7. 50 The compound of the present invention exhibits greater in vitro anti-hMPV virus activity compared to JNJ-8003 and comparative example D1. 50 Smaller, the results are shown in Table 2.
[0782] Table 2. In vitro activity of compounds at hMPV (EC) 50
[0783] Where A represents EC 50 <0.5μM.
[0784] 4. The C60 of compounds 50 Measurement
[0785] Vero-E6 cells were cultured in growth medium (DMEM, 10% heat-inactivated FBS, 1% Penn / Strep) at a density of 2.5 × 10⁶ cells per well. 4 100 μL of cells were seeded into 96-well cell culture plates and incubated overnight at 37°C. The DMSO solution of the test compound was serially diluted with maintenance medium (DMEM, 2% heat-inactivated FBS, 1% Penn / Strep) at an initial concentration of 200 μM, followed by two-fold serial dilutions for six gradients. A solvent control was set up with DMSO equivalent to the minimum dilution of the drug. After washing the cells twice with PBS, the serial dilutions of each test compound and maintenance medium were added sequentially to the cell culture plates, with a total volume of 100 μL, and two replicates for each concentration. Negative control wells containing only cells and background control wells without cells were also included.
[0786] After placing the culture plates in a 37°C cell culture incubator for 48 hours, the absorbance values of each well at 450 nm and 650 nm were measured using the CCK-8 assay. The experiment was repeated at least twice, and the data were subjected to biological statistical analysis. The CCK-8 values of each compound and the comparative compound JNJ-8003 were calculated using GraphPad Prism 7. 50 The compound of the present invention, compared with JNJ-8003 and Comparative Example D1, has a higher concentration of C2C.50 The results are shown in Table 3.
[0787] Table 3 CC of compounds 50
[0788] 5. Lung tissue distribution
[0789] Experimental animals: A total of 18 female animals (BALB / c mice: 6-8 weeks old, weighing approximately 20g; or SD rats: 6-8 weeks old, weighing approximately 200g). Three of these were reserved for use or for blank matrix collection. Animals were fasted overnight before administration and allowed free access to food and water 2 hours after administration.
[0790] Animal solvent: 40% PEG400 - 10% Tween - 80-50% water;
[0791] Administration method: Oral;
[0792] PK Sample Collection: Plasma and Tissue Samples: Three animals from each group were sampled at 15.0 min, 1.0 h, 2.0 h, 7.0 h, and 10.0 h post-drug administration (at each time point, 3 animals). Samples were collected at 50–75 mg / kg. After intramuscular anesthesia, blood samples were collected via the abdominal aorta or other suitable sites to induce death. The animals were then perfused with physiological saline, and lung tissue was harvested and rinsed with physiological saline. Whole blood collection: Anticoagulant EDTA-K2 was used. After all blood samples were collected, the samples were centrifuged at 3000g for 10 minutes at 4°C on wet ice within 1.0 h. The centrifuged plasma samples were then placed in cryovials and directly transferred to a -80°C freezer for storage until analysis. Lung tissue samples: After all animals were euthanized, tissue samples were temporarily stored on wet ice or transported to a -80°C freezer.
[0793] Analysis and detection: 15 plasma samples and 15 lung tissue samples were tested for the compound (lung tissue was homogenized at a ratio of 1g:4mL homogenate).
[0794] Biological sample analysis: Using Analyst software 1.6.2 or later, the chromatographic peak areas of the analyte and internal standard were collected. The analyte concentration in the calibration standard was then subjected to a weighted (W = 1 / x²) least squares method, performing a linear regression between the plasma / lung analyte concentration (x) and the peak area ratio (y). The resulting regression equation (y = ax + b) is the standard curve. Based on the standard curve of the analytical batch, the AUC (area under the curve) of the analyte in the plasma / lung of the test animals was calculated. The lung-blood ratio was used as the AUC. 肺 and AUC 血浆 The ratio of .
[0795] Table 4. Lung tissue distribution of the compounds
[0796] The compounds of this invention (compounds 3 and 23) have a better lung-to-blood ratio, constituting a significant advantage in drug development. By increasing the lung-to-blood ratio (lung exposure / plasma exposure), the exposure of the drug in the circulatory system (blood) is minimized while ensuring effective drug concentration in the target organs, effectively reducing the risk of adverse reactions, broadening the therapeutic window, and improving clinical drug safety and patient tolerability.
[0797] 6. In vitro inhibition assay of human potassium ion channels (hERG)
[0798] Experimental equipment: SyncroPatch384 fully automated patch clamp
[0799] Experimental Procedure: The test compound was diluted with DMSO to prepare a 10 mM stock solution. On the day of detection, 30 μL of the 10 mM stock solution was added to a 96-well plate and diluted using the Bravo automated liquid workstation. First, a 3-fold serial dilution was performed with DMSO. 10 μL of the compound stock solution was added to 20 μL of DMSO and serially diluted 3-fold to 6 intermediate DMSO concentrations. Then, 2 μL of the 6 intermediate DMSO concentrations was added to 248 μL of extracellular fluid and diluted 125-fold to the final detection concentration, up to 80 μM. Finally, the solution in the 96-well plate was transferred to 60 μL of each well in a 384-well plate for analysis. During the detection process, the instrument automatically adds 40 μL of the compound solution to a detection plate containing 40 μL of extracellular fluid, diluting it twofold to the final detection concentration. The highest test concentration of the compound is 40.00 μM, followed by six concentrations: 40.00, 13.33, 4.44, 1.48, 0.49, and 0.16 μM. The DMSO content in the final test concentration does not exceed 0.4%, as this concentration of DMSO has no effect on the hERG potassium channel. The entire dilution process is performed by the Bravo instrument.
[0800] The compound of the present invention, within the detection concentration range of this experiment, IC50 50 IC greater than that of comparative example D1 50 This indicates that the compound hERG of the present invention is significantly superior to that of comparative example D1, as shown in Table 5.
[0801] Table 5. In vitro inhibition test of human potassium channel (hERG)
Claims
1. The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, Its features are, Ring A is an 8-12 membered bicyclic fused heteroaryl group or a 5-7 membered heteroaryl group, wherein the 8-12 membered bicyclic fused heteroaryl group is optionally surrounded by one or more -C groups. 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 Cycloalkyl substitution, wherein -C 3-5 cycloalkyl, -C 1-3 Alkyl, -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group is optionally substituted with one or more halogens or D, and / or the substituents on the two adjacent atoms of the 8-12 membered bicyclic fused heteroaryl group form a 3-6 membered heterocycloalkyl group with the atom to which they are attached; the 5-7 membered heteroaryl group is optionally substituted with -C 1-3 Alkyl or 5-8-membered heteroaryl groups are substituted, wherein the 5-8-membered heteroaryl group is further optionally replaced by one or more halogens or -C. 1-3 Alkyl substitution; p is 0, 1, 2, 3, 4 or 5; R 1 each independently halogen, -C 1-3 alkyl or -C 1-3 haloalkyl; R 2 is -H, halogen, -C 1-5 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, said -C 1-5 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl is optionally substituted with one or more halogen; R 3 -C 1-5 alkyl or -C 3-6 cycloalkyl, said -C 1-5 alkyl and -C 3-6 cycloalkyl is optionally substituted with one or more -OH, -NH2, or halogen; or R 2 R 3 The C atoms connected to it form a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is surrounded by one or more -C atoms. 1-3 Alkyl and / or -C(=O)NH2 substitution; L 1 is a bond or -(CH2) n O(CH2) m -; each of n, m is independently 0, 1, 2 or 3; And at least one of the following conditions must be met: (a) R 2 -C 1-5 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, said -C 1-5 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl is optionally substituted with one or more halogen; (b)R 2 R 3 The C atoms connected to it form a 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is surrounded by one or more -C atoms. 1-3 Alkyl and / or -C(=O)NH2 substitution; (c) Ring A is an optionally substituted 8-12 membered bicyclic fused and heteroaryl group, R 3 -C replaced by one or more -OH groups 1-5 Alkyl groups or -C groups optionally substituted with one or more -OH, -NH2, or halogens 3-6 cycloalkyl; (d) Ring A is an optionally substituted 8-12 membered bicyclic fused heteroaryl, R 2 is -Cl; (e) Ring A is a 10-12 membered bicyclic fused and heteroaryl group that is optionally substituted.
2. The compound, its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts according to claim 1, characterized in that, R 2 is -H, -Cl, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, said -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl is optionally substituted with one or more halogen.
3. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that, Ring A is an 8-10 membered bicyclic fused and heteroaryl group, optionally bounded by one or more -C groups. 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 Cycloalkyl substitution, wherein -C 1-3 Alkyl, -C 3-5 cycloalkyl, -C 1-3 Alkyl or -OC 3-5 The cycloalkyl group is optionally substituted with one or more -F or D groups, or the substituents on two adjacent atoms of the 8-10 membered bicyclic fused and heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atom to which they are attached; preferably a 9-10 membered bicyclic fused and heteroaryl group; Preferably, the heteroatom of the bicyclic fused heteroaryl group is N or O; and / or the number of heteroatoms is 2 or 3, preferably 2; More preferably, the bicyclic fused heteroaryl group is and / or More preferably, the bicyclic fused heteroaryl group is and / or The bicyclic fused and heteroaryl groups are optionally replaced by one or more methyl, ethyl, difluoromethyl, trifluoromethyl, -CD3, cyclopropyl, or other compounds. Methoxy, -OCD3 or cyclopropyloxy substitution; and / or The substituents on the two atoms of the bicyclic fused group and the heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atoms they are attached to, wherein the heteroatom of the heterocyclic alkyl group is O; and / or the number of heteroatoms is 1 or 2, preferably 2; more preferably 5 membered heterocyclic alkyl group; even more preferably, the substituents on the two atoms of the bicyclic fused group and the heteroaryl group form a 3-6 membered heterocyclic alkyl group with the atoms they are attached to.
4. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that, Ring A is a 5-membered heteroaryl, optionally substituted with one or more 6-membered heteroaryl, -C 1-3 alkyl, said 6-membered heteroaryl further optionally substituted with one or more halogen or -C 1-3 alkyl; Preferably, the number of heteroatoms in the 5-membered heteroaryl group is 1 or 2, preferably 2; and / or the heteroatoms are N, S, or O, preferably N and / or S; more preferably, the 5-membered heteroaryl group is and / or Preferably, the 6-membered heteroaryl group has 1 or 2 heteroatoms, more preferably 2; and / or the heteroatoms are N, S, or O, preferably N; more preferably, the 6-membered aromatic heterocycle is More preferably, ring A is a... Replacement And optionally substituted with one or more methyl groups, the Further optionally substituted with one or more -F or methyl groups; preferably, the It can be further optionally replaced by one or more -F.
5. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-3, characterized in that, p is 0, 1 or 2, preferably 1 or 2, more preferably 1; Preferably, R 1 The structure formed with the ring it is in is Or R 1 The structure formed with the ring it is in is and / or R 1 each independently is halogen, preferably -F or -Cl, more preferably -F; More preferably, R 1 The structure formed with the ring it is in is 6. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-5, characterized in that, R 2 -H, -F, -Cl, -C 1-3 Alkyl, -C 1-3 alkoxy or -C 3-4 cycloalkyl, the -C 1-3 Alkyl or -C 1-3 The alkoxy group is optionally substituted with one or more -F groups; preferably, R... 2 The derivative is -H, -F, -Cl, methyl, ethyl, cyclopropyl, or methoxy, wherein the methyl, ethyl, or methoxy group is optionally substituted with one or more -F groups; more preferably, R... 2 It can be -H, -Cl, methyl, ethyl, cyclopropyl, methoxy, or difluoromethyl; Preferably, R 2 -C 1-3 Alkyl or -C 3-4 cycloalkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; preferably, R... 2 -C 1-3 Alkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R... 2 It is methyl, ethyl, or difluoromethyl; more preferably, R 2 It is a methyl group.
7. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-6, characterized in that, R 3 -C 1-3 Alkyl groups, optionally substituted with one or more -OH or -NH2 groups; preferably, R 3 It is n-propyl or isopropyl, optionally substituted with a -OH or -NH2 group; more preferably, R 3 for Or R 3 -C 3-6 Cycloalkyl groups, optionally substituted with one or more -OH or -NH2 groups; preferably, R 3 It is cyclopropyl, optionally substituted with one or more -OH or -NH2 groups; more preferably, R 3 for 8. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-5, characterized in that, R 2 R 3 The C group connected thereto forms a 5-membered heterocyclic group, wherein the 5-membered heterocyclic group is surrounded by one or more -C groups. 1-3 Alkyl and / or -C(=O)NH2 substitution; preferably, the number of heteroatoms in the 5-membered heterocyclic group is 1, and the heteroatom is O; more preferably, the 5-membered heterocyclic group is It is substituted with one or more methyl groups and / or -C(=O)NH2; more preferably, for Even more preferably, for 9. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-8, characterized in that, L 1 is -(CH2) n O(CH2) m -; n, m are each independently 0 or 1 ; preferably, L 1 is -O-.
10. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-9, characterized in that, The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, have the structure represented by formula (Ia): wherein R 1 , R 2 , R 3 , p, L 1 each independently is according to any one of claims 1 to 9; R 4 is H or -C 1-3 alkyl; R 5 -C 1-3 alkyl, -C 1-3 alkoxy or -OC 3-5 cycloalkyl, said -C 1-3 alkyl, -C 1-3 alkoxy or -OC 3-5 cycloalkyl is optionally substituted with one or more halogen or D; or R 4 with R 5 to form a 3-6 membered heterocycloalkyl group; X 1 , X 2 each independently C or N; X 3 is CH, O, S or N; X 4 CR 6 or NR 6 ; R 6 H, halogen, -C 1-3 alkyl or -C 3-5 cycloalkyl, said -C 1-3 alkyl or -C 3-5 cycloalkyl is optionally substituted with one or more D or halogen; Preferably, R 1 Each is independently a halogen, -C 1-3 Alkyl or -C 1-3 Haloalkyl, p is 0, 1, 2, 3, 4 or 5; R 2 is -Cl, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, said -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl is optionally substituted with one or more halogen, hydroxy and alkyl; R 3 -C 1-5 alkyl, said -C 1-5 alkyl is optionally substituted with one or more -OH, -NH2, or halogen; R 4 is H or -C 1-3 alkyl; R 5 -C 1-3 alkyl, -C 1-3 alkoxy or -OC 3-5 cycloalkyl, said -C 1-3 alkyl, -C 1-3 alkoxy or -OC 3-5 cycloalkyl is optionally substituted with one or more halogen or D; or R 4 with R 5 to form a 3-6 membered heterocycloalkyl group; X 1 , X 2 each independently C or N; X 3 is CH, O, S or N; X 4 CR 6 or NR 6 ; R 6 H, halogen, -C 1-3 alkyl or -C 3-5 cycloalkyl, said -C 1-3 alkyl or -C 3-5 cycloalkyl is optionally substituted with one or more D or halogen; L 1 is a bond or -(CH2) n O(CH2) m -; n, m are each independently 0, 1, 2 or 3; More preferably, R 2 is -C 1-3 alkyl or -C 3-4 cycloalkyl, said -C 1-3 alkyl is optionally substituted with one or more -F; still more preferably, R 2 is -C 1-3 alkyl, said -C 1-3 alkyl is optionally substituted with one or more -F; again preferably, R 2 is methyl, ethyl or difluoromethyl; still more preferably, R 2 is methyl.
11. The compound, its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts according to claim 10, characterized in that, R 4 is H, methyl or ethyl, preferably H; and / or R 5 is H, methyl, methoxy, ethoxy or cyclopropoxy, optionally substituted with one or more F or D; preferably methyl, methoxy or cyclopropoxy, optionally substituted with one or more F or D; more preferably, R 5 is methoxy, cyclopropoxy, trifluoromethyl or -OCD3; and / or R 4 With R 5 The linkage forms a 3-6 membered heterocyclic alkyl group; preferably, R 4 With R 5 The heterocyclic alkyl group is linked to form a 4-6 membered heterocyclic alkyl group, wherein the heterocyclic alkyl group has 1 or 2 heteroatoms; and / or the heteroatoms of the heterocyclic alkyl group are O or N; more preferably, the heteroatoms of the heterocyclic alkyl group are O; even more preferably, the structure formed by the heterocyclic alkyl group and the adjacent ring is as follows: Further preferred is Even more preferably, ring A is 12. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to claim 10 or 11, characterized in that, X 3 is CH, O or N, preferably CH or O; and / or X 4 For CR 6 or NR 6 R 6 H, -C 1-3 Alkyl or -C 3-5 cycloalkyl, the -C 1-3 Alkyl or -C 3-5 The cycloalkyl group is optionally substituted with one or more D or F; preferably, R 6 The methyl or cyclopropyl group is optionally substituted by one or more D or F groups; more preferably, R 6 It is methyl, difluoromethyl, cyclopropyl, -CD3 or 13. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 10-12, characterized in that, X 1 , X 2 , X 3 , and X 4 contain at least one heteroatom; preferably, X 1 , X 2 , X 3 , and X 4 contain one heteroatom; More preferably, X 4 For NR 6 X 1 X 2 X 3 For CH; or X 1 X 2 One is N, the other is C, and X 3 For CH, X 4 For CR 6 ;X 3 For O, X 1 X 2 For CH, X 4 For CR 6 ; More preferably, ring A is 14. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-9, characterized in that, The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, has the structure represented by formula (Ib): wherein R 1 , R 2 , R 3 , p, L 1 each independently are according to any one of claims 1-9; R 7 -C 1-3 alkyl, preferably methyl; R 8 -H, -C 1-3 alkyl or halogen, preferably -H, methyl or -F, more preferably -H or -F; Preferably, R 2 -C 1-3 Alkyl or -C 3-4 cycloalkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R 2 -C 1-3 Alkyl, the -C 1-3 The alkyl group is optionally substituted with one or more -F groups; more preferably, R... 2 It is methyl, ethyl, or difluoromethyl; more preferably, R 2 It is a methyl group.
15. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-9, characterized in that, The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, has the structure represented by formula (Ic): wherein R 1 , R 2 , R 3 , p, L 1 are each independently according to any one of claims 1 to 9; R 4 is H or -C 1-3 alkyl; R 5 H, -C 1-3 alkyl or -OC 3-5 cycloalkyl, said -C 1-3 alkyl or -OC 3-5 cycloalkyl is optionally substituted with one or more D; or R 4 with R 5 linkage to form a 3-6 membered heterocycloalkyl group; R 6 H, -C 1-3 alkyl or 3-6 membered cycloalkyl, said -C 1-3 alkyl is optionally substituted with one or more D or halogen; Preferably, R 4 is H, methyl or ethyl, preferably H; and / or Preferably, R 5 H, methoxy, ethoxy, or cyclopropoxy, wherein the methoxy, ethoxy, or cyclopropoxy is optionally substituted with one or more D; preferably methoxy, wherein the methoxy is optionally substituted with one or more D; more preferably, R 5 It is methoxy or -OCD3; more preferably methoxy; or Preferably, R 4 With R 5 The linkage forms a 3-6 membered heterocyclic alkyl group; preferably, R 4 With R 5 The heterocyclic alkyl group is linked to form a 4-6 membered heterocyclic alkyl group, wherein the heterocyclic alkyl group has 1 or 2 heteroatoms; and / or the heteroatoms of the heterocyclic alkyl group are O or N; more preferably, the heteroatoms of the heterocyclic alkyl group are O; even more preferably, the structure formed by the heterocyclic alkyl group and the adjacent ring is as follows: Further preferred is and / or R 6 The alkyl group is H, methyl, ethyl, or a 3-5 membered cycloalkyl group, wherein the methyl or ethyl group is optionally substituted with one or more D groups or halogens; preferably, R 6 The methyl group is methyl or cyclopropyl, wherein the methyl group is optionally substituted by one or more D or F groups; more preferably, R 6 It is methyl, -CD3, -CHF2 or cyclopropyl; more preferably methyl.
16. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-9, characterized in that, The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, have the structure represented by formula (I'): Among them, rings A and R 1 R 2 R 3 p, each independently according to any one of claims 1-9; and / or The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, have the structure represented by formula (Ia'): Among them, R 1 R 2 R 3 R 4 R 5 p, X 1 X 2 X 3 X 4 Each independently according to any one of claims 10-13; and / or The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, have the structure represented by formula (Ib'): Among them, R 1 R 2 R 3 R 7 R 8 p, each independently according to claim 14; and / or The compound represented by formula (I), its stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof, have the structure represented by formula (Ic'): Among them, R 1 R 2 R 3 R 4 R 5 Each of p is independent of the claims 15.
17. The compound, its stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof according to any one of claims 1-16, characterized in that, The compounds represented by formula (I), their stereoisomers, isotopic derivatives, or pharmaceutically acceptable salts thereof include the following structures:
18. A pharmaceutical composition, characterized in that, It comprises at least one compound according to any one of claims 1-17, its stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers and / or additives.
19. The use of a compound, stereoisomer thereof, isotopic derivative thereof, or pharmaceutically acceptable salt thereof, according to any one of claims 1-17, or a pharmaceutical composition according to claim 18, in the preparation of a medicament for the prevention or treatment of viral infection; preferably, the viral infection is an infection caused by respiratory syncytial virus and human metapneumovirus.
